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Abstract 
Haemochromatosis is one of the most common autosomal recessive disorders amongst 
populations of northern European ancestry. It is a condition characterised by iron overload, 
which, if untreated, contributes to morbidity and mortality. As diagnosis is often delayed 
owing to the non-specific nature of early symptoms, population screening programs have 
been suggested to reduce the consequential burden of disease. To date, a paucity of robust 
health economic evidence regarding haemochromatosis screening has been cited as a key 
barrier to the establishment of such programs internationally. This thesis investigates and 
generates health economic evidence for haemochromatosis and related interventions, with 
a focus on population screening programs.  
Chapter 1 presents a general overview of haemochromatosis and health economic concepts 
pertinent to this thesis. 
Chapter 2 presents a systematic review of all health economic evidence regarding 
haemochromatosis screening and related interventions. Most of the evidence identified in 
the review related to population screening programs. The economic methodologies 
employed and the quality of epidemiologic evidence incorporated into these models were 
flawed in most studies, reducing their validity and generalizability. The gaps in current 
knowledge that were identified in this review guided the subsequent direction of this thesis. 
The systematic review did not identify any robust health state utility value data for 
haemochromatosis. Whilst four studies included in the review incorporated utility values into 
cost-effectiveness models, these were set at unrealistically high levels, with no description of 
the source of these provided. Chapter 3 aimed to robustly quantify the quality of life burden 
associated with haemochromatosis by measuring health state utility values.  A national, 
online survey of people with haemochromatosis was conducted, which allowed for 
calculation of utilities for different categories of severity of haemochromatosis. These utility 
values, which provide insight into the quality of life impacts of haemochromatosis, were 
incorporated into the population screening model. 
In the absence of published literature quantifying the economic burden associated with 
haemochromatosis, a national cost of illness study was undertaken, and is reported in Chapter 
4. Costs were estimated from the patient, government and societal perspectives, with societal 
costs extrapolated to the Australian population.  These costs are the first to be published that 
quantify the economic burden of haemochromatosis. Whilst Chapters 3 and 4 provide 
information on the size of the burden associated with haemochromatosis, Chapter 6 identifies 
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strategies to address this. 
Chapter 5 provides a detailed description of the construction and validation of the health 
economic model for screening for haemochromatosis. A state-transition Markov model using 
probabilistic decision analysis was constructed and validated for the Australian adult 
population of northern European ancestry. 
Chapter 6 presents the results generated from the health economics model. The target 
populations were males aged 30 years and females aged 45 years, both of northern European 
ancestry, and neonates irrespective of ancestry. Three population screening strategies 
(genotyping with a blood sample, genotyping with a buccal sample, sequential screening with 
two consecutive iron studies and confirmatory HFE genotyping) were modelled for adults and 
one for neonates (HFE genotyping). The current status quo was the comparator, which 
comprises a combination of cascade and opportunistic screening. From the government 
perspective, genotyping with a blood sample was the most cost-effective approach for males; 
for females, sequential screening was considered to be the most cost-effective. For male and 
female neonates, screening was associated with cost savings and increased effectiveness, 
thereby dominating the current status quo. 
This thesis presents a range of studies that were conducted to address the substantial 
knowledge gaps identified in the systematic review.  Both the health state utility data and 
cost of illness data can be used to populate future health economic models regarding 
haemochromatosis interventions. The results of the modelling work provide medical and 
reimbursement decision-makers with robust data when considering future resource 
allocation decisions pertaining to screening for haemochromatosis. 
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Chapter 1: Introduction and outline 
1.1  Introduction to hereditary haemochromatosis  
High Iron Fe (HFE)-associated hereditary haemochromatosis is one of the most common 
autosomal recessive disorders amongst populations of northern European ancestry. Clinically 
it is characterised by excessive absorption of dietary iron, which is predominantly stored in 
the parenchymal tissue of the heart, liver and pancreas, leading to increased morbidity and 
mortality [1-3]. 
Iron overload related to haemochromatosis was first identified in 1889 by a German 
pathologist, Dr Frederich von Recklinghausen [4].  In a book published in 1935, the English 
gerontologist Dr Joseph Sheldon reported haemochromatosis to be a rare condition with an 
estimated prevalence of between 1 in 2,000 and 1 in 5,000. He claims to be the first to link 
haemochromatosis with an inborn metabolic disorder, as described in an excerpt of his book 
below.  
[5] 
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Sheldon conducted a review of case studies of haemochromatosis patients and noted that 
proceeding diagnosis, most patients experienced complications related to infections and 
diabetes. Due to an absence of effective treatments, predominantly for diabetes, most 
patients died within 18 months of diagnosis [5]. 
[5] 
In 1952, two English physicians by the names of Davis and Arrowsmith documented the 
effectiveness of venesection as a treatment for iron overload related to haemochromatosis 
[6].  More than two decades later, haemochromatosis was shown to involve the human 
leukocyte antigen (HLA), which provided clear evidence that the condition was inheritable [7]. 
This discovery was followed by that of Feder and colleagues who, in 1996, identified a 
mutation of the HFE gene that was associated with haemochromatosis [8]. Whilst several 
mutations of this gene that are associated with haemochromatosis have since been identified 
(e.g. C282Y, H63D, S56C), C282Y homozygotes account for between 80 and 90% of the burden 
of disease [9, 10].   
Hereditary haemochromatosis is an autosomal recessive genetic disorder. For disease to 
occur (i.e. iron overload and related co-morbidities), two copies of the mutated gene must be 
present. For two unaffected parents who are both carriers of a HFE mutation, there is a 25% 
chance that each child will be homozygous for a haemochromatosis mutation, or a compound 
heterozygote involving two of these mutations (Figure 1.1). 
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Figure 1.1: Autosomal recessive inheritance (reproduced from Kashmiri [11]) 
 
 
1.1.1 Prevalence of haemochromatosis 
Prevalence of the most commonly documented mutations of the HFE gene – C282Y and H63D 
– vary by racial ancestry, as displayed in Table 1.1. Amongst populations of northern European 
ancestry, the prevalence of C282Y homozygosity is estimated to range between 0.68% and 
0.74% [12, 13]. A lower estimate has been reported for Caucasians (0.44%) as this population 
group is not limited to northern Europeans [10]. The prevalence rate of the C282Y genotype 
is notably lower for Native Americans (0.11%), Hispanics (0.027%), African Americans 
(0.014%) and Pacific Islanders (0.012%) [10]. In contrast, amongst Asian populations, the 
estimated prevalence is just 0.000039%, and no C282Y homozygote mutations were reported 
for two small populations of Aboriginal Australians [10, 14]. As haemochromatosis is an 
autosomal recessive disorder, a carrier of the C282Y gene in combination with a wild-type 
gene (i.e. no mutation) will not experience iron-overload related to haemochromatosis. The 
estimated carrier prevalence rate for populations of northern European ancestry is 10% [10]. 
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The prevalence rates for H63D homozygotes and compound heterozygotes (C282Y/H63D) are 
greater than for C282Y homozygotes (Table 1.1). For example, amongst Caucasians 
prevalence of H63D homozygosity has been estimated to be 2.4% [10], and in comparison 
with C282Y homozygosity prevalence, is higher for all other ancestry groups. However, 
dramatically lower clinical penetrance is associated with these genotypes, accounting for 
approximately 10% of the burden of disease [9, 15]. 
Table 1.1: Prevalence of common HFE mutations by ancestry groups 
Study population C282Y/C282Y 
(%) 
H63D/H63D 
(%) 
C282Y/H63D 
(%) 
Northern European 0.68 [12] 1.89[16] 2.4 [12] 
Caucasians  0.44 [10] 2.4 [10] 2.0 [10] 
Native Americans 0.11 [10] 1.3 [10] 0.77 [10] 
Hispanics 0.027 [10] 1.1 [10] 0.33 [10] 
African Americans 0.014 [10] 0.089 [10] 0.071 [10] 
Pacific Islanders  0.012 [10] 0.20 [10] 0.096 [10] 
Asian 0.000039 [10] 0.20 [10] 0.0055 [10] 
Aboriginal Australian 0 [14] 0.52 [14] n/r 
n/r: not reported  
To put this ancestry-dependent prevalence into context, it has been hypothesised that the 
C282Y mutation first occurred in northern Europe, most likely either in the British Isles or 
Scandinavia [17]. The allele frequency map in Figure 1.2 [17] clearly shows the highest 
frequencies of the C282Y allele have been identified in Ireland and Finistère, a department in 
the westernmost part of France, followed by regions of the United Kingdom and Scandinavia. 
A study of the mitochondrial DNA of C282Y homozygotes found that the C282Y mutation likely 
occurred subsequent to human migration from Africa into Europe, approximately 4,000 years 
ago [18]. Further, the C282Y mutation can be dated back approximately 70 generations [19], 
and may have been an adaptive mutation in an environment in which dietary iron was scarce.   
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Figure 1.2: European distribution of the C282Y mutation (reproduced from Lucotte & 
Dieterlen, pp 263 [17])
 
 
1.1.2 Penetrance of haemochromatosis 
Estimates of the clinical penetrance rate (i.e. those with the mutation exhibiting symptoms) 
of haemochromatosis have varied greatly since the 1935 publication of Joseph Sheldon’s 
work. At that time, it was considered a largely fatal disorder, with most patients dying within 
two years of diagnosis, due to irreversible organ damage and lack of treatments [5]. As a result 
of ongoing research and development of clinical interventions, haemochromatosis today is 
infrequently a fatal condition. Increased awareness of the condition combined with effective 
diagnostic tests and treatment leading to improved patient outcomes. 
Over the past two decades reported rates of clinical penetrance for C282Y homozygotes have 
varied between 2% and 76% [9, 12, 20-33]. This variation is in part due to different definitions 
of penetrance being employed. Penetrance has been variably defined as: cirrhosis of the liver 
and hepatocellular carcinoma; multiple signs, symptoms and comorbidities including elevated 
iron studies, fatigue, and arthritis; through to irreversible organ damage. This variation has 
resulted in a somewhat unclear body of literature pertaining to penetrance.  To address this 
uncertainty, the European Association for the Study of the Liver published a Consensus paper 
in 2000 recommending the use of four stages or categories of haemochromatosis [34]. These 
categories, outlined in Table 1.2, allow for capture of all aspects of haemochromatosis, and 
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adoption of these will improve the generalizability and communication of research in this 
field. These categorise have been adopted throughout this thesis, in order to clearly define 
penetrance of HFE-haemochromatosis. 
Table 1.2: Categories of haemochromatosis[34] 
Category 1 Genetic mutation only (C282Y homozygotes, H63D heterozygotes and compound 
heterozygotes) 
Category 2 Genetic mutation and elevated iron studies, either transferrin saturation or serum 
iron 
Category 3 Genetic mutation, elevated iron levels and early symptoms (e.g. arthritis, fatigue, 
lethargy) 
Category 4 Genetic mutation, elevated iron levels and organ damage (e.g. liver cirrhosis, 
hepatocellular carcinoma, heart disease, Type 2 diabetes) 
   
To date, only a small number of studies have published data based on these categories. A 
large Australian study of people with haemochromatosis used Categories 3 and 4 to define 
clinical penetrance [12]. Amongst this random sample, a penetrance rate of 13.9% was 
reported for C282Y homozygotes, with sex-specific rates of 28.4% for males and 1.2% for 
females. The lower penetrance observed for females is largely due to menstruation, which 
reduces iron stores on a regular basis [32, 35, 36].  A second study using these four categories 
was based on a French haemochromatosis registry [37].  Categories 2, 3 and 4 were all defined 
as clinical penetrance: 24% of registry patients were assessed as being in Category 2, 58% in 
Category 3 and 18% in Category 4. This was not, however, a representative sample, as it was 
likely that patients on the register had been diagnosed with haemochromatosis due to being 
symptomatic, therefore resulting in an under-estimate of the proportion of patients in 
Category 1. 
Recent work has focused on identifying variants of genes other than HFE that, when present 
with a homozygous C282Y mutation, mediates the likelihood of iron-overload, i.e. 
penetrance. To date, promising work has focused on a variant of the GNPAT gene [38-40].   
DNA sequencing of C282Y homozygotes with either severe iron overload or no iron overload 
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showed that presence of this variation (GNPAT p.D519G) was associated with the iron-
overloaded group [40]. 
1.1.3 Diagnosis of haemochromatosis 
Diagnosis of haemochromatosis is typically carried out using a combination of serum iron 
studies and HFE genotyping, with approaches similar across countries. The Australian 
guidelines for diagnosis of haemochromatosis specify two patient groups: first degree 
relatives of a person diagnosed with haemochromatosis and those identified incidentally [41, 
42]. For a first degree relative, diagnosis initially occurs through HFE genotyping, which, if 
found to be positive for a haemochromatosis-related mutation, is followed by iron studies. 
For the other patient group, diagnosis occurs sequentially: two elevated transferrin saturation 
tests and/or serum ferritin (the second fasting), followed by confirmatory HFE genotyping. 
Prior to the availability of genotyping, liver biopsies were commonly used to confirm a 
diagnosis of haemochromatosis. Similarly, the guidelines published by American Association 
for the Study of Liver Diseases recommends diagnosis by conducting iron studies, specifically 
transferrin saturation and serum ferritin, followed by HFE genotyping if elevated. Alternately, 
for first degree relatives of a haemochromatosis patient, simultaneous genotyping and iron 
studies should be conducted [43].  In the UK, recommendations for screening are similar, in 
that diagnosis is recommended by sequential iron studies (the second fasting), with a focus 
on transferrin saturation. If both results are elevated, confirmatory HFE genotyping is 
recommended [44].  
1.1.4 Treatment of haemochromatosis 
Treatment for haemochromatosis related iron overload focuses on reducing iron stores. 
When a patient commences treatment prior to organ damage, normal life expectancy is 
retained [45]. The most common treatment for iron overload is therapeutic venesection. 
Venesection typically involves removal of 500ml of blood, which equates to removal of 200 
to 250mg of iron from bodily stores [43, 46, 47]. Depending on the extent of iron overload at 
diagnosis, venesection can be required on a weekly to fortnightly basis for up to two years to 
return iron stores to a therapeutic range. This initial stage of treatment is completed when 
serum ferritin is in the low normal range: 20-50µg/L; or a sustained decrease in haemoglobin 
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to under 11g/dl has been reached [42, 46]. At this point, maintenance treatment commences, 
involving venesection three to four times annually with regular monitoring of iron status. 
Whilst no randomised controlled trials have been conducted for this treatment, its 
effectiveness from observational research has been well-documented [33, 44, 48, 49], and 
ethical considerations preclude controlled trials.   
 
A small proportion of patients do not tolerate venesection, experiencing negative effects such 
as fatigue and vasovagal reactions [50], and it is contraindicated in patients with severe 
cardiac disease and hypoproteinaemia [51, 52]. For these patients, iron chelation therapy and 
erythrocytapheresis are alternatives. There are three forms of iron chelation therapy: 
deferoxamine which is provided parenterally, and two oral agents: deferiprone and 
deferasirox. Deferasirox is the most recent iron chelation therapy to be made available, and 
marks a substantial improvement from the earlier formulations, as it requires once daily 
dosing with an oral tablet in a community-based setting. In contrast, deferoxamine is 
administered parenterally as an infusion, in some cases for 12 hours per day, five days per 
week. Deferiprone is available in liquid and tablet form, and frequently taken three times daily 
[46]. Whilst all three iron chelation agents result in reduced iron stores, adverse events such 
as increased local skin reactions, susceptibility to infections, cataracts, ototoxicity and 
transient renal failure have been reported [46, 53].  
 
Erythrocytapheresis is an alternative treatment for iron overload which involves apheresis in 
which the erythrocytes are removed from the whole blood; an effective approach to reducing 
iron stores. In a randomised controlled trial (RCT), this form of treatment was compared to 
venesection in a cohort of recently diagnosed haemochromatosis patients. The authors 
reported a significantly reduced number of treatments for the erythrocytapheresis group to 
return to therapeutic iron levels, however the economic costs associated with this treatment 
were 3.5 times that of venesection [50]. 
 
The point at which treatment should commence, i.e. when the patient is iron-overloaded, is 
unclear in the literature. In 2000 the European Association for the Study of the Liver (EASL) 
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published a consensus statement on haemochromatosis noting that guidelines on 
commencement of treatment were based on empirical evidence in most countries [34]. As a 
result, there are limited cut-off points for results of serum ferritin or transferrin saturation 
tests that indicate treatment. Serum ferritin of 300µg/l for males and menopausal women 
and 200µg/l for pre-menopausal women are considered markers of iron-overload [54], 
however, inflammation, cytolysis and excessive intake of alcohol can also increase serum 
ferritin [46]. It is accepted that when serum ferritin is ≥1,000µg/l, treatment is clearly 
indicated. However, for haemochromatosis patients with serum ferritin in the ranges of 200-
1,000µg/l in pre-menopausal females and 300-1,000µg/l in other patients, the point at which 
to commence treatment is less clear. Patient preference and clinical judgement are 
recommended to guide such decision-making [47].  
 
Transferrin saturation is considered the most useful test for diagnosing iron overload [21, 44, 
46]. In many settings, two consecutive elevated transferrin saturation tests are conducted, 
the second fasting [42].  The cut-off ranges that have been suggested as indicative of iron-
overload, and therefore treatment, are 55% for males and between 45% [43] and 50% for 
females and 55% for males [44, 46, 55].    
1.2  Introduction to health economics 
Health economics is the study of scarcity and resource allocation in the health sector.  It is a 
specialist field of economics, which incorporates many elements of microeconomic theory 
[56].  The seminal paper published in 1963 by Kenneth Arrow has been credited as marking 
the birth of health economics [57]. Arrow argued that the ‘medical care industry’ was 
characterized by unique factors such as significant government intervention and asymmetric 
information, unlike other fields of study in economics. From this point on, health economics 
developed into a specialist field within the discipline of economics. 
1.2.1 Economics and/of the healthcare sector 
The proportion of gross domestic product (GDP) spent on health in developed countries has 
grown in recent decades.  The average proportion of health spending (as a proportion of GDP) 
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in countries that are members of the Organisation for Economic Co-operation and 
Development (OECD) increased from 7.3% in 2000 to 8.9% in 2013 [58, 59]. Whilst the Global 
Financial Crisis has slowed growth rates in many European countries, the demand for health 
services has not followed this trend [60].   
In Australia, the ratio of health expenditure to GDP has increased from 8.53% in 2003/04 to 
9.78% in 2013/14 (Figure 1.3) [61]. There are several factors that underpin this growth.  
Demographic change, in the form of an ageing population, is considered a major driver of 
increased expenditure in many developed countries [59], as health expenditure is 
substantially higher for older adults than children. In 2008/09, Australian expenditure per 
person was approximately 20 times higher for adults aged 85 years or older than for children 
aged between ages 5 and 14 years [62].  Other important drivers of growth in health 
expenditure include technological advancements and increased consumer expectations [63, 
64].  
Figure 1.3: Ratio of health expenditure to GDP, Australia 2003/04-2013/14 [61] 
 
1.2.2 Key concepts in health economics 
Whilst a full exploration of health economic concepts is beyond the scope of this chapter, a 
brief discussion of key concepts provides background to the conceptual and methodological 
approaches employed in this thesis.  
Opportunity cost 
Limited resources result in the need to make choices between viable alternatives, which are 
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often mutually exclusive [63]. The opportunity cost of the choice is the value of the next best 
alternative forgone [65].  The opportunity costs associated with health funding decisions are 
often measured using health economic evaluations such as cost effectiveness analyses [66]. 
Efficiency 
There are three primary types of efficiency that are considered in health economic 
evaluations: Pareto or allocative, technical and cost efficiency [67]. Efficiency is related to 
opportunity cost and can be defined as either maximizing the output for an opportunity cost, 
or alternately, minimizing the opportunity cost of producing an output [63]. When a state of 
resource allocation is achieved at which point it is impossible to reallocate resources without 
causing an uncompensated reduction in the wellbeing or utility of another individual, this is 
referred to as Pareto-efficiency or alternatively, allocative efficiency [63]. Technical efficiency 
refers to the relationship between resources and, in the health sector, health outcomes. 
Technical efficiency is achieved when the maximum achievable output is produced using the 
resources that are technically necessary to produce that output [63, 68].  Lastly, cost 
efficiency refers to a state in which an output is produced using the least costly combination 
of resources whilst maintaining technical efficiency [63, 69]. 
Health Equity 
Health equity refers to the absence of avoidable disparities in health, irrespective of the 
social, demographic, economic or geographic characteristics [70], and is an important 
consideration in health policy and resource allocation decisions.  Equity is informed by a range 
of theoretical approaches such as egalitarianism and libertarianism. The prevailing approach 
espoused by a society will govern the manner in which equity is considered. In Australian 
society, egalitarianism has been the dominant philosophical approach underpinning cultural 
and political attitudes and policy [71]. The most notable outcome of this in the health sector 
is the national public health insurance scheme (Medicare) that is available to all Australian 
citizens, irrespective of income or wealth. Health equity in a country such as Australia is based 
on the notion that all people should have the opportunity to attain their full health potential 
in the absence of systematic disparities [72].   
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Value in health care 
The growth in health expenditure has contributed to an increased focus on ensuring value in 
health care expenditure [73]. Value, in this context, refers to the desirability of an 
intervention, technology or resource due to the benefits associated with it, such as enhanced 
effectiveness. Building on this, value in health care (expenditure) is measured by outcomes 
and costs, rather than metrics such as number of surgeries performed or the number of 
nurses employed [74].  Value in health care (expenditure) refers to all stakeholders working 
together to maximize the efficient use of resources to achieve outcomes needed by patients 
or the community [63]. The field of health economics is well-placed to contribute to this 
change in focus. Data from high quality clinical and epidemiological studies can be 
incorporated into economic analyses to help inform decisions around health resourcing to 
maximize value in decision making.  
1.2.3 Health economic evaluations 
One of the primary purposes of conducting economic evaluations in the health care sector is 
to inform the decision making process regarding the efficient use of limited resources [69].  
To this end, health economic evaluations must involve the quantification of the costs and 
effectiveness associated with an intervention or policy and the next best alternative, so called 
full economic evaluations.  
There are three commonly used forms of full economic evaluations: cost-benefit analysis, 
cost-effectiveness analysis and cost-utility analysis. Cost-benefit analyses measure the 
resources used to provide an intervention and the outcomes associated with it, in monetary 
units. The underlying principle of this form of analysis is that if the benefits are greater than 
the costs, social welfare will be improved [64]. One of the limitations inherent in this approach 
is the need to value benefits or outcomes in monetary units, which can be difficult to 
accomplish in some circumstances [69].  In several cost-benefit analyses, a value of 100,000 
United State Dollars (USD) has been used for one year of life, and USD6 million for a human 
life [75]. Calculating the value of a human life is a difficult task from both technical and 
philosophical perspectives [64, 76].   
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Cost-effectiveness analysis avoids the need to value outcomes or effects in monetary units, 
instead measuring these in health units. There are two forms of cost-effectiveness analysis: 
the standard approach measuring effectiveness on a unidimensional scale (such as life years 
gained or cases detected), and cost-utility analysis, which employs measures of effectiveness 
such as quality adjusted life years (QALYs).  QALYs combine quality of life with quantity of life, 
and allow for comparison across different interventions (see Section 1.2.5).  
There are also several forms of partial economic evaluations, but these cannot be used to 
inform questions of efficiency. Partial health economic evaluations are limited to 
consideration of the costs associated with one of more intervention or health state, or 
alternatively, they evaluate the costs and consequences of one intervention with no 
comparator [77].  A cost of illness study, a commonly conducted form of economic analysis, 
quantifies the economic burden associated with a condition.   
In all forms of economic analysis, a perspective is adopted, such as that of the payer, the 
patient or society. Relevant costs associated with the condition of study are then calculated 
and reported from that perspective. Different types of costs can be reported, depending on 
the aim of the study. Over the past 20 years, development regarding the concepts and 
terminology around types of costs has occurred. As health economics has its foundations in 
the field of economics, costs have commonly been reported using conventional terminology 
of direct, indirect and intangible costs. It is generally agreed that direct costs include all costs 
arising from the utilization of goods and services related to a health condition or an 
intervention of study. Over recent years, there has been an increasing number of papers 
published that have broken these costs down to health sector and other sector costs to 
further increase understanding of where costs are incurred [78-80]. Indirect costs typically 
refer to productivity losses or time-loss costs, which are calculated using either the human 
capital approach or the friction cost method [81]. The human capital approach includes all 
time not worked as lost productivity, whereas the friction cost method only counts 
productivity loss for the time until another worker can take over the role.  There are several 
aspects of costing that continue to be debated, with no clear consensus achieved. The 
approach to cost studies adopted in this study is that it is best informed by the target audience 
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of the analysis, the population and the intervention or disease being studied. 
1.2.4 Health state utility values 
Utility, in health economics, refers to an individual or society’s preference for specific health-
related states and are used as the quality of life component in calculating a QALY [63, 69]. 
Utility may be measured in multiple ways, some of the more common approaches are time-
trade off and standard gamble exercises, and multi-attribute utility instruments (MAUIs) [82].  
The time trade-off approach involves providing participants with two alternatives: a chronic 
health state for time t (life expectancy for the chronic condition), and full health for x amount 
of time, followed by death. The amount of time (x) in full health is varied until the participant 
becomes indifferent to the alternatives. The utility is thus derived: x/t.  
An alternative approach is the standard gamble in which participants are provided with two 
alternatives to choose between. The first alternative has two probability-based outcomes: 
returning to full health after t years (probability=p), or immediate death (probability=1-p). 
The second alternative is a certain outcome in which the participant remains in a chronic 
health state for life. The probability (p) is varied until the participant is indifferent towards 
the alternatives. The utility score for the condition of interest is this final probability [63, 69].  
MAUIs are commonly used in cost-effectiveness analyses as they provide a straightforward 
approach to measuring utilities [83]. The most commonly used MAUIs are the EuroQol-5D 
(EQ-5D), Short-Form 6D (SF-6D) and Health Utilities Index (HUI) instruments.  The Assessment 
of Quality of Life (AQoL) instruments, which were developed in Australia, have been gaining 
popularity in recent years due to their superior level of sensitivity to various health states, 
particularly those with a psychosocial component [84]. Whilst each MAUI has their strengths 
and limitations, they provide an effective method to elicit utility data from clinical and 
epidemiological studies. 
1.2.5 Quality adjusted life years (QALYs) 
QALYs are a commonly used measure of effectiveness in cost-utility analyses. National 
funding bodies such as the the Australian Government’s Medical Services Advisory Council 
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(MSAC) and the Pharmaceutical Benefits Advisory Council (PBAC) and the UK’s National 
Institute for Health and Care Excellence (NICE) prefer QALYs to be included in assessments of 
new technologies and interventions. The QALY provides a metric that allows for comparison 
across different interventions. Calculation of a QALY is carried out with the following formula: 
𝑄𝑄𝐴𝐴𝐴𝐴𝐴𝐴 = 1 × 𝑈𝑈 
Where U is the utility value associated with that year of life. A QALY can be calculated over 
multiple years using the formula:  
QALY = � 𝐹𝐹𝑖𝑖𝑈𝑈𝑖𝑖(1 + 𝑑𝑑)𝑡𝑡𝑇𝑇=𝑚𝑚𝑚𝑚𝑚𝑚
𝑡𝑡=1
 
Where Fi is the function of the probability that the individual is alive at each year, d is the 
discount rate (see Section 1.2.8) and Ui is the utility value for each year [85].  This measure 
facilitates the quantification of the differences in effectiveness between two interventions 
with differing morbidity and/or mortality impacts, allowing for the calculation of an 
incremental cost-effectiveness ratio (ICER).  
1.2.6 Incremental cost-effectiveness ratio (ICER) 
An ICER is a summary statistic of the cost-effectiveness of an intervention, and estimates the 
cost associated with the gain of one additional QALY. The numerator of the ICER incorporates 
the costs of the status quo or other comparator subtracted from the cost associated with the 
new intervention. Cost-offsets related to a new treatment should be taken into account. The 
denominator comprises the effectiveness associated with the status quo subtracted from the 
effectiveness associated with the new intervention. This allows for the calculation of an ICER 
associated with the new intervention.  The formula to calculate an ICER is:  
𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 = Cost (𝑛𝑛𝑛𝑛𝑛𝑛) − Cost (𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑞𝑞𝑠𝑠𝑞𝑞)Effectiveness (𝑛𝑛𝑛𝑛𝑛𝑛) − Effectiveness (𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑞𝑞𝑠𝑠𝑞𝑞) 
A cost-effectiveness plane is a useful way of understanding potential ICERs (Figure 1.4). If the 
new intervention is less costly and more effective than the status quo (which sits at the point 
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where the x and y axes intercept), then the new intervention is said to dominate the status 
quo. Alternately, if the new intervention is more costly and less effective, then it is dominated 
by the status quo. Frequently, a new intervention will be in the remaining two quadrants: 
either more costly and more effective, or less effective and less costly, than the status quo.  
Figure 1.4: Cost-effectiveness plane [86] 
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assessments, the recommended discount rate for costs and effects varies by countries. In the 
US a discount rate of 3% is recommended [91], a rate of 3.5% is recommended in the UK [92], 
and in Australia, a higher rate of 5% is recommended [93]. The formula to discount a cost or 
effect in arrears is: 
𝑃𝑃𝑃𝑃𝑛𝑛𝑠𝑠𝑛𝑛𝑛𝑛𝑠𝑠 𝑣𝑣𝑠𝑠𝑣𝑣𝑠𝑠𝑛𝑛 =  𝑋𝑋(1 + 𝑃𝑃)𝑠𝑠 
 where X is the outcome of interest (the cost of effect), r is the discount rate and t is the time, 
commonly the number of years in the future.   
1.2.9 Economic modelling in health economic evaluations 
Modelling is an approach applied in health economic evaluations that allows for the 
extrapolation of costs and health outcomes in the absence of real-world data. This is a 
particularly useful approach when it is improbable that real-world data can be obtained due 
to resourcing, ethical or time horizon considerations [94]. Modelling allows for the 
comparison of multiple interventions over variable time horizons within hypothetical cohorts.  
Decision tree analysis is a commonly used approach in health economic modelling. The 
structure of a decision tree represents potential clinical pathways, with preferably evidence-
based estimates of the likelihood of particular events occurring governing progress of the 
hypothetical cohort through the tree.  The probabilities of events will be influenced by the 
interventions being considered. In turn the costs and effectiveness of competing 
interventions, and their ICERs can be calculated.  
An advanced form of a decision tree is the Markov model. This type of model consists of 
discrete states which the hypothetical cohort can move between over time. Movement 
between these Markov states is guided by transition probabilities. Each movement by the 
cohort occurs over a discrete time period (e.g. 1 year), referred to as a ‘Markov cycle’.  Upon 
completion of one Markov cycle, the cohort commences a subsequent cycle in the Markov 
states determined by the transition probabilities for the Markov state they were just in. 
Movements or transitions will occur for a predetermined number of cycles or until everyone 
transitions into an absorbing state. The key feature of the Markov model is ‘memorylessness’, 
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in that transition between states is independent of past or future states, allowing for 
stochastic progress through the model.  This is particularly useful when modelling chronic 
health states such as haemochromatosis.  
1.2.10 Summary of health economics 
Health economic evaluations provide important information that can aid decision makers in 
the decision making process This thesis brings together many of the concepts introduced 
above, in order to establish health economic evidence for screening for haemochromatosis. 
This evidence encompasses the quantification of both the economic and health-related 
quality of life burdens associated with the condition, and the cost-effectiveness of population-
based screening for haemochromatosis in Australia.  
1.3  What is the need for health economic evaluations of haemochromatosis and 
related interventions in Australia?  
Population screening programs for hereditary haemochromatosis have been proposed in 
several countries with high rates of prevalence [28, 34, 95-98]. Decisions regarding the 
implementation of population screening programs are largely based on the screening criteria 
published by Wilson and Jungner in 1968 (Textbox 1) [99] . Haemochromatosis is a condition 
that meets these criteria [100], with the exception of criterion point 9: ‘The cost of case 
finding (including diagnosis and treatment of patients diagnosed) should be economically 
balanced in relation to possible expenditure on medical care as a whole’  [99]. To date, a lack 
of robust health economic evidence for haemochromatosis screening programs has been 
cited as a barrier to implementation of such a program [34, 101-103].  To address this, a 
systematic review was undertaken to evaluate the quality of health economic evidence for 
haemochromatosis screening (Chapter 1).  Whilst almost all studies concluded that screening 
was cost-effective, most contained flawed assumptions and/or methodological limitations, 
thereby reducing the validity of the results. Further, four studies employed utility values of 
unidentified sources when evaluating the cost-effectiveness of screening.  The values for 
health states including asymptomatic haemochromatosis, cirrhosis of the liver, heart disease 
and type 2 diabetes were higher than reported for comparable normative population utility 
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data, likely leading to underestimates in gains of effectiveness of screening. In addition, the 
systematic review did not identify any literature reporting on the economic burden associated 
with haemochromatosis. The conclusions of this review concurred with statements regarding 
the paucity of robust health economic evidence for screening for haemochromatosis. The 
gaps identified in this review informed the subsequent direction of the studies in this thesis, 
as outlined in Section 1.4.  
 Textbox 1: Wilson and Jungner’s screening criteria [99]  
1. The condition sought should be an important health problem; 
2. There should be an accepted treatment for patients with recognized disease; 
3. Facilities for diagnosis and treatment should be available; 
4. There should be a recognizable latent or early symptomatic stage; 
5. There should be a suitable test or examination; 
6. The test should be acceptable to the population; 
7. The natural history of the condition, including development from latent to declared 
disease, should be adequately understood; 
8. There should be an agreed policy on whom to treat as patients; 
9. The cost of case finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical 
care as a whole; 
10. Case finding should be a continuing process and not a “once and for all” project. 
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1.4  Research objectives 
The specific research aims examined within this thesis are outlined below: 
1. To evaluate all published health economic evidence for hereditary haemochromatosis 
(Chapter 2). 
2. Quantify the health-related quality of life burden associated with hereditary 
haemochromatosis (Chapter 3). 
3. Quantify the economic burden associated with hereditary haemochromatosis in 
Australia, from the perspective of the patient, government and society (Chapter 4). 
4. Construct and validate a health economics model for haemochromatosis employing 
Australian specific cost and utility data (Chapter 5).  
5. Evaluate the cost-effectiveness of population screening programs for Australia 
(Chapter 6).  
1.5  Structure of this thesis 
Chapter 1 provides an overview of hereditary haemochromatosis and health economic 
concepts.  
Chapter 2 presents a systematic review of all health economic studies for hereditary 
haemochromatosis. Studies included are predominantly focused on economic aspects of 
screening interventions. 
Chapter 3 presents data on the health-related quality of life burden associated with 
haemochromatosis using health state utility values.  
Chapter 4 provides an estimate on the economic burden associated with haemochromatosis 
in Australia.   
Chapter 5 describes the construction and validation of a new model for screening for 
haemochromatosis in Australia. This papers presents data on the projected life expectancy 
and lifetime costs of C282Y homozygotes, along with the costs associated with the current 
approach to screening in Australia. 
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Chapter 6 presents the results of the cost-effectiveness model for adult and neonatal 
screening strategies. Costs and effectiveness of each strategy are presented, along with an 
estimate of the number of correct diagnoses from each strategy. 
Chapter 7 discusses and summarises the material presented in this thesis, and makes 
comments regarding the future directions for research in this field.
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Chapter 2: A systematic review and narrative synthesis of 
health economic studies conducted for hereditary 
haemochromatosis 
2.1 Preface 
This chapter describes a systematic review of all health economic data pertaining to 
haemochromatosis. The review summarises the interventions studied, methodological 
approaches employed, underpinning assumptions and a synthesis of results. Most of the 
identified literature related to the evaluation of the cost-effectiveness of population 
screening programs. The health economic methodologies employed and the quality of 
epidemiologic evidence incorporated into these models were flawed in many studies, 
reducing their validity and generalizability. The review highlighted gaps in the current 
literature, which informed the work presented in subsequent chapters.  
 
This chapter has been published in Applied Health Economics and Health Policy (Appendix 
2A).  
de Graaff, B., Neil, A., Sanderson K, Si, L., Yee, K.C. & Palmer AJ. “A Systematic Review and 
Narrative Synthesis of Health Economic Studies for Hereditary Haemochromatosis” Applied 
Health Economics and Health Policy. October 2015; 13(5): 469-83. 
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2.2 Abstract 
Background:  Hereditary haemochromatosis (HH) is a common genetic condition amongst people of 
northern European heritage.  HH is associated with increased iron absorption leading to 
parenchymal organ damage and multiple arthropathies. Early diagnosis and treatment prevents 
complications. Population screening may increase early diagnosis, but no programs have been 
introduced internationally: a paucity of health economic data is often cited as a barrier.  
Objective: To conduct a systematic review of all health economic studies in HH.  
Methods: Studies were identified through electronic searching of economic/biomedical databases. 
Any study on HH with original economic component was included. Study quality was formally 
assessed. Health economic data were extracted and analysed through narrative synthesis.  
Results: Thirty-eight studies met the inclusion criteria. The majority of papers reported on costs or 
cost-effectiveness of screening programs. Whilst most concluded screening was cost-effective 
compared with no screening, methodological flaws limit the quality of these findings. Assumptions 
regarding clinical penetrance, effectiveness of screening, health state utility values (HSUVs), 
exclusion of early symptomatology (such as fatigue, lethargy and multiple arthropathies) and 
quantification of costs associated with HH were identified as key limitations. Treatment studies 
concluded therapeutic venepuncture was the most cost effective intervention.  
Conclusions: There is a paucity of high quality health economic studies relating to HH. The 
development of a comprehensive HH cost-effectiveness model utilising HSUVs is required to 
determine whether screening is worthwhile. 
 
2.3 Introduction 
Hereditary haemochromatosis (HH) is an autosomal recessive disorder characterised by increased 
iron absorption. It is one of the most common genetic disorders amongst people of northern 
European ancestry [1-3]. A defect in the HFE gene has been found to be the predominant cause of 
HH with several mutations identified:  C282Y, H63D and S56C [4-6].  Between 80 and 90% of people 
diagnosed with iron-overload related to HH have been found to be homozygous for the C282Y 
mutation [7, 8]. The H63D and S56C mutations are less commonly associated with iron overload or 
related disease unless present with the C282Y mutation, i.e. a compound heterozygote [9, 10].  
Prevalence of C282Y homozygosity is highest amongst people of northern European ancestry with a 
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prevalence of approximately 1 in 150 to 200, whilst in people of other ancestries it is considerably 
lower: 1 in 300 Hispanics; 1 in 1,000 Native Americans; 1 in 1,000, 000 Asians [10-14]. Amongst 
people of northern European ancestry, the prevalence of C282Y/H63D heterozygotes is relatively 
common, being found in approximately 1 in 50 people, i.e. 4 times as common than the C282Y 
homozygote, whilst C282Y/S56C heterozygote prevalence is approximately 1 in 200, i.e. as common 
as the C282Y homozygote [5, 15]. In turn, a much smaller proportion of these compound 
heterozygotes will develop iron overload as compared with the C282Y homozygotes. 
 
Clinically, HH is characterised by increased serum iron and iron stores [2, 16, 17]. The excess iron is 
stored in the parenchymal tissues of the liver, heart and pancreas. Early symptoms of HH-related 
iron overload include fatigue, lethargy, loss of appetite, and joint pain, most commonly in the fingers 
[18, 19]. Subsequent symptoms may include multiple arthropathies, Type 2 diabetes, impotence, 
fibrosis, cirrhosis and carcinoma of the liver, and heart disease [20-24]. The rate of clinical 
penetrance of HH has been somewhat controversial in the literature. This is in large part due to 
different definitions of penetrance: some authors have defined HH penetrance as liver cirrhosis, 
whilst others have included elevated iron studies through to cirrhosis and hepatocellular carcinoma. 
Recent epidemiological literature has reported penetrance (defined as early symptoms through to 
irreversible organ damage) of C282Y homozygosity to be 28.4% for males and 1.2% for females [11].   
 
HH is currently diagnosed through targeted and/or opportunistic iron studies, most commonly 
transferrin saturation (TfS) and serum ferritin (SF) (phenotyping). If TfS and SF are found to be 
elevated, in the absence of other contributing factors HH is suspected and a genetic test may be 
ordered (genotyping) [15, 25].   Treatment is effective and straightforward, consisting of regular 
therapeutic venepuncture (TV). If this is contraindicated, erythrocytapheresis is an alternative 
treatment in which red blood cells are separated from whole blood via apheresis [26].  
 
Due to the non-specific nature of the early symptoms of iron overload (in that they can be 
experienced by people with iron levels within the clinically normal range), diagnosis is often delayed 
until after irreversible organ damage has occurred [27, 28]. Population screening programs have 
been suggested as a way to reduce the burden of disease associated with HH [29-38]. There are 
several options for HH screening, varying with regard to who should be screened: whole populations 
or sub-populations at greatest risk; and how they should be screened: genotyping and/or 
phenotyping. 
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The effectiveness of large scale screening for HH involves three main parameters: uptake of 
screening; sensitivity and specificity of screening tests; and adherence to treatment.  Studies 
reporting on uptake of HH screening have been conducted in a wide range of settings with differing 
populations and screening techniques. Just one randomised controlled trial has been conducted, 
which involved random allocation of UK-based general practice patients to either phenotype or 
genotype screening [39]. In this study an uptake rate of 32% was reported. A pilot screening 
program in Australian schools reported an uptake rate of 33% [40], whilst a second Australian study 
investigating workplace screening reported 5.8% uptake [41]. In contrast to these studies, a large 
study in a Norwegian county which invited all inhabitants aged over 20 years of age to be screened 
for HH in combination with other conditions reported an uptake rate of 70% [42].  
 
The sensitivity and specificity of biochemical tests for HH iron overload depend on the cut-off points 
used.  The HEIRS study, which involved screening almost 100,000 participants for HH, concluded that 
TfS, a commonly used diagnostic test, has a low sensitivity and is highly biologically variable, thereby 
limiting its utility as a screening tool [43]. The authors also noted that whilst SF increases with iron 
overload, several other factors can also cause elevated SF levels, such as fatty liver and alcohol 
consumption, which decreases its sensitivity as a screening tool [43]. With regard to genotyping for 
C282Y homozygotes, a systematic review reported sensitivity ranged between 91.3% and 92.4%, and 
specificity between 98.8% and 100% [44]. 
 
Few studies have reported on adherence to HH treatment. In a workplace setting, compliance to 
treatment (TV) was reported to be 100% over a 12 month period [45]. However, a longitudinal study 
following participants over nine years reported that whilst adherence was high during the early 
stage of the study (80%), it decreased linearly to 33% in the ninth year [46]. 
 
Early symptoms of iron overload are vague and can be missed by physicians. A delay in diagnosis of 
HH could lead to end organ damage [27, 28]. Early detection and treatment of HH can improve 
clinical outcomes of patients with HH and result in normal life expectancy [47]. As such, strategies 
for early detection can reduce the burden of disease associated with HH. Different approaches have 
been suggested to increase the rate of early diagnosis, including enhanced training of physicians in 
combination with cascade screening and population screening. Whilst HH fulfils several of the 
criteria set out by the World Health Organization for diseases that may warrant population screening 
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programs [48], a lack of rigorous health economic evaluations to support efficient resource 
allocation has been cited as a barrier [29, 30, 41, 49]. 
 
To our knowledge, no comprehensive systematic reviews of health economic studies have been 
published on all approaches to HH screening programs or treatment. This study seeks to ascertain 
what economic evidence is available to support: 1. Population or targeted screening for HH; and 2. 
Treatment of HH.  
2.4 Methods 
The systematic review was performed using the Campbell and Cochrane Economics Methods Group 
(CCEMG) guidelines [50, 51]. Studies that included full or partial economic evaluations relating to HH 
were included. Full economic evaluations involve a comparison of the costs and consequences of 
two or more alternative interventions; partial economic evaluations involve examination of costs 
and/or consequences of either one or more interventions [52]. The target interventions were kept 
broad, allowing for inclusion of all possible screening and treatment studies. Studies using 
hypothetical populations in decision models were also included. No limits of language of publication 
were included. The only exclusion criteria were the absence of any health economic data reported 
within the publication or reviews of other work. 
 
Information sources 
Five health economic/economic databases- Centre for Reviews and Dissemination (CRD) including 
Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database (HTAD) 
and NHS Economic Evaluation Database (NHSEED), Cost Effectiveness Analysis Registry (CEA 
Registry), and EconLit, and four biomedical databases - PubMed, Scopus, Embase (including 
Medline), and the Cochrane Collaboration were searched in June 2014 using a pre-defined search 
strategy detailed in Table 1. In addition, hand searching of citations from relevant papers, previous 
reviews and industry documents was performed.  The search strategy comprised an abridged PICO 
standard (which references the participants, interventions, comparisons and outcomes), Medical 
Subject Headings (MeSH) terms and economic search filters. Following this initial search, review of 
title and abstract was conducted to finalise included studies.  
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Table 1: Search strategy, conducted June 2014 
 
Long Search #1 AND #2 AND #3 NOT #4 
#1 Economic filters (outcome) "economic evaluation" OR cost OR effectiveness OR "cost 
effectiveness" OR "cost benefit” OR “cost analysis” OR "cost utility" 
OR CUA OR CBA OR CEA OR "health economic*" OR economic* OR 
“direct cost” OR “indirect cost” OR “intangible cost” OR “health care 
cost” in Title, Abstract or Keywords 
#2 Participant haemochromatosis OR  hemochromatosis OR “bronze diabetes” OR 
“iron overload” in Title, Abstract or Keywords 
#3 Intervention screening OR “health screening” OR prevention OR “early 
intervention” OR treatment OR prevent in Title, Abstract or Keywords 
#4 Excluding NOT animal in Title, Abstract or Keywords  
MeSH Search (("Costs and Cost Analysis" explode all trees [Mesh] OR "Cost-Benefit 
Analysis" explode all trees [Mesh] OR "Cost of Illness" explode all 
trees [Mesh] OR "Cost Savings" explode all trees [MESH]) AND 
“Haemochromatosis” explode all trees [Mesh] OR 
“Hemochromatosis” explode all trees [Mesh])  
 
 
Data collection process 
Data were extracted on key parameters, including study design, sample size, duration of screening 
program, authorship, year of publication, country in which the study was conducted and study 
characteristics (screening parameters, setting, target group). Health economic metrics such as type 
of evaluation, year of assessment, currency, perspective, costs assessed, time frame, discount rate, 
methods for measuring and valuing outcomes and summary measure of efficiency calculated were 
recorded. Health economic studies were evaluated using the British Medical Journal Economic 
Evaluation Working Party (BMJ checklist) [53].  The BMJ checklist consists of 35-items, and a 36th 
item on generalizability. Each item was given a score: ‘1’ if the item was performed, ‘0’ if it was not 
and ‘N/A’ if the item was not applicable to the study. Equal weighting was given to each item. The 
number of ‘1’ items was summed, and using the number of applicable items as the denominator the 
proportion was calculated, providing the final score as a percentage [54]. Studies were defined as 
low (<50%), moderate (50-75%) and high quality (>75%). 
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Figure 1: Flow diagram of study selection 
 
 
 
 
 
 
 
 
 
 
2.5 Results 
Study selection 
A flow diagram of the search strategy is shown in Figure 1. The electronic search yielded 2,026 
studies. Economic databases generated 34 studies (CRD, including DARE, HTAD and NHSEED (n=28), 
CEA Registry (n=4), and EconLit (n=2), and biomedical databases produced 1,992 studies, (PubMed 
(n=872), Scopus (n=643), Embase (including Medline; n=475), the Cochrane Collaboration (n=2)).  
After removal of duplicates, 1,066 studies were reviewed against the inclusion/exclusion criteria. 
1,028 papers were excluded following screening of title and abstract. Papers that were excluded 
were neither partial nor full economic evaluations relating to HH. Thirty-eight studies met the 
inclusion criteria. Study selection was carried out by BdG and LS and data extraction conducted by 
BdG. 
Characteristics of the Economic Analyses 
Study Characteristics 
Characteristics of the studies are presented in brief in Table 2 (and in detail in the appendix), 
grouped by intervention and methodological quality. Scores derived from the BMJ checklist are 
included in Table 2, however these should be interpreted with caution. The checklist is designed for 
authors to ensure they adhere to methodological requirements: it is not ideally suited to scoring the 
Initial Search (n=2026) 
Title reject (n=960) 
     DUP (n=960) 
  
Title accept (n=1066) 
Abstract reject (n=1029) 
     DUP: 43 
     NHE:944 
     MRE: 42 
  
Abstract accept (n=44) 
Paper accept June 2014 (n=38) 
  
Paper reject (n=8) 
     DUP: 1 
     MRE:6 
     ABS:1 
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robustness of the results of those papers. For example, with regard to the criterion on effectiveness, 
whilst a study may meet this criterion (i.e. stating the source of effectiveness data), the quality of 
this data is not captured by the checklist. Without proper consideration of the quality and 
appropriateness of the evidence and methodology employed, the robustness of results obtained 
remains uncertain. To balance this concern, the quality of the data that was used in economic 
evaluations will be discussed following a review of the more general characteristics of analyses. 
 
Ten countries were represented: 11 studies originated from the US and seven from Canada. The 
remaining studies were from Germany, UK, Australia, the Netherlands, Norway, France, Switzerland 
and Italy. One paper was published in French, which was translated by AP. Publications spanned 25 
years, from 1989 to 2014.  
 
Of the 38 papers accepted, most examined costs associated with screening strategies (n=33); three 
reported costs associated with treatment for HH [55-57]  and single papers reported on hospital 
costs associated with HH [58] and financial implications of allogeneic use of HH blood donations [59].  
Chapter 2: A systematic review and narrative synthesis of health economic studies conducted for hereditary 
haemochromatosis  
  
36 | P a g e  
 
Table 2: Characteristics of studies 
Screening studies 
(n=33) 
Score 
(BMJ 
check-
list) 
Study design Population Screening strategies Perspective Outcomes 
Categorised high quality (n=11); quality score >75% 
Rogowski, 2009 [68] 97% Probabilistic decision 
analytic model, Markov 
modelling; CEA 
Hypothetical cohort of 30year 
old male Caucasians 
1. No screen; 2. Phenotype- TfS x 2; 3. 
Sequential- elevated TfS and genotype;  
4. genotype- C282Y (all strategies are 
modelled for population (P) and cascade 
(C) screening separately) 
Third party 
payer 
No screen cf. strategy 3C= €41425; strategy 
3P=€123996; 
strategy 4P=€161248  
Gagne et al, 2007 [7] 94% Computer simulation, 
decision model (decision 
tree); CEA 
Hypothetical cohort from 
Quebec 
165 algorithms of screening test, including 
phenotyping and genotyping 
Health 
system 
Cost saving: phenotype screen (LE=75.6, CAN$121)  
v. no screen v. (LE=68.6, CAN$143) 
Bryant et al, 2009 [44] 94% Decision analysis model 
(decision tree) 
Hypothetical cohort: 45 year 
old male; family members 
If raised TfS and SF: genotype v. liver 
biopsy: family: biochemical phenotype v. 
genotype  
Health 
system 
Genotyping v. liver biopsy for male= £216 saved/case 
detected. Biochemical v. genotyping for family 
=£7,982/case detected  
Cooper et al, 2008 [60] 94% Decision analysis model 
(decision tree); CEA 
Hypothetical cohort: 45 year 
old male; family members 
Confirmatory test: genotype v. liver 
biopsy  
Government £73,823 v. 83,068/case detected 
Adams et al, 1995a [61] 88% Decision analysis model 
(decision tree); CEA, CUA 
Hypothetical cohort of blood 
donors and siblings 
No screen v. phenotype (UIBC, TfS, SF) Third party 
payer 
$433,927 v. $307,567$/strategy for donors and 
siblings 
Adams et al, 1995b [62] 88% Decision analysis model 
(decision tree); CUA 
Children of HMZ, aged 10-
40years 
No screen v. phenotype Third party 
payer 
Screening: $5,798/ HMZ identified; incremental cost 
savings:$12  at age 10, $65 at age 20, $245 at age 40 
 
Stuhrmann et al, 2005 
[69] 
 
 
81% 
 
Quasi-experimental; cost 
description 
 
Health insurants 
 
Genotype 
PCR & restriction digest; 2 ASO methods; 
SPOLA; Microarray 
 
Third party 
payer 
 
€11.20/test, €16.35/test, €13.79/test, €15.70/test 
Hickman et al, 2000 [70] 81% Quasi-experimental; cost 
description 
Tertiary hospital patients UIBC Service 
provider 
$2268.77/HH diagnosis 
 
Adams & Valberg, 1999 
[8] 
 
78% 
 
Decision analysis model 
(decision tree); CUA 
 
Hypothetical cohort of 
voluntary blood donors and 
siblings of HMZ 
 
No screen v. phenotype v. genotype 
 
Third party 
payer 
 
$0.97 v. $2.10 to -$178.00 (with varying cost of 
genotype test) (Incremental cost saving/person (c.f. 
no screen)) 
Phatak et al, 1994 [63] 78% Decision analysis model 
(decision tree); CEA 
Hypothetical cohort of 30 year 
old white males 
No screen v. phenotype (TfS), liver biopsy Societal Cost saving 
Patch et al, 2005 [39] 76% Decision analysis model 
(decision tree); CEA; RCT 
General practice patients Phenotype (TfS) v. genotype Government £5.76 v. £9.43/person screened; 
£1440 v. £2358/HH case detected 
Chapter 2: A systematic review and narrative synthesis of health economic studies conducted for hereditary 
haemochromatosis  
  
37 | P a g e  
 
Categorised moderate quality (n=10); quality score 50-75%  
Asberg et al, 2002 [32] 75% Markov model; CUA Hypothetical cohort of 1,000 
males aged 30 
No screen v. phenotype Third party 
payer 
Screening: $250/QALY 
Vardarli* et al, 2009 [73] 71% Quasi-experimental; CEA Hospitalized diabetic patients Sequential: elevated ferritin, TfS,C282Y 
genotyping; elevated TfS, genotyping  
 
Third party 
payer 
€15.60/pt & €4110/HH; €14.25/pt & €3754/HH  
Schoffski et al, 2000 [64] 70% Decision analysis model 
(decision tree); CEA 
Hypothetical cohort of 25year 
old males 
No screen v. genotype Third party 
payer 
Per person tested: €1.62 v. €7.26 
LYG=€4441 
Bassett et al, 1997 [65] 68% Decision analysis model 
(decision tree); CEA 
Hypothetical Phenotype & liver biopsy v. phenotype, 
liver biopsy & cascade v. phenotype & 
genotype   
Government Screening with liver biopsy: $5,079-8,813/ HH 
identified 
Screening with genotyping: $3,954-4,410/ HH 
identified 
Buffone & Beck, 1994 
[67] 
63% Markov model; CEA Hypothetical cohort of 25 year 
old males 
No screen v. phenotype screen and 
treatment 
Societal $605/LYG 
Smith et al, 1997 [74] 62% Quasi-experimental; CEA Workplace Phenotype: TfS; if elevated, fasting TfS, if 
elevated liver biopsy 
Third party 
payer 
$90205/ program 
$39.32$/screening 
$18,041/ HH 
El-Serag et al, 2000 [88] 61% Decision analysis model 
(decision tree); CEA 
Siblings and children of 
probands 
No screen v. phenotyping v. genotyping Societal Strategies ranged between $508-3665/LYG 
Adams & Kertesz, 1992 
[82] 
55% Quasi-experimental; cost 
analysis  
Siblings of probands Phenotype v. HLA typing Third party 
payer 
$1,150-1,450 v. $1,800-2,100 per (screening of a 
family of four) 
Beutler & Gelbart, 2000 
[83] 
50% Non-experimental, 
descriptive study; cost 
description 
n/a Genotyping Laboratory $8.62/test 
Ropert-Bouchet, 2012 
[84] 
50% Non-experimental, 
descriptive study; cost 
description 
People with HH n/a Third party 
payer 
n/a                      
Categorised low quality (n=12); quality score <50%  
Barton et al, 2002 [75] 44% Quasi-experimental; CEA Workplace Phenotype Third party 
payer 
$8,826/HH identified 
Adams, 1998 [76] 42% Quasi-experimental; CEA Children of HMZ Phenotype v. spousal genotyping Health 
service 
$58,200 v. $35,600/strategy 
Jacobs et al, 2005 [77] 40% quasi-experimental; CEA Hospital inpatients No screening guideline v. sequential Third party 
payer 
€2380 v. €2600 (per HH diagnosis pre and post 
guideline implementation) 
Stave et al, 1999 [71] 36% Quasi-experimental; cost 
description 
Workplace Phenotype Third party 
payer 
$27850/program 
Bhavnani et al, 2000 [78] 35% Quasi-experimental; CEA Blood samples from hospital 
inpatients, outpatients and GP 
patients  
Sequential (phenotype followed by 
genotype) 
Laboratory £117/HH identified 
Asberg et al, 2001 [42] 32% Quasi-experimental; CEA General population aged ≥20 
years 
Sequential Third party 
payer 
$390/HH identified 
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Baer et al, 1995 [79] 
 
29% Quasi-experimental; CEA Community health centre; 
males aged ≥30years 
Phenotype  Third party 
payer 
$65,000/HH identified 
Adams et al, 2000 [80] 22% Quasi-experimental; CEA Voluntary blood donors Phenotype (x2) v. genotype UIBC; TfS Service 
provider 
UIBC $5,570/HMZ identified 
Lederle, 1989 [85] 22% Non-experimental; cost 
description 
n/a Phenotype n/s $24,804/HH diagnosis 
Balan et al, 1994 [81] 15% Quasi-experimental; CEA Community health centre Phenotype  Service 
provider 
$5,631-8,447/HH identified 
Timms et al, 2002 [72] 5% Quasi-experimental; cost 
description 
Community-based patients 
diagnosed with 
chondrocalcinosis 
Genotype: PCR/SSP & PCR/RFLP Service 
provider 
£1/test; £64/HH 
Delaveyne et al, 2004* 
[89] 
- Abstract of CEA; model Population screening v. family 
screening 
SF and TfS with confirmatory genotyping 
for C282Y.  
n/s €3.6-19.5 million v. €78,000 ( per program) 
Treatment and other studies (n=5)     
Rombout-Sestrienkova 
et al, 2012 [55] 
 
79% RCT; cost analysis Newly diagnosed HH patients Treatment: phlebotomy v. 
erythrocytapheresis 
Societal €71.49 v. €251.18 (per procedure); 
€4438 v. €3005 
Mariani et al, 2005 [56] 53% Non-experimental-
descriptive, case series; 
cost analysis 
Patients with severe HH Treatment: erythrocytapheresis plus 
erythropoietin v. phlebotomy 
Service 
provider 
€602 v. €35 (Total mean costs) 
Stefashyna et al, 2014 
[57] 
38% Quasi-experimental; cost 
analysis  
Volunteer blood donors whole blood donation v. double-
erythrocytapheresis 
Service 
provider 
USD186 v. 238, but fewer treatments required for 
latter. 
Gribble et al, 2009 [59] 38% Non-experimental; cost 
description 
HH blood donors n/a Service 
provider 
$6000 v. $20345 
Dye et al, 2011 [58] n/a Non-experimental, cost 
analysis 
Hospital morbidity data system  n/a Service 
provider 
$21,349, $2,827 
Note: * abstract only; ~ refers to prevalence of HH and suspected iron overload in population;  Cost saving refers to total cost of caring for a HMZ with no screening minus the total cost of 
screening, calculated for a range of ages. 
ASO allele-specific oligonucleotide; CEA cost effectiveness analysis; CUA cost utility analysis; HMZ homozygote; LYG Life Year gained; n/a not applicable; n/s not stated; PCR polymerase chain 
reaction; RFLP restriction fragment length polymorphism; SF serum ferritin; Sfe serum iron; SPOLA Solid-phase oligonucleotide ligation assay; SSP sequence specific primers; TfS Transferrin 
saturation; UIBC unsaturated 
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Screening 
Of the 22 screening studies, most were quasi-experimental; and almost half (n=14) employed some 
form of modelling. The quasi-experimental studies usually incorporated a cost-effectiveness analysis; 
most modelled studies used decision modelling techniques, most commonly a simple decision tree 
(n=11) [7, 8, 39, 44, 60-66]. In addition, three studies employed Markov modelling [32, 67, 68]. Other 
studies were a combination of quasi-experimental and cost description [69-72], quasi-experimental 
and cost effectiveness analysis [42, 73-81], quasi-experimental and cost analysis [82]. There were 
three non-experimental studies including a cost description [83-85].   
 
The economic perspective of the screening studies was reported as third party payer in 48% of 
studies [8, 32, 42, 61, 68, 69, 71, 73-75, 77, 79, 82, 84, 86, 87]; service provider in 12% [72, 76, 80, 
81]; societal [37, 67, 88], government [39, 60, 65] and pathology laboratory [70, 78, 83] in 9% 
respectively  and health system in 6% [7, 44]. Perspective was not evident in 6% [85, 89].  All 
screening papers reported direct costs only. Unit costs were sourced from government 
reimbursement rates in 19% [7, 32, 42, 65, 68, 88], national/local set/benchmarked prices [39, 44, 
60, 70] or laboratory prices [77, 83, 88] in 9% respectively, health insurance companies [74, 75] in 
6%, and hospital costs [63], laboratory supplier [69] or from an organisation representing medical 
specialists [88] in 3% of studies respectively. The source of cost data was not reported in 50% (n=16)  
[8, 61, 62, 64, 67, 71-73, 76, 78-82, 85, 89].  
 
The majority of studies that used decision analysis methods (n=14) modelled screening programs 
over lifetime (71%) [7, 8, 32, 61-64, 67, 68, 88]. A single modelled study had a time horizon of <1 
year [39], and in four modelling studies the time horizon was either unclear or not stated [44, 60, 65, 
89]. Most quasi-experimental studies used a time horizon of ≤1 year [69-71, 73, 78, 79], and single 
studies used a time horizon of two [42], four [77], five [82] and 11.5 years [75] respectively. In four 
quasi-experimental studies the time horizon was not stated [72, 74, 76, 80]. Of the three non-
experimental studies, two used a time horizon of one year or less [83, 85] and one study did not 
report this [84].  
 
Discount rates were reported in 46% of studies in which this was applicable, most commonly 3% 
annually [55, 61-63, 68, 88]. These studies originated from the USA [63, 88], Canada [8, 61, 62] and 
Germany [68]. A second German study employed differential discounting, using 5% for costs and 0% 
for effectiveness [64].  No discounting of costs or consequences was reported in 46% of screening 
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studies which may have methodologically benefitted from this [7, 32, 39, 60, 75, 84]. The remaining 
studies did not discount costs or consequences as the timeframe of the study did not warrant this, 
i.e. less than 12 months’ time horizon. 
 
Treatment and other economic papers 
Five studies were identified that reported other economic aspects of HH. All studies reported direct 
costs only, with the exception of Rombout-Sestrienkova, who reported both direct and indirect costs 
[55]. Two of the treatment papers reported on studies of a duration greater than one year [55, 57] 
and the third study did not provide a timeframe. No treatment studies reported discounting costs or 
effects. 
 
Studies compared costs between TV and erythrocytapheresis [55], [57], and erythrocytapheresis and 
erythropoietin in comparison with TV [56]. The latter was a case study of three patients, which 
provided clear details regarding the treatment regimen. Of the two studies comparing TV and 
erythrocytapheresis, one was an RCT with a well-defined protocol, which, whilst underpowered, 
provided a useful approach to compare treatment arms [55].  The final study was observational and 
had several methodological shortcomings which limited the validity of the findings [57].    
 
 A further two papers were identified that examined other economic aspects related to HH. Gribble 
and colleagues examined the effect of a potential Food and Drug Administration (FDA) variation on 
use of HH donated blood for allogeneic purposes in the US [59]. Another study was identified that 
reported costs associated with hospitalisation of HH patients in an Australian jurisdiction [58]. 
 
Methodological assessment 
The overall mean quality score of studies was 57.9% (SD=24.6). For screening studies, eleven were 
high quality (33%), ten moderate quality (30%), and 36% (n=12) were low quality. The mean quality 
score of the three treatment papers was 56.58% (SD=21.1), and the two papers reporting other 
economic aspects of HH returned a mean quality score of 47.0% (SD=12.0) 
 
Synthesis of results 
Screening 
Table 2 displays a summary of the study characteristics of the papers, with the full summary in the 
appendix. A large degree of heterogeneity between the studies was identified, in respect to 
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estimates of prevalence, penetrance, uptake of screening, screening approaches, phenotypic 
thresholds, target populations, perspective of the economic analyses and country. Systematic 
reviews that identify studies with a large degree of heterogeneity should not involve a meta-analysis 
of the data [90].  A narrative synthesis was therefore undertaken, employing the approach outlined 
by Popay and colleagues [91]. 
 
Whilst the majority of studies reported both phenotypic and genotypic screening programs to be 
cost-effective, the evidence regarding effectiveness was of low quality in some studies. Effectiveness 
of screening programs can be measured through uptake of screening amongst the target population, 
adherence to treatment and number of cases detected. These estimates are, in turn, dependent 
upon prevalence and penetrance estimates. 
 
Both prevalence and penetrance estimates for HH are highly variable and difficult to precisely 
ascertain, which necessarily increases uncertainty in modelled studies. The modelled studies 
considered in this review used population prevalence estimates for C282Y homozygosity ranging 
between 0.2% and 0.7% for persons of northern European heritage [7, 8, 32, 44, 60-65, 67, 68]. A 
small number of studies employed sensitivity analyses around prevalence estimates  [7, 63, 68, 89], 
which were similar to recent epidemiological estimates of C282Y homozygosity of between 0.44% 
and 0.68% amongst persons of northern European heritage [11, 13]. Clinical penetrance rates were 
highly variable, in part due to different definitions of penetrance being employed. Regarding C282Y 
homozygotes, estimates for males ranged between 0.035 and 0.76 [7, 8, 32, 44, 60-64, 66-68] and 
for females 0.28 and 0.32 [8, 44, 60-62]. 
 
Uptake of population screening programs was either not considered or considered to be absolute in 
almost all models [7, 8, 32, 44, 60-67]. Where probability estimates of uptake of screening were 
reported, these varied considerably. Estimates were highest amongst voluntary blood donors (0.97) 
[80], a workplace (0.85) [75] and a general Norwegian population (0.70) [42]. More conservative 
estimates were used for German health insurants (~0.003) [69], and from a UK RCT (0.32) [39]. One 
study assumed the probability of interest in population screening to be 0.805, and of this group, an 
uptake rate of 0.058. Adherence to treatment was only considered in five modelled studies. Four of 
these used estimates of between 80% and 90% [32, 61, 62, 64], whilst a fifth used a more 
conservative estimate of 33% [68]. According to the author of this latter study, the use of this lower 
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estimate was based on the commonly used assumption of 50% for adherence to drug treatment, 
and that a lower rate for more demanding interventions should be used. 
 
The screening strategies that were examined included biochemical phenotype (serum ferritin, 
transferrin saturation, unsaturated iron binding capacity, alanine transaminase), biochemical 
phenotype with confirmatory liver biopsy, genotype and sequential (combination of both phenotype 
and genotype or different phases for biochemical tests).  The approaches to screening varied 
considerably, particularly for biochemical investigations (see Table 3). Genotyping was used to 
confirm a diagnosis of HH in most studies published after 1999, i.e. following the identification of the 
HFE mutation [4].   
 
For iron studies, the cut-off points used to indicate iron overload and/or a diagnosis of HH varied:  
TfS for mixed cohorts ranged between ≥45-60% [39, 44, 65, 73, 74, 77, 78, 80, 92], ≥50-55% for 
females [7, 8, 42, 61, 62, 71, 75, 76] and ≥55-60% for males [7, 8, 42, 61-63, 71, 75, 76, 79]. The cut-
off points for SF were <110µg/l - 300 µg/l for females [7, 8, 44, 71, 75, 82]; 200µg/l-500µg/l for males 
[7, 8, 71, 75, 79, 82] and 280-400µg/l for a mixed cohort [77].  HFE genotyping was conducted for 
either C282Y [8, 44, 60, 64, 68, 69, 73, 76, 80, 89] or both C282Y and H63D mutations [7, 72, 78, 88, 
93, 94] .  
 
The heterogeneity of biochemical testing approaches makes comparison across studies not possible. 
Whilst TfS and SF were commonly used in economic evaluations of screening, investigators from the 
HEIRS study found that non-fasting and fasting TfS and SF were not ideally suited to this task [27]. 
Genotyping was included in most evaluations following the development of the test for the mutation 
of the HFE gene.  In a systematic review, sensitivity of the C282Y genotype test was reported to 
range between 91.3% and 92.4%, and specificity between 98.8% and 100% [44], making this a more 
effective test for HH screening. 
 
Assumptions regarding prevalence, penetrance, sensitivity and specificity of tests, uptake of 
screening and adherence to treatment were highly variable across modelled studies, reflecting the 
paucity of robust data in the earlier years of economic analysis of HH-related interventions. 
However, more reliable probability estimates taken from epidemiological studies have improved the 
validity of recent CE models. 
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Table 3: Biochemical phenotype screening approaches 
Approach to biochemical phenotype screening 
Number of 
studies 
TfS (non-fasting) followed by TfS (fasting), SF [8, 32, 37, 42, 62, 65, 67] 
TfS followed by genotype [65, 68] 
TfS [80, 88] 
TfS (non-fasting) [39, 65] 
TfS (non-fasting) followed by TfS (fasting) [74] 
TfS, SF followed by TFS, SF~ [77] 
TfS followed by TfS [68] 
TFS (fasting followed by TFS, SF, FBC, AST, ALT (fasting) [79] 
UIBC followed by TfS followed by SF [61] 
ALT followed by TfS  & SF followed by SF followed by genotype [78] 
UIBC [80] 
UIBC followed by TfS [7] 
UIBC followed by genotype [7] 
UIBC followed by TFS followed by SF, genotype [70] 
SI [88] 
SI, TfS (fasting) followed by SF [76]  
SI (fasting) followed by SI, TIBC, SF* [92] 
TfS followed by UIBC [7] 
TI followed by SF [71] 
7 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Note: Studies reported multiple screening strategies; sequential testing is carried out when the initial test result is elevated 
* The second stage of testing is conducted on the initial blood sample but in a different laboratory 
~ One of these tests is conducted after over fasting 
Gagne et al investigated 165 screening algorithms. Only the three most cost-effective are included in this table. 
Abbreviations: TfS: Transferrin saturation, SF: serum ferritin; UIBC: Unsaturated iron binding capacity; SI: serum iron; ALT: 
alanine transaminase; TI: Transferrin index 
 
 
Utilities 
All four of the CUA studies on screening [8, 61, 62, 95] assigned utility weights for cirrhosis, diabetes, 
heart failure and/or combinations of these, however the source of these weights was not stated. 
Adams and colleagues did not report the utility weight used for other states, i.e. homozygotes with 
no clinical symptoms of iron overload-related conditions [8, 61, 62]. Asberg and colleagues assumed 
a basal utility weight of 1.00 for all HH conditions, with the exception of cirrhotic patients, who were 
assigned a value of 0.95 [95], notably higher than published elsewhere.  Uhlig and colleagues 
reported a mean utility measure for the Norwegian population using the SF-6D of 0.803 [96]. Dan 
and colleagues measured the utilities of US patients with cirrhosis and reported a utility of 0.64 using 
the SF-6D [97]. Similarly, two studies by Adams and colleagues used utility values of 0.8 for 
symptoms of cirrhosis, 0.9 for diabetes and 0.5 for heart failure (the third study did not report the 
values used [61]). In contrast to these estimates, Fryback and colleagues published utility population 
norms for the US [98].  Using the SF-6D, mean population norms for persons aged 35-74 ranged 
between 0.79 and 0.81, and using the EQ-5D, ranged between 0.87 and 0.89. This suggests that, with 
the possible exception of heart failure, Adams’ estimated utility weights were higher than would be 
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expected if participants’ utility scores were measured directly; and the potential utility gains 
underestimated. Of note, none of the studies incorporated utility weights associated with arthritis. 
Adams and Speechley found that amongst a small sample of HH patients, arthritis strongly affected 
quality of life, more so than cirrhosis and diabetes [99]. Consequently, CUA studies that do not 
include utility weights associated with arthritis may be under-estimating the impact this condition 
has on overall health associated with HH.  
 
Treatment and other studies 
This review identified three economic evaluations of HH treatment. Two of these studies concluded 
that TV was a more cost-effective strategy than erythrocytapheresis [55] and erythrocytapheresis 
plus erythropoietin [56]. The third study did not find double-erythrocytapheresis to be superior to 
TV from a cost perspective [57]. 
 
Costs of other aspects of HH were assessed in two partial economic analyses. The first was a cost 
description study which assessed hospital costs [58]. The authors reported that between 2000 and 
2006, disorders of iron metabolism cost USD2,828 per admission (2007/08 USD).  
 
The second study was a cost analysis assessing potential revenue earned from a policy variance 
allowing for red blood cell (RBC) product to be sourced from HH venesected blood [59]. When 
comparing loss of revenue from provision of free venepuncture services to HH patients with 
potential revenue from collection of RBC units, a favourable financial outcome was identified 
 
2.6 Discussion 
To date, this is the first comprehensive systematic review of health economic studies of all aspects of 
HH screening and treatment. To our knowledge, just one other systematic review of health 
economic evidence and genetic screening has considered HH. This review assessed the economic 
evidence for screening a range of disorders, one of which was HH [100]. Our current review critically 
appraises all full and partial economic evaluations of genetic and phenotypic screening programs 
and treatment approaches for HH. A meta-analysis was not possible due to the high degree of 
heterogeneity between the studies.  
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Screening 
Whilst almost all studies evaluating any form of screening program in comparison with no screening 
concluded screening to be cost effective [32, 64, 67, 88] or cost saving [7, 8, 61-63], methodological 
limitations undermine the robustness of these results. In cost effectiveness studies the assessment 
of effectiveness is the crucial first step [52]. A paucity of effectiveness data (prevalence, penetrance, 
uptake of screening and adherence to treatment), particularly in studies conducted prior to 2000, 
contributed to the use of highly variable estimates in modelled studies. As the body of HH literature 
has grown considerably in the past decade, the quality of data used to populate economic models of 
HH interventions has improved. 
 
In modelling studies using more than 150 algorithms, Gagne and colleagues found that clinical 
penetrance rates had a large effect on the assessment of cost effectiveness [7]. Penetrance rates are 
subject to more variability than prevalence, in part due to different definitions of penetrance: 
ranging from elevated iron studies to life threatening comorbidities related to iron overload. The 
European Assoication for the Study of the Liver (EASL) identified this inconsistency in 2000 and 
recommended use of four distinct categories of HH, ranging from genetic mutation only, through to 
organ damage [29]. A recent Australian epidemiological study reported penetrance (including early 
symptoms such as arthritis of the metacarpophalangeal joints through to irreversible organ damage) 
as 28.4% for males and 1.2% for females [11].  Penetrance of cirrhosis amongst C282Y homozygotes 
has been reported by several studies, with estimates ranging between 2% and 6%  [11, 38, 42].   
Earlier studies included in this review used markedly higher rates for developing life-threatening 
disease manifestations (commonly described as cirrhois and heart disease): 40 to 76% for males and 
28 to 32% for females [8, 61, 62, 67]. More recent studies have used lower estimates ranging 
between 1.6% to 5.6% [7, 68] that are in-keeping with recent epidemiological data.  
 
An important aspect to consider regarding economic implications of a large-scale screening program 
is uptake of screening. Whilst many modelled studies did not consider this, so implicitly assumed 
100% uptake, amongst those that did, estimates were variable, as were the study populations 
considered. Amongst voluntary blood donors, an uptake rate of 97% was used [80], 85% for a US 
workplace [75] and 70% for the general population of a Norwegian county [42]. These latter two 
studies used estimates based on clinical studies in which a broad range of health interventions were 
offered, not just HH screening. It is likely that this broad range of interventions enhanced uptake 
more so than if HH screening was offered on its own. In support of this, far lower rates were 
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reported for German health insurants (0.3%) [69] and from a UK general practice setting (32%) [39] 
for HH-only screening.  One study assumed a probability of interest in screening for the German 
male population screening of 5.8%, and of this group, an uptake rate of 80.5% [68]. 
 
Adherence to treatment is another important aspect of the cost effectiveness of HH screening 
programs. Both treatment costs and disease-related costs when treatment is not adhered to, impact 
significantly on effectiveness and long-term costs [68]. Of the five studies that considered 
adherence, four of these used estimates of between 80 and 90% [32, 61, 62], and the fifth used an 
estimate of 33% [68]. This latter estimate was based on the commonly used assumption of 50% for 
adherence to drug treatment, and that a lower rate for more demanding interventions should be 
used [68]. In addition, a longitudinal study of HH treatment noted a linear decrease in adherence 
from 80% to 33% by year nine [46]. This suggests that the assumptions regarding adherence in 
earlier studies was highly optimistic, potentially increasing the cost-effectiveness of screening 
interventions. 
 
Whilst assumptions are necessary when calculating the cost-effectiveness of HH screening programs, 
these have generated uncertainty regarding the findings. This is understandably more of an issue 
amongst studies that were conducted when little data was available regarding key parameters. 
However, of the more recent studies published, Rogowski’s economic analysis was the only one to 
be based on an objective assessment of the effectiveness of screening. Many of the studies 
contained in this review, particularly the early studies, contain assumptions that cannot be 
supported and may lead to incorrect conclusions being drawn as to the cost-effectiveness of 
screening. 
 
Almost all of the modelled studies employed decision analysis techniques using decision trees, with 
short time-horizons (i.e one year or less). The nature of HH, whether treated or not, is one which 
affects the patient for their lifetime, therefore to fully capture the costs and effects, models should 
ideally be conducted over a lifetime. Further, models would use probabilistic decision analysis to 
incorporate uncertainty of key parameters, and Markov modelling to capture long-term costs and 
effects. Just one paper did this [68], and two used decision trees and Markov modelling [32, 67]. 
 
Whilst targeted screening of individuals at high risk of HH and iron overload (i.e. offspring and 
siblings of HH probands) has been adopted by many governments and is viewed as a cost effective 
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approach, questions remain regarding the cost effectiveness of population screening. In the current 
review, just one paper was identified that reported population screening to be not cost effective 
[68]. This study by Rogowski was of very high quality according to the BMJ checklist, and is the 
highest quality cost effectiveness study of HH screening to date.  
 
Rogowski’s modelled study aimed to calculate the cost effectiveness of three screening strategies 
(genotypic, phenotypic and sequential) for the German Caucasian male population aged 30 years 
and male offspring of HH probands. This model assumed that genetically HH positive people ‘with 
elevated serum iron values would be offered phlebotomies; [and] annual serum iron testing would be 
offered to all others’.  Rogowski does not provide a definition of ‘elevated’ serum iron values, which 
is in keeping with the EASL guidelines. These guidelines make note of the fact that internationally, 
recommendations regarding commencement of TV are based on empirical evidence, making it 
unclear when treatment should commence. Different cut-off points indicative of iron overload and 
the consequential need for treatment will necessarily alter the number of participants requiring 
treatment, and therefore the costs associated with the strategy. Again in accordance with EASL 
guidelines, the study assumed annual SF monitoring for C282Y homozygotes who do not have 
elevated serum iron levels at the time of diagnosis. The study concluded that targeted sequential 
screening of male offspring was the most cost-effective strategy.  
 
Annual SF monitoring for C282Y homozygotes who do not have elevated serum iron levels at the 
time of diagnosis whilst in accordance with EASL guidelines, is not a universal strategy. For example 
countries such as Australia recommend retesting every two to five years [15]. Further, Adams and 
Barton note longitudinal studies of patients with HH suggest that many HH probands will not 
develop iron overload, thereby rendering annual iron studies excessive [101]. As such, there may be 
an overestimation of costs in the screening arm of Rogowski’s model and the impact of alternative 
strategies is appropriate.   
 
Utilities 
Another aspect of economic evaluations that requires further attention in the future are the utility 
weights included. To-date, no studies have used reliable utility weights when conducting CUA of HH 
screening programs. The four studies identified in this review used estimates of unknown source 
that were likely to be higher than expected if measured directly from a sample of HH patients [8, 32, 
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61, 62]. Potential utility gains could be grossly underestimated. More research investigating utility 
weights for the various stages of HH would contribute to more robust cost utility analyses. 
 
The penetrance estimates used in Adams’ three studies for life-threatening conditions (heart failure, 
cirrhosis, hepatocellular carcinoma and diabetes) were 0.43 for males and 0.28 for females.  Asberg 
and colleagues (2002) defined penetrance as cirrhosis, and used a probability estimate of 0.049. The 
estimates used by Adams and colleagues are higher than found in recent epidemiological data, 
noted above, whereas Asberg’s is within the range reported. Adam’s utility estimates for each 
condition were found to be higher for most conditions than reported in the literature [102-104], as 
were the penetrance estimates. The use of these inflated estimates is likely to lead to incorrect 
results. Whilst Asberg used a penetrance estimate that was in keeping with recent epidemiological 
data, which ranges between 0.02 and 0.06 [11, 38, 42], the utility score of 0.95 assigned to this state 
is notably higher than reported for non-HH patients with cirrhosis (ranging between 0.67 and 0.75) 
[102]. 
 
The HSUVs incorporated into the economic evaluations reviewed focused on cirrhosis, type 2 
diabetes and heart disease. Other health conditions/states, such as fatigue and arthritis, were not 
considered.  In part, this may have been due to uncertainty surrounding the aetiology and the 
subjective measurement of these conditions. However, relatively high rates of HH-related 
osteoarthritis have been reported [105-107], and quality of life amongst HH patients has been found 
to be more negatively impacted upon by arthritis than cirrhosis or diabetes [99]. Therefore, ignoring 
utility estimates related to arthritis may underestimate utility gains from HH interventions.  With 
care, HSUV for a range of health states related to HH should be included in CUA, with the net effect 
of multiple morbidities preferably captured via a validated multi-attribute utility instrument.  
 
One of the strengths of this review was there were no limitations on language or date of publication. 
Although a meta-analysis was not possible, it is clear that whilst most full economic evaluations 
reported HH screening programs to be cost effective or cost-saving, there were methodological 
limitations in these studies that impact the robustness of the findings. Further rigorous, full 
economic evaluations are required to resolve some of the controversies regarding the economic 
aspects of screening programs. More robust modelling, incorporating a more complete 
understanding of the costs associated with HH and accurate utility weights, will make a valuable 
contribution to this debate.  
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Screening 
studies 
(n=32) 
Score 
(BMJ 
check-
list) 
Origin Study 
design 
Population Partic-
ipants 
n 
Control 
 
Screening 
strategies 
Pheno- 
type cut-off 
points 
Genotype Model 
probability 
assumptions 
Costs included Time 
horizon 
Discount 
rate 
Perspective Outcomes 
Categorised high quality (n=11); quality score >75% 
Rogowski, 
2009 [68] 
97% Germany Probabilistic 
decision 
analytic 
model, 
Markov 
modelling; 
CEA 
Hypothetical 
cohort of 
30year old 
male 
Caucasians 
n/a yes, n/a  1. No screen;  
2. Phenotype- TfS x 
2; 3. Sequential- 
elevated TfS and 
genotype;  
4. genotype- C282Y 
(all strategies are 
modelled for 
population (P) and 
cascade (C) 
screening 
separately) 
n/s C282Y HMZ PR=0.004 
PE=0.035 
U=0.805 (of 
0.058 of 
population 
who are 
interested) 
A=0.33 
Printed material, 
DNA tests, 
ambulatory care 
(reimbursement 
rates), incurred for 
cirrhosis 
Lifetime 3% Third party  
payer 
No screen cf. 
strategy 3C= 
€41425; strategy 
3P=€123996; 
strategy 
4P=€161248  
Gagne et al, 
2007 [7] 
94% Canada Computer 
simulation, 
decision 
model 
(decision 
tree); CEA 
Hypothetical 
cohort from 
Quebec 
1 million yes, n/a 165 algorithms of 
screening test, 
including 
phenotyping and 
genotyping 
Multiple C282Y and 
H63D 
combined 
genotypes 
PR= 0.002 
C282YHMZ, 
0.024 
compound 
HTZ 
PE=0.05-0.9 
C282YHMZ, 
0.005 
U=n/r 
A=n/r 
 
Multiple medical 
services, blood tests, 
treatments for HH, 
cirrhosis, diabetes, 
cardiomyopathy, 
liver biopsy 
Lifetime Not 
conducted 
Health  
system 
Cost saving: 
phenotype screen 
(LE=75.6, 
CAN$121)  v. no 
screen v. (LE=68.6, 
CAN$143) 
Bryant et al, 
2009 [44] 
94% UK Decision 
analysis 
model 
(decision 
tree) 
Hypothetical 
cohort: 45 
year old 
male; family 
members 
n/a yes, n/a If raised TfS and SF: 
genotype v. liver 
biopsy: family: 
biochemical 
phenotype v. 
genotype  
TfS>45%, 
SF>300 µg/l 
C282Y HMZ PR=0.038 
PE= 0.76 ♂ 
and 0.32 ♀ 
U=n/r 
A=n/a 
DNA test, 
biochemical tests, 
TV, liver biopsy, 
health appts 
Testing and 
treatment 
period 
n/a Health  
system 
Genotyping v. liver 
biopsy for male= 
£216 saved/case 
detected. 
Biochemical v. 
genotyping for 
family 
=£7,982/case 
detected  
Cooper et al, 
2008 [60] 
 
 
 
94% UK Decision 
analysis 
model 
(decision 
tree); CEA 
Hypothetical 
cohort: 45 
year old 
male; family 
members 
n/a yes, n/a Confirmatory test: 
genotype v. liver 
biopsy  
n/a C282Y HMZ PR=0.0038~ 
PE= 0.76 ♂ 
and 0.32 ♀ 
U=n/r 
DNA test, 
biochemical tests, 
TV, liver biopsy, 
health appts 
Testing and 
treatment 
period 
n/a Government £73,823 v. 
83,068/case 
detected 
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 A=n/a 
Adams et al, 
1995a [61] 
88% Canada Decision 
analysis 
model 
(decision 
tree); CEA, 
CUA 
Hypothetical 
cohort of 
blood donors 
and siblings 
10,000 yes, n/a No screen v. 
phenotype (UIBC, 
TfS, SF) 
TfS<50% for ♀ 
and >60% for 
♂ 
n/a PR=0.003 
PE: life-
threatening 
disease 0.43 
♂ and 0.28 ♀ 
U=n/r 
A=0.8 
Blood tests, HLA 
typing, TV, liver 
biopsy with and 
without 
complications, 
treatments for heart 
failure, cirrhosis 
(ambulatory and 
hospital), diabetes, 
medical 
consultations 
Lifetime 3% Third party  
payer 
$433,927 v. 
$307,567$/strategy 
for donors and 
siblings 
Adams et al, 
1995b [62] 
88% Canada Decision 
analysis 
model 
(decision 
tree); CUA 
Children of 
HMZ, aged 
10-40years 
255 n/a No screen v. 
phenotype 
TfS<55% for ♀ 
and >60% for 
♂ 
 PR=0.003 
HMZ, 
0.010HTZ 
PE: life-
threatening 
disease 0.43 
♂ and 0.28 ♀ 
U=n/r 
A=0.9 
Treatments for 
heart failure, 
cirrhosis, 
hepatocellular 
carcinoma, diabetes  
Lifetime 3% Third party 
 payer 
Screening: $5,798/ 
HMZ identified; 
incremental cost 
savings:$12  at age 
10, $65 at age 20, 
$245 at age 40 
Stuhrmann 
et al, 2005 
[69] 
 
81% Germany Quasi-
experimental; 
cost 
description 
Health 
insurants 
3930 n/a Genotype 
PCR & restriction 
digest; 2 ASO 
methods; SPOLA; 
Microarray 
n/a C282Y HMZ n/a DNA test kit, 
personnel time, 
filter paper, postage 
Present n/a Third party  
payer 
€11.20/test 
€16.35/test 
€13.79/test 
€15.70/test 
Hickman et 
al, 2000 [70] 
81% Australia Quasi-
experimental; 
cost 
description 
Tertiary 
hospital 
patients 
5182 n/a UIBC <30µmol/l C282Y HMZ n/a Laboratory testing: 
UIBC, TfS 
Present n/a Service  
provider 
$2268.77/HH 
diagnosis 
Adams & 
Valberg, 
1999 [8] 
78% Canada Decision 
analysis 
model 
(decision 
tree); CUA 
Hypothetical 
cohort of 
voluntary 
blood donors 
and siblings 
of HMZ 
10,000 & 
 50 
n/a No screen v. 
phenotype v. 
genotype 
TfS<50% for ♀ 
and >60% for 
♂; SF<150µg/l 
for ♀ and 
>200µg/l for ♂ 
C282Y HMZ PR=0.003 
PE: life-
threatening 
disease 0.43 
♂ and 0.28 ♀ 
U=n/r 
A=n/r 
Treatments for 
heart failure, 
cirrhosis, 
hepatocellular 
carcinoma, diabetes, 
blood collection fee, 
testing, staffing 
Lifetime 3% Third party  
payer 
$0.97 v. $2.10 to -
$178.00 (with 
varying cost of 
genotype test) 
(Incremental cost 
saving/person (c.f. 
no screen)) 
Phatak et al, 
1994 [63] 
78% US Decision 
analysis 
model 
(decision 
tree); CEA 
Hypothetical 
cohort of 30 
year old 
white males 
n/a yes, n/a No screen v. 
phenotype (TfS), 
liver biopsy 
 
55% 
n/a PR=0.003 
PE=0.5 
U=n/r 
A=n/r 
Blood tests, liver 
biopsy, TV, liver 
MRI, treatment for 
hepatocellular 
carcinoma, diabetes, 
Lifetime 3%  Societal Cost saving 
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heart failure, liver 
transplantation 
Patch et al, 
2005 [39] 
76% UK Decision 
analysis 
model 
(decision 
tree); CEA; 
RCT 
General 
practice 
patients 
502 
(phenotype 
arm); 574 
(genotype 
arm) 
n/a Phenotype (TfS) v. 
genotype 
≥45% C282Y HMZ 
and 
C282Y/H63D 
heterozygotes 
PR=n/a 
PE=n/a 
U=0.32 
A=n/a 
Invitation to 
screening, sample 
packs and handling, 
consumables, blood 
tests and analysis, 
medical consultation 
Current n/a Government £5.76 v. 
£9.43/person 
screened; 
£1440 v. £2358/HH 
case detected 
 Categorised moderate quality (n=10); quality score 50-75%  
Asberg et al, 
2002 [32] 
75% Norway Markov 
model; CUA 
Hypothetical 
cohort of 
1,000 males 
aged 30 
n/a n/a No screen v. 
phenotype 
n/s n/a PR=0.007 
EAMR 
(cirrhosis) 
=0.049 
U=n/r 
A=0.8 
Reagent costs for 
blood tests at first 
and second 
screening, medical 
consultation, liver 
biopsy 
Lifetime n/s Third party  
payer 
Screening: 
$250/QALY 
Vardarli* et 
al, 2009 [73] 
71% Germany Quasi-
experimental; 
CEA 
Hospitalized 
diabetic 
patients 
527 n/a Sequential: 
elevated ferritin, 
TfS,C282Y 
genotyping; 
elevated TfS, 
genotyping  
 
TfS>45% 
Ferritin n/s 
C282Y HMZ n/a Reagents and staff 
time 
Present n/a Third party  
payer 
€15.60/pt & 
€4110/HH; 
€14.25/pt & 
€3754/HH  
Schoffski et 
al, 2000 [64] 
70% Germany Decision 
analysis 
model 
(decision 
tree); CEA 
Hypothetical 
cohort of 
25year old 
males 
n/a yes, n/a No screen v. 
genotype 
n/a C282Y HMZ PR=0.0025 
PE=0.1 
U=n/r 
A=0.9 
 
DNA test, TV, 
treatments 
diabetes, cirrhosis, 
cardiomyopathy, 
heart failure, liver 
transplantation and 
follow-up care 
Lifetime 5% for costs, 
0% effects 
Third party  
payer 
Per person tested: 
€1.62 v. €7.26 
LYG=€4441 
Bassett et al, 
1997 [65] 
68% Australia Decision 
analysis 
model 
(decision 
tree); CEA 
Hypothetical n/a n/a Phenotype & liver 
biopsy v. 
phenotype, liver 
biopsy & cascade v. 
phenotype & 
genotype   
TfS ≥45%, 55% C282Y HMZ PR=0.0036 
PE=n/r 
U=n/r 
A=n/a 
Blood tests: initial 
and repeat, medical 
consultations 
n/s n/s Government Screening with liver 
biopsy: $5,079-
8,813/ HH 
identified 
Screening with 
genotyping: 
$3,954-4,410/ HH 
identified 
Buffone & 
Beck, 1994 
[67] 
63% US Markov 
model; CEA 
Hypothetical 
cohort of 25 
year old 
males 
n/a n/a No screen v. 
phenotype screen 
and treatment 
n/s n/a PR=0.003 
PE=0.4-0.5 
U=n/r 
A=n/r 
Blood tests, liver 
biopsy, TV, 
treatment for 
disease 
Lifetime Not 
performed 
Societal $605/LYG 
Smith et al, 
1997 [74] 
62% US Quasi-
experimental; 
CEA 
Workplace 2294 n/a Phenotype: TfS; if 
elevated, fasting 
 TfS>55% or 
TfS >45% & SF 
>300ng/ml for 
n/a n/a Blood tests: initial 
and repeated, 
general and 
Present n/a Third party  
payer 
$90205/ program 
$39.32$/screening 
$18,041/ HH 
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TfS, if elevated liver 
biopsy 
♀ and 
>400ng/ml for 
♂  
specialist medical 
consultations, 
administrative costs 
of screening 
program 
El-Serag et 
al, 2000 [88] 
61% US Decision 
analysis 
model 
(decision 
tree); CEA 
Siblings and 
children of 
probands 
n/a n/a No screen v. 
phenotyping v. 
genotyping 
 
n/s 
C282Y HMZ 
and 
heterozygotes 
PR=0.1 (HTZ) 
PE: 
cirrhosis=0.3, 
type 2 
diabetes=0.2. 
heart 
failure=0.05 
U=n/r 
A=n/r 
 
DNA and blood 
tests, TV, treatment 
for cirrhosis, 
diabetes, 
hepatocellular 
carcinoma, heart 
failure 
Lifetime 
(from age 
10 for 
children 
and age 45 
for siblings 
of probands 
3% Societal Strategies ranged 
between $508-
3665/LYG 
Adams & 
Kertesz, 
1992 [82] 
55% Canada Quasi-
experimental; 
cost analysis  
Siblings of 
probands 
105 n/a Phenotype v. HLA 
typing 
SF: >200µg/l 
for  ♀ , 
>350µg/l for 
♂; TfS>55% 
n/a n/a HLA typing, blood 
tests, medical 
consultation, liver 
biopsy 
5yrs n/s Third party 
 payer 
$1,150-1,450 v. 
$1,800-2,100 per 
(screening of a 
family of four) 
Beutler & 
Gelbart, 
2000 [83] 
50% US Non-
experimental, 
descriptive 
study; cost 
description 
n/a n/a n/a Genotyping n/a n/a n/a Staff time, 
material costs, 
overheads 
n/s n/a Laboratory $8.62/test 
Ropert-
Bouchet, 
2012 [84] 
50% France Non-
experimental, 
descriptive 
study; cost 
description 
People with 
HH 
n/a n/a n/a n/a n/a n/a Blood tests, medical 
consultations, 
hospital costs 
n/a n/a Third party  
payer 
               n/a                      
 Categorised low quality (n=12); quality score <50%  
Barton et al, 
2002 [75] 
44% US Quasi-
experimental; 
CEA 
Workplace 2,199 n/a Phenotype TfS >50% for ♀ 
and >60% for 
♂; SF 
>200ng/ml for 
♂ and 
>300ng/ml for 
♀ 
n/a n/a Blood tests, general 
and specialist 
medical 
consultations, liver 
biopsy, (paid by 
insurers) 
n/s n/s Third party  
payer 
$8,826/HH 
identified 
Adams, 
1998 [76] 
42% Canada Quasi-
experimental; 
CEA 
Children of 
HMZ 
291 n/a Phenotype v. 
spousal genotyping 
TfS<55% for ♀ 
and >60% for 
♂ 
n/a n/a Blood and DNA 
tests, medical 
consultations 
n/s n/a Health  
service 
$58,200 v. 
$35,600/strategy 
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Jacobs et al, 
2005 [77] 
40%  quasi-
experimental; 
CEA 
Hospital 
inpatients 
456 422 No screening 
guideline v. 
sequential 
TfS>50% and 
SF>560ng/ml 
n/a n/a Laboratory costs for 
blood and DNA 
tests, liver biopsy 
and one day hospital 
stay 
4 yrs n/a Third party  
payer 
€2380 v. €2600 
(per HH diagnosis 
pre and post 
guideline 
implementation) 
Stave et al, 
1999 [71] 
36% US Quasi-
experimental; 
cost 
description 
Workplace 1968 n/a Phenotype TfS>50% ♀, 
60% ♂; SF 
>290ng/ml ♀, 
322ng/ml ♂; 
liver biopsy 
n/a n/a Blood tests, medical 
consultation 
Present n/a Third party  
payer 
$27850/program 
Bhavnani et 
al, 2000 [78] 
35% UK Quasi-
experimental; 
CEA 
Blood 
samples from 
hospital 
inpatients, 
outpatients 
and GP 
patients  
35,069 n/a Sequential 
(phenotype 
followed by 
genotype) 
ALT<50µ/l; 
TfS<60% 
n/a n/a Blood and DNA tests Present n/a Laboratory £117/HH identified 
Asberg et al, 
2001 [42] 
32% Norway Quasi-
experimental; 
CEA 
General 
population 
aged ≥20 
years 
64,717 n/a Sequential TfS ≥50% for ♀ 
and 55% for ♂; 
SF 110µg/l for 
♀ and 200µg/l 
for ♂ 
n/a n/a Reagent cost of 
initial screen, 
second screen costs 
and medical 
consultation 
n/s n/s Third party  
payer 
$390/HH identified 
Baer et al, 
1995 [79] 
 
29% US Quasi-
experimental; 
CEA 
Community 
health centre; 
males aged 
≥30years 
3,977  n/a Phenotype  TfS≥62%; 
SF≥500µg/l 
n/a n/a Blood tests, liver 
biopsy 
n/s n/a Third party  
payer 
$65,000/HH 
identified 
Adams et al, 
2000 [80] 
22% Canada Quasi-
experimental; 
CEA 
Voluntary 
blood donors 
5,211 n/a Phenotype (x2) v. 
genotype UIBC; TfS 
TfS>45% n/a n/a Blood tests n/s n/a Service  
provider 
UIBC $5,570/HMZ 
identified 
Lederle, 
1989 [85] 
22% US Non-
experimental; 
cost 
description 
n/a n/a n/a Phenotype n/a n/a n/a Blood tests, liver 
biopsy 
Present n/a n/s $24,804/HH 
diagnosis 
Balan et al, 
1994 [81] 
15% US Quasi-
experimental; 
CEA 
Community 
health centre 
12,258 n/a Phenotype  Serum 
Iron≥180µg/dl
; ≥62% SIBC; 
SF≥400µg/l 
n/a n/a Blood tests, TV, liver 
biopsy, medical 
consultation 
1990 n/a Service  
provider 
$5,631-8,447/HH 
identified 
Timms et al, 
2002 [72] 
5% UK Quasi-
experimental; 
cost 
description 
Community-
based 
patients 
diagnosed 
with 
128 3011 Genotype: PCR/SSP 
& PCR/RFLP 
n/a n/a n/a DNA tests: 
laboratory based 
Present n/s Service  
provider 
£1/test;  
£64/ 
HH 
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chondrocal-
cinosis 
Delaveyne 
et al, 2004* 
[89] 
- France Abstract of 
CEA; model 
Population 
screening v. 
family 
screening 
n/a n/a SF and TfS with 
confirmatory 
genotyping for 
C282Y.  
n/s n/r n/r n/s 1 year n/a n/s €3.6-19.5 million v. 
€78,000 ( per 
program) 
 Treatment and other studies (n=5)  
 
 Origin Study 
design 
Population Participants 
n 
Control 
n 
Intervention   Time 
horizon 
Costs 
included 
Disc
-
ount 
rate 
Costs Outcome 
measure 
Outcome 
Rombout-
Sestrienkova 
et al, 2012 
[55] 
 
79% Netherlands RCT; cost 
analysis 
Newly 
diagnosed 
HH patients 
19 19 Treatment: phlebotomy v. 
erythrocytapheresis 
  3 years Treatment and 
productivity 
n/a 
 
 
 
 
Direct 
and 
indirect 
€/procedure; 
Total mean 
costs (€) 
€71.49 v. €251.18 
(per procedure); 
€4438 v. €3005 
Mariani et 
al, 2005 [56] 
53% Italy Non-
experimental-
descriptive, 
case series; 
cost analysis 
Patients 
with severe 
HH 
3 n/a Treatment: 
erythrocytapheresis plus 
erythropoietin v. phlebotomy 
  n/a Treatment 
sessions 
n/s Direct €/treatment €602 v. €35 (Total 
mean costs) 
Stefashyna 
et al, 2014 
[57] 
38% Switzerland Quasi-
experimental; 
cost analysis  
Volunteer 
blood 
donors 
86 donors with 
early, 
uncomplicated 
HH 
n/a whole blood donation v. 
double-erythrocytapheresis 
  n/s Treatment  n/s Direct USD/treatment USD186 v. 238, but 
fewer treatments 
required for latter. 
Gribble et al, 
2009 [59] 
38% US Non-
experimental; 
cost 
description 
HH blood 
donors 
17 17 
(retrospective 
case review 
of same 
cohort) 
n/a   1 year TV, blood 
donations 
n/a Direct Net revenue 
pre and post 
FDA variance 
for blood 
donations 
$6000 v. $20345 
Dye et al, 
2011 [58] 
n/a Australia Non-
experimental, 
cost analysis 
Hospital 
morbidity 
data system  
n/a n/a n/a   6 years hospitalisations n/a Direct $/patient, 
$/admission 
$21,349, $2,827 
Note: * abstract only; ~ refers to prevalence of HH and suspected iron overload in population; # of those interested in screening. ~ Cost saving refers to total cost of caring for a HMZ with no screening minus the total 
cost of screening, calculated for a range of ages 
ASO allele-specific oligonucleotide; C cascade screening; CEA cost effectiveness analysis; CUA cost utility analysis; EAMR refers to Excess annual mortality rate; HH person with hereditary haemochromatosis; 
HMZ homozygote; LYG Life Year gained; MRI magnetic resonance imaging; n/a not applicable; n/s not stated; P population screening; PCR polymerase chain reaction; RFLP restriction fragment length 
polymorphism; SF serum ferritin; Sfe serum iron; SIBC saturation of iron binding capacity; SPOLA Solid-phase oligonucleotide ligation assay; SSP sequence specific primers; TfS Transferrin saturation; TIBC Total 
iron binding capacity; UIBC unsaturated iron binding capacity.  
USD = US Dollar, EUR = Euro, GBP = British Pound, AUD = Australian Dollar, CAD = Canadian Dollar 
PR refers to prevalence, PE to penetrance, I=interested in screening, U= uptake of screening, A= adherence to treatment  
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Chapter 3: Quality of life utility values for hereditary 
haemochromatosis in Australia  
3.1  Preface 
When considering the introduction of a new health intervention, it is important to establish 
the clinical, quality of life and economic burdens associated with the targeted condition, i.e. 
the size of the problem that screening is seeking to prevent, and thus the potential gains to 
be made. Health state utility is of particular interest as it captures the quality of life burden 
associated with haemochromatosis disease states, and is a metric that can be used in health 
economic evaluations. 
The preceding chapter presented a summary of the global evidence relating to health 
economic aspects of hereditary haemochromatosis. Whilst no robust health state utility data 
for people with haemochromatosis was identified in the review, four studies incorporated 
utility values in modelled evaluations of the cost-effectiveness of screening for 
haemochromatosis. These studies used utility values set at unrealistically high levels, of 
unknown sources. The use of inaccurate utility estimates will likely result in incorrect 
estimates of the incremental cost-effectiveness associated with an intervention.   
Chapter 3 presents the results of a cross-sectional observational study reporting health state 
utility values for a haemochromatosis cohort. A national, online survey was conducted, which 
allowed for the calculation of utilities for different categories of severity of 
haemochromatosis. These utility values, which provide insight into the quality of life impacts 
related to haemochromatosis, are the first to be published, and can be incorporated into 
health economic models for haemochromatosis. 
This chapter has been published in Health and Quality of Life Outcomes (Appendix 3A).  
de Graaff, B., Neil, A., Sanderson, K., Yee, K.C. & Palmer AJ. “Quality of life utility values for 
hereditary haemochromatosis in Australia” Health and Quality of Life Outcomes.  February 
2016; 14(31). 
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3.2  Abstract 
AIM: Hereditary hemochromatosis (HH) is a common autosomal recessive disorder amongst 
persons of northern European heritage.  If untreated, iron accumulates in parenchymal 
tissues causing morbidity and mortality. As diagnosis often follows irreversible organ damage, 
screening programs have been suggested to increase early diagnosis. A lack of economic 
evidence has been cited as a barrier to establishing such a program. Previous analyses used 
poorly estimated utility values. This study sought to measure utilities directly from people 
with HH in Australia.  
METHODS: Volunteers with HH were recruited to complete a web-based survey. Utility was 
assessed using the Assessment of Quality of Life 4D (AQOL-4D) instrument. Severity of HH 
was graded into four categories. Multivariable regression analysis was performed to identify 
parameters associated with HSUV.  
RESULTS: Between November 2013 and November 2014, 221 people completed the survey.  
Increasing severity of HH was negatively associated with utility. Mean (standard deviation) 
utilities were 0.76 (0.21), 0.81 (0.18), 0.60 (0.27), and 0.50 (0.27) for categories 1-4 HH 
respectively. Lower mean utility was found for symptomatic participants (categories 3 and 4) 
compared with asymptomatic participants (0.583 v. 0.796). Self-reported HH-related 
symptoms were negatively associated with HSUV (r=-0.685). 
CONCLUSIONS: Symptomatic stages of HH and presence of multiple self-reported symptoms 
were associated with decreasing utility. Previous economic analyses have used higher utilities 
which likely resulted in underestimates of the cost effectiveness of HH interventions. The 
utilities reported in this paper are the most robust available, and will contribute to improving 
the validity of future economic models for HH.  
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3.3  Introduction 
Hereditary hemochromatosis (HH) is a common autosomal recessive disorder in populations 
of northern European heritage [1, 2]. It is characterised by increased iron absorption caused 
by a defect in the HFE gene. Several mutations have been identified: C282Y, H63D and S56C 
[3-5]. C282Y homozygosity accounts for 80 to 90% of people diagnosed with iron-overload, 
with the other mutations uncommonly associated with iron overload. [6, 7].  It has been 
hypothesised that HH is most prevalent in northern European populations due to a mutation 
occurring in Central Europe, hence the description ‘Celtic mutation” [8]. Prevalence of C282Y 
homozygosity has been reported to be between 1 in 150 to 200 persons of Northern European 
ancestry. Amongst populations of different heritage, prevalence is much lower: 1 in 300 
Hispanics; 1 in 1,000 Native Americans; 1 in 1,000, 000 Asians [9-13]. Whilst prevalence of 
other genotypes is more common (1 in 50 C282Y/H63D compound heterozygotes), the 
burden of disease associated with these mutations is low [4, 14]. 
In a proportion of C282Y homozygotes, elevated hepcidin production increases the 
absorption of dietary iron, which is stored in the parenchymal tissues of the heart, liver and 
pancreas. If left untreated, iron overload can be a cause of morbidity and mortality, including 
multiple arthropathies, type 2 diabetes, liver disease and heart disease [15-17]. HH and iron 
overload is commonly diagnosed by conducting iron studies (transferrin saturation and serum 
ferritin) with confirmatory genotyping. Treatment consist of regular therapeutic 
venepuncture.  
Rates of clinical penetrance (i.e. expression of disease) reported in literature vary, in part due 
to different definitions.  Some authors have defined penetrance as irreversible organ damage, 
such as cirrhosis or hepatocellular carcinoma, whilst other have included a spectrum of health 
states, from elevated iron stores and serum iron through to irreversible organ damage. 
Recent studies have reported rates of cirrhosis of the liver amongst C282Y homozygotes to 
be between 2 and 6% [10, 18, 19]. When penetrance is defined as elevated iron stores and 
serum iron through to irreversible organ damage, rates of 28.4% for male and 1.2% for female 
C282Y homozygotes have been recently reported [10].  
Whilst diagnosis and prevention of iron overload in genetically susceptible patients is 
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relatively straightforward, the vague nature of early symptomatology, in that this can be 
experienced by people with clinically normal iron levels, contributes to some patients being 
diagnosed only after irreversible organ damage has occurred [20-23]. Effective treatment is 
readily available, therefore early diagnosis and timely treatment leads to substantial 
improvements in patient outcomes.  Population screening strategies have been proposed as 
an approach to increase early identification of people with HH, thereby reducing the potential 
burden of disease associated with iron overload [24-28].  
Whilst HH is a condition that fulfils several of the criteria set out by the World Health 
Organisation for population screening programs [29], a lack of robust health economic data 
has been cited as a hurdle to implementing such a program [24, 25, 30, 31]. Considerable 
limitations have been identified in the economic evaluations of HH screening programs that 
have been published to date [32, 33]. 
Cost effectiveness and cost utility analyses give rise to a ratio of the difference in costs and 
effectiveness between two or more health interventions. Multi-attribute utility instruments, 
such as the AQOL-4D and EQ-5D, allow for calculation of an individual’s utility. Quality 
adjusted life years (QALYs) are calculated by combining a utility with an outcome such as life 
years gained (LYG). QALYs are the preferred unit of measurement of many decision makers, 
such as the UK’s National Institute for Health and Care Excellence (NICE) [34] and the 
Australian Pharmaceutical Benefits Advisory Committee (PBAC) [35]. 
Cost effectiveness analyses and cost utility analyses give rise to a ratio of the difference in 
costs and effectiveness between two or more health interventions. The cost of an 
intervention is measured in monetary units and effectiveness may be measured 
unidimensionally for cost effectiveness analyses (e.g. life years gained) or by means of a 
multidimensional instrument (such as the EQ-5D, SF-6, AQOL-4D) for cost utility analyses.  
Importantly, multi-attribute utility instruments allow for calculation of an individual’s utility 
(HSUV): a measure of the strength of preference for a particular health state. Utilities are 
measured on a scale of zero to one, with one representing full health, and zero, death. Some 
instruments such as the AQOL-4D and the EQ-5D allow for negative values, as certain states 
may be considered worse than death [36, 37]. When a utility is combined with life years 
gained (LYG), the outcome reflects both morbidity and mortality: quality adjusted life years 
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(QALYs). A cost per QALY can then be reported,  the preferred unit of measurement of many 
decision makers, such as the UK’s National Institute for Health and Care Excellence (NICE) [34] 
and the Australian Pharmaceutical Benefits Advisory Committee (PBAC) [35]. 
To date, just four cost utility studies of HH screening programs have been published [33].  The 
studies did not report the sources of the utilities used, and the estimates employed for 
conditions such as healthy state, heart disease and cirrhosis of the liver were markedly higher 
than reported for comparable populations [33]. Such use of elevated utility values is likely to 
result in underestimates of the potential gains associated with screening programs, which in 
turn may impact on policy decisions regarding provision of HH screening programs. 
The purpose of this study was to assess the utilities for a sample of people with HH with 
different stages of disease severity using a multi-attribute utility instrument.  
3.4  Methods 
A web-based cross-sectional study using convenience sampling was conducted across 
Australia. Multiple recruitment strategies were used: the national support group, 
Hemochromatosis Australia (HA), sent emails to all members on behalf of the researchers 
informing them of the project and the web address; the link to the survey was placed on HA’s 
website; flyers outlining the study were sent to large Australian metropolitan hepatology, 
haematology and gastroenterology clinics, along with general practitioners sourced from HA’s 
referral network; advertisements were placed on social media sites; and newspaper articles 
about the condition and the study were published. In addition, case finding was conducted in 
all Tasmanian public hospitals. All patients admitted between July 2009 and June 2014 with a 
diagnosis of HH, as identified in the International Statistical Classification of Diseases and 
Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM) by code E831: 
Disorders of Iron Metabolism, were sent letters by the research group, informing them of the 
study and inviting them to participate. Only names and postal details were supplied to the 
researchers. Eligibility criteria included a diagnosis of haemochromatosis, residing in 
Australia, aged 18 or older and provision of written informed consent. The survey instrument 
is included in Appendix 3B. Ethical approval for the study was granted by the Tasmanian 
Health and Medical Research Ethics Committee (H0013564).  
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Measurements 
HSUV 
Utility was measured using the Assessment of Quality of Life 4D instrument (AQOL-4D) [38]. 
The AQOL-4D is a 12 item questionnaire that provides a global health state utility value. It 
consists of four separate dimensions: independent living, relationships, mental health and 
senses. The HSUV is scored on a scale from -0.04 to 1.00. A score of one represents optimal 
health, a score of zero represents a state equivalent to death, and scores less than zero 
represent states worse than death [38].  This instrument was chosen as it is sensitive to a 
broad range of conditions and health states [39], Australian population normative data were 
available for comparison [40], and due to cost and software limitations associated with the 
use of other instruments. AQOL HSUV were calculated using syntax supplied by the AQOL 
Group [41].  
HH-related health states 
Stages of HH were categorised using the framework published by the European Association 
for the Study of the Liver (EASL) [16]. The expert panel identified a lack of generalizability of 
much of the research into HH, in part due to researchers and clinicians using different 
definitions or descriptions of HH, i.e. genetic mutation only, through to organ damage. To 
address this, EASL recommended using uniform categorisation of the different stages of HH. 
These categories are described in Table 1. Participants were provided with this matrix, and 
asked to categorise their condition. These self-categorisations were verified by cross-checking 
responses with regard to recent experience of HH comorbidities. Just one discrepancy was 
identified: recoding for the more conservative categorisation was carried out and 
comorbidities were assumed to be unrelated to HH.  
Table 1: Categories of HH [11] 
Category 1 Genetic mutation only (C282Y homozygotes, H63D heterozygotes and compound 
heterozygotes) 
Category 2 Genetic mutation and elevated iron studies, either transferrin saturation or serum iron 
Category 3 Genetic mutation, elevated iron levels and early symptoms, including arthritis, fatigue 
Category 4 Genetic mutation, elevated iron levels and organ damage 
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Lists of commonly reported HH-related comorbidities and symptoms were compiled 
following a review of the literature. Comorbidities included osteoarthritis, liver diseases 
(fibrosis, cirrhosis, hepatocellular carcinoma), heart failure, cardiomyopathy, Type 2 diabetes 
and porphyria cutanea tarda. Participants were asked if they had been diagnosed with each 
condition and if it was a) related to HH, b) not related to HH, or c) unsure if related to HH. 
Only conditions for which the participant stated were related to HH were included in 
analyses. In order to capture data on possible undiagnosed comorbidities and general 
symptoms of iron overload, participants were asked if they had experienced a range of 
symptoms in the last three months that they considered were related to HH. Symptoms 
associated with HH included the general effects of iron overload, such as fatigue, along with 
symptoms of liver disease, heart failure, cardiomyopathy, arthritis, porphyria cutanea tarda 
and changes to the reproductive system (e.g. decreased libido).  
Statistical analyses 
Statistical analyses were performed using SPSS version 20.0.0. Chi square and ANOVA were 
used for descriptive statistics. Differences between HH utilities and data from other 
population groups were analysed using T-tests and Kruskal Wallis one way analysis of 
variance. Linear regression was carried out to identify the association between co-morbidity 
count and utility. Pearson correlation coefficients were calculated for utility values and 
severity of HH. 
3.5  Results 
Demographics 
Two hundred and seventy participants self-completed a web-based survey between 
November 2013 and November 2014 as part of a national cost of illness study for HH.  Two 
hundred and twenty one participants completed the AQOL-4D. The demographic 
characteristics of participants are presented in Table 2. The only notable difference between 
participants who completed the AQOL-4D and those who did not was that the former were 
more likely to be employed full time (X2=4.254, p=0.026) (Table 2).  
Due to the sampling techniques, it is not possible to quantify the number of people who 
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viewed information regarding the study, thus calculating a response rate.  However, for the 
case finding at all Tasmanian public hospitals, a response rate of 20% was observed (37 
participants from 189 letters). 
Table 2: Demographic characteristics of the sample 
 AQol-4D completers 
n=221 
AQoL-4D 
non-completers 
n=47 
p value 
Age, mean ±SD 52.7 ±14.2   53.6±13.2 0.694 
Sex (male) 41.6% 41.3% 0.552 
Relationship status: 
currently married/defacto 
 
79.6% 
 
68.1% 
 
 
0.066 
Country of birth: 
Australia 
United Kingdom 
 
83.7% 
9.0% 
 
85.1% 
8.5% 
 
0.506 
0.584 
 
Highest level of education 
completed*: 
<yr 12 
certificate, Trade etc 
yr 12 
uni + 
 
 
 
24.7% 
31.7% 
10.4% 
35.7% 
 
 
 
25.0% 
39.4% 
3.0% 
33.3% 
 
 
 
0.565 
0.245 
0.149 
0.476 
Labour force participation:  
 employed full time 
employed part-time 
self-employed  
retired 
Unemployed 
 
32.1% 
15.4% 
9.0% 
25.3% 
5.4% 
 
17.0% 
14.9% 
10.6% 
19.1% 
4.3% 
 
0.026 
0.568 
0.455 
0.242 
0.542 
* For this question, n=33 for the non-completer group. 
 
AQOL-4D HSUV 
The mean utility for all participants using the AQol-4D was 0.66 (±0.26), with a range of -0.04 
to 1.00 (95%CI 0.63-0.70) (Table 3).  This was lower than the Australian population norm 
estimated using the AQoL-4D of 0.81 (n=8839, SD=0.22, 95%CI 0.81-0.82) [40].   
Univariate analyses were carried out to examine utilities for age and sex (Table 3). This 
showed similar values for males (0.69) and females (0.64) (p=0.163). Utilities were also 
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examined by age deciles and sex. Whilst slightly higher mean utility values were reported for 
males for most age deciles, none of these differences were found to be statistically significant. 
Overall, utility was highest for participants aged between 30 and 39 (0.72), and lowest for 
those aged 70-79 (0.61). 
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Table 3: Comparison of HH cohort and Australian population normative utility values [23] 
Variables Mean 
HSUV 
95% CI n Males Females Population 
norm HSUV 
95% CI 
 Mean 
HSUV 
95% CI n Mean 
HSUV 
95% CI n 
Age 
group: 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
 
 
0.67 
0.72 
0.66 
0.63 
0.67 
0.61 
 
 
0.55-0.80 
0.62-0.80 
0.57-0.74 
0.54-0.70 
0.61-0.73 
0.47-0.73 
 
 
10 
30 
39 
52 
67 
16 
 
 
0.75 
0.78 
0.72 
0.62 
0.70 
0.63 
 
 
0.53-1.00 
0.66-0.90 
0.57-0.84 
0.47-0.75 
0.62-0.78 
0.47-0.76 
 
 
2 
7 
15 
19 
34 
11 
 
 
0.65 
0.70 
0.62 
0.63 
0.65 
0.56 
 
 
0.49-0.70 
0.59-0.81 
0.50-0.74 
0.54-0.71 
0.54-0.74 
0.21-0.92 
 
 
8 
23 
24 
33 
33 
5 
 
 
0.86 
0.84 
0.81 
0.80 
0.80 
0.76 
 
 
0.85-0.87 
0.83-0.85 
0.80-0.82 
0.78-0.81 
0.78-0.81 
0.76-0.79 
Sex 
Male 
Female 
 
0.69 
0.64 
 
0.64-0.75 
0.60-0.69 
 
92 
129 
  
0.82 
0.81 
 
0.81-0.83 
0.80-0.81 
All 0.66 0.63-0.70 221  0.81 0.81-0.82 
Note: HSUV refers to health state utility values; 95%CI refers to the 95% confidence interval 
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Reporting of utility by stages of severity of HH (Table 1) can help mitigate any bias due to the 
sampling approach. A trend of decreasing HSUV was identified with stages three and four 
(Table 4).  A Pearson correlation coefficient was calculated to assess the relationship between 
mean utility and stages of HH: a moderate negative correlation was found (r= -0.366; 
p<0.001). Whilst lower mean HSUV were reported for female participants for each category, 
these differences were not significant.  
 
Table 4: Mean utility values by categories of HH by sex 
Categories of HH HSUV mean  SD n 95%CI 
All participants 
Category 1 
 
0.76 
 
0.21 
 
20 
 
0.67-0.85 
Category 2 0.81 0.18 63 0.76-0.85 
Category 3 0.60 0.27 115 0.55-0.658 
Category 4 0.50 0.27 23 0.39-0.61 
All categories 0.66 0.26 221 0.63-0.70 
Males 
Category 1 
Category 2 
Category 3 
Category 4 
All categories 
 
0.88 
0.85 
0.59 
0.59 
0.69 
 
0.10 
0.12 
0.28 
0.23 
0.27 
 
6 
29 
45 
12 
92 
 
0.78-0.98 
0.80-0.89 
0.51-0.68 
0.44-0.74 
0.64-0.75 
Females 
Category 1 
Category 2 
Category 3 
Category 4 
All categories 
 
0.71 
0.77 
0.60 
0.41 
0.64 
 
0.235 
0.21 
0.26 
0.29 
0.26 
 
14 
34 
70 
11 
129 
 
0.58-0.84 
0.70-0.85 
0.54-0.66 
0.22-0.60 
0.60-0.69 
Note: HSUV refers to health state utility values; SD standard deviation; 95%CI refers to the 95% confidence interval 
 
To investigate the impact of symptomatic HH on utility, the four categories of HH were 
combined into asymptomatic (categories 1 and 2), and symptomatic (categories 3 and 4) 
participants. Utility was significantly lower for the symptomatic group for males (0.85 v. 0.59: 
H=25.36, p<0.001), females (0.75 v. 0.58: H=14.90, p<0.001) and overall (0.80 v. 0.58: 
H=38.79, p<0.001) (Table 5). 
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Table 5: Mean utility values of symptomatic HH 
Categories of HH HSUV 
mean  
SD n 95%CI Between groups* 
All participants 
Categories 1 & 2 
 
0.80 
 
0.19 
 
83 
 
0.76-0.84 
 
H=38.79, p<0.001 
Categories 3 & 4 0.58 0.27 138 0.54-0.63  
All categories 0.66 0.26 221 0.63-0.70  
Males 
Categories 1 & 2 
Categories  3 & 4 
All categories 
 
0.85 
0.59 
0.69 
 
0.11 
0.27 
0.26 
 
35 
57 
92 
 
0.82-0.89 
0.52-0.67 
0.64-0.75 
 
H=25.36, p<0.001 
Females 
Categories 1 &2 
Categories 3 & 4  
All categories 
 
0.75 
0.58 
0.64 
 
0.22 
0.27 
0.64 
 
48 
81 
129 
 
0.69-0.82 
0.52-0.64 
0.60-0.69 
 
 
H=14.90, p<0.001 
Note: HSUV refers to health state utility values; SD standard deviation; 95%CI refers to the 95% confidence interval 
* Kruskal Wallis one way analysis of variance was used for this test for significance. 
 
In keeping with these findings, evaluation of the impact of HH related comorbidities on utility 
found all comorbidities were related to lower mean utility than reported for participants 
reporting no comorbidities (0.76) and the entire HH cohort (0.66) (Table 6). Using the sample 
mean utility value as the reference case (0.66), participants self-reporting arthritis related to 
HH had a lower mean utility (0.52: F(1,198)=10.854, p=0.001). Whilst lower mean utility 
values were reported for fibrosis, cirrhosis, heart failure, cardiomyopathy, diabetes and 
porphyria cutanea tarda, only small numbers of participants reported these co-morbidities, 
therefore these should be interpreted with caution (Table 6). 
 
Participants were also asked to report on experience of symptoms related to HH and iron 
overload in the preceding three months (Table 7). Participants were asked if they thought 
these symptoms were related to HH, possibly related or not related. Only participants 
reporting their symptoms to be related to HH were included to minimise over-reporting. Of a 
maximum of 20 symptoms and conditions, the median number experienced by the sample 
was 3 (SD=3.8, range 0-15). When compared with the reference HSUV, all symptoms were 
associated with lower utility. A Pearson correlation coefficient was calculated to assess the 
relationship between symptom count and HSUV, and a strong negative correlation was found 
(r= -0.685; p<0.001) (Figure 1). 
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Table 6: Mean utility values by self-reported HH-related comorbidities 
HH-related comorbidities* mean HSUV SD n 
All participants 
no comorbidity 
arthritis  
fibrosis  
cirrhosis 
heart failure 
cardiomyopathy  
diabetes 
porphyria cutanea tarda 
 
0.76 
0.52 
0.53 
0.61 
0.58 
0.30 
0.52 
0.02 
 
0.21 
0.25 
0.29 
0.31 
0.24 
- 
0.33 
- 
 
100 
35 
7 
5 
3 
1 
4 
1 
Males 
no comorbidity 
arthritis  
fibrosis 
cirrhosis 
 
0.76 
0.59 
0.69 
0.74 
 
0.25 
0.23 
0.05 
0.16 
 
39 
15 
5 
3 
Females 
no comorbidity 
arthritis  
fibrosis 
cirrhosis 
 
0.76 
0.48 
0.12 
0.42 
 
0.19 
0.26 
0.02 
0.45 
 
61 
20 
2 
2 
Note: HSUV refers to health state utility values; SD standard deviation 
*Participants were asked if they had been diagnosed with these conditions and that they were considered to be related to 
HH and iron overload. Participants with these conditions, but were unsure if they were related to HH were not included in 
this analysis. 
 
Figure 1: Linear regression of HSUV and symptom count related to HH 
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Table 7: Mean utility values for HH related symptoms 
Experienced in the last 3 
months 
mean 
HSUV 
SD n Males Females 
mean 
HSUV 
SD n mean 
HSUV 
SD n 
General effects 
Chronic fatigue 
 
0.55 
 
0.29 
 
102 
 
0.56 
 
0.306 
 
37 
 
0.55 
 
0.29 
 
65 
Weakness 0.49 0.26 87 0.51 0.28 33 0.48 0.26 54 
Unexplained weight loss 0.42 0.40 10 1.00 - 1 0.35 0.36 9 
Unexplained weight gain 0.50 0.26 30 0.37 0.31 8 0.55 0.23 22 
Liver disease 
Abdominal swelling 
 
0.40 
 
0.25 
 
35 
 
0.41 
 
0.33 
 
9 
 
0.39 
 
0.22 
 
26 
Abdominal 
pain/discomfort 
0.47 0.26 47 0.51 0.31 12 0.46 0.25 35 
Enlarged liver 
(hepatomegaly) 
0.40 0.24 15 0.57 0.19 6 0.29 0.21 9 
Heart-related problems 
Swelling of your feet 
and/or ankles 
 
0.46 
 
0.23 
 
47 
 
0.43 
 
0.24 
 
17 
 
0.48 
 
0.22 
 
30 
Shortness of breath- 
walking quickly or uphill 
0.50 0.27 64 0.54 0.27 24 0.48 0.26 40 
Shortness of breath- 
walking on level ground 
0.36 0.26 29 0.39 0.26 14 0.33 0.27 15 
Shortness of breath- 
resting in a chair 
0.31 0.25 8 0.32 0.45 3 0.21 0.24 5 
Heart failure or weak 
heart 
0.30 - 1 0.30 - 1 - - - 
Abnormal heart rhythm/ 
arrhythmia 
0.55 0.23 25 0.61 0.17 8 0.52 0.26 17 
Heart disease 0.52 0.27 6 0.49 0.28 5 0.71 - 1 
Arthritis 
Swollen/tender 
metacarpophalangeal 
joints (fingers/hands) 
 
0.48 
 
0.25 
 
58 
 
0.47 
 
0.30 
 
21 
 
0.49 
 
0.22 
 
37 
Other joint 
stiffness/pain/ache 
0.55 0.26 96 0.6 0.26 39 0.51 0.24 57 
Skin changes 
Change in skin colour 
 
0.45 
 
0.29 
 
25 
 
0.50 
 
0.35 
 
8 
 
0.43 
 
0.27 
 
17 
Increased facial hair 
growth 
0.32 0.21 14 - - - 0.32 0.21 14 
Reproductive 
Loss of libido and/or 
erectile dysfunction 
 
0.49 
 
0.27 
 
49 
 
 
0.48 
 
0.27 
 
17 
 
0.49 
 
0.28 
 
32 
Unexplained confusion 
and/or memory loss 
0.40 0.24 53 0.39 0.25 18 0.41 0.24 35 
Note: HSUV refers to health state utility values; SD standard deviation 
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3.6  Discussion 
This is the first study that reports HSUV measured directly from a cohort with HH. This is of 
importance, as a lack of robust health economic data has been cited as a barrier to 
implementing population screening programs for HH [25, 30, 31, 42]. The utility values 
calculated in this study provide robust estimates that can be used in future economic models 
of screening interventions.   Whilst the sampling strategy may have introduced bias, this has 
been mitigated by reporting utility values for categories of HH rather than across the study 
population in general. These values can then be used in combination with penetrance rates 
in economic models for HH interventions.  
 
Symptomatic stages of HH (categories three and four [25]) were associated with lower utility 
than asymptomatic stages. The values for all four categories are useful, as they incorporate 
all aspects of HH and related conditions and can be used to populate cost utility analyses 
(CUA) health economic models. Previous CUA models have only incorporated specific 
comorbidities which are associated with significant morbidity and mortality: cirrhosis, 
diabetes and heart failure, with no consideration of common comorbidities such as arthritis, 
or symptoms such as fatigue. This may be related to the relatively high prevalence of both 
fatigue and arthritis amongst other populations, and the difficulties surrounding the 
aetiologies of both, however there is evidence suggesting that the prevalence of both is higher 
amongst some HH patients. The prevalence of fatigue amongst general practice patients has 
been estimated to be between 1.4-7.0% of encounters [43-46]. Work by Allen and colleagues 
has reported a much higher rate of 22% for C282Y homozygotes with elevated serum ferritin 
levels (greater than 1,000µg/l) [10].  Similarly, arthritis, specifically osteoarthritis, is prevalent 
in Australia, with 9% reporting this condition [47]. Allen and colleagues reported use of 
arthritis medication as a proxy measure for arthritis, noting that 20% of C282Y homozygotes 
with serum ferritin greater than 1,000µg/l reported use of these medications. In combination, 
these data guided the decision to include arthritis and fatigue in the current study. 
 
To date, just four CUA have been published on HH screening programs, none of which cited 
the sources of the utility values employed [7, 48-50]. Values were assigned for cirrhosis, 
diabetes and heart failure, and in some cases, combinations of these.  In a Norwegian study 
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[48], a basal utility value of 1.00 was assumed for all HH conditions except cirrhosis, which 
was assigned a utility of 0.95, values that are substantially higher than those reported here. 
Two Canadian studies, by the same research group, used utilities of 0.8 for cirrhosis, 0.9 for 
diabetes, 0.5 for heart failure, 0.72 for cirrhosis and diabetes, 0.78 for cirrhosis and heart 
failure, 0.87 for diabetes and heart failure and 0.70 for a combination of cirrhosis, diabetes 
and heart failure [7, 49]. A fourth study did not provide the utility values used in the modelling 
[50]. Some concerns arise in respect of these estimates. First, in comparing these utility values 
to US population normative data, a disparity appears: the mean utility derived from the SF-
6D ranged from 0.79 to 0.81 for persons aged 35 to 74, and similarly, using the EQ-5D, mean 
utility ranged between 0.87 and 0.89 [51].  The fact that the utility estimates that were used 
in cost utility analyses for participants with health conditions such as cirrhosis and diabetes 
are similar to or higher than those reported for the general US population indicates these 
estimates may be incorrect. The likely overestimates of HSUV for HH-related conditions are 
likely to lead to underestimates of potential utility gains associated with screening 
interventions. 
 
Second, disease specific HSUV used in these cost utility analyses are also higher than 
suggested in published literature. A meta-analysis of utility values for liver diseases using a 
range of approaches to measure utility reported a mean of 0.75 for compensated cirrhosis 
(range 0.65-0.90) and 0.67 for decompensated cirrhosis (range 0.57-0.81) [52]. Whilst our 
study did not differentiate cirrhosis in this manner, amongst the small number of participants 
reporting this condition (n=5), the mean utility (0.61) was slightly lower than reported for 
decompensated cirrhosis but within the range reported.  In contrast, the published cost utility 
analyses used values of 0.95 [48] and 0.8 [7, 49], higher than the mean values reported for 
both compensated and decompensated cirrhosis [52]. Similarly, a meta-analysis of utility 
values for diabetes reported a mean of 0.76 (range 0.53-0.88) [53]. In our study, a mean of 
0.52 was reported (n=4), slightly lower than the lower range reported in this meta-analysis. 
In the three HH CUA, one used a utility value for diabetes of 1.00 [48], and two used a value 
of 0.9 [7, 49], both notably higher than published estimates. 
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Mean utility for heart failure varies depending on the severity of the condition. From a large, 
multi-site trial that used the EQ-5D, mean utility for different levels of severity based on the 
New York Heart Association (NYHA) classifications were: class I: 0.815, class II: 0.720, class III: 
0.590, class IV: 0.508 [54].  Our study reported a mean of 0.58, however data were available 
for only three participants, and all were in different NYHA classes. The two Canadian CUA 
models used a utility value of 0.5 [7, 49], which is similar to the NYHA class 4. In contrast, the 
Norwegian study assumed a utility of 1.00, which is not in keeping with estimates in the 
current literature [48]. 
 
To date, no HH CUA has incorporated HSUV related to arthritis. This is surprising as arthritis 
related to iron overload is commonly reported amongst patients diagnosed with HH [10, 55-
57]. Whilst HRQoL is not synonymous with HSUV, it can serve as an indicator. A study 
examining the effects of a range of HH-related comorbidities using the SF-36 found that, 
compared to cirrhosis and diabetes, arthritis was the single strongest factor that impacted on 
HRQoL [58]. Whilst the paper was published in 1996, no subsequent studies have 
incorporated utility values for arthritis. Hawthorne and colleagues, using the AQOL-4D, 
reported the Australian normative utility value for arthritis as 0.69 (SD 0.26). Our study 
reported a lower mean value of 0.52 (SD 0.25, n=35). In the current study, both self-reported 
diagnosis of arthritis related to HH and symptoms suggestive of arthritis were associated with 
lower mean utility than the sample mean (0.52, 0.48, 0.66 respectively). 
 
Limitations of this study include cross-sectional design and use of convenience sampling. 
Convenience sampling, which was used as a result of available resourcing, may limit the 
generalizability of these results. Further, the majority of the respondents were female, 
despite higher penetrance amongst males.  To minimise sampling bias, we have focused on 
utility values for categories of disease and symptomatology for males and females separately. 
Whilst an overall sample mean HSUV is likely to be affected by under- or over-reporting from 
participants with more health problems, the mean values for each category are not affected. 
This allows for these values, in combination with penetrance estimates from robust 
epidemiological studies, to be used in HH health economic models. 
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A further limitation of this study was the reliance on participants’ self-report regarding 
experience of HH related comorbidities and symptoms. Whilst participants were asked if the 
comorbidities were related to HH, even with clinical verification, it is difficult to be certain of 
the aetiology of these. Whilst it can be argued that there may be some over-reporting of 
symptoms and comorbidities believed to be caused by HH, to minimise this possibility, cases 
in which participants were unsure of the aetiology have been excluded. Symptoms and 
comorbidities were only included when participants stated that they were related to HH. 
Lastly, the small number of participants reporting HH-related comorbidities was also a 
limitation. Whilst utility values were calculated wherever possible, the small number of 
respondents means that these data should be interpreted with caution and that no 
meaningful comparisons can be made between these comorbidities.  
 
In conclusion, this is the first study to report utility values measured directly from people with 
HH. Despite study limitations, these values are the best available to date, and can be used to 
populate health economic models investigating the cost utility of HH interventions. 
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Abstract
Background: Hereditary hemochromatosis (HH) is a common autosomal recessive disorder amongst persons of
northern European heritage. If untreated, iron accumulates in parenchymal tissues causing morbidity and mortality.
As diagnosis often follows irreversible organ damage, screening programs have been suggested to increase early
diagnosis. A lack of economic evidence has been cited as a barrier to establishing such a program. Previous
analyses used poorly estimated utility values. This study sought to measure utilities directly from people with HH in
Australia.
Methods: Volunteers with HH were recruited to complete a web-based survey. Utility was assessed using the
Assessment of Quality of Life 4D (AQOL-4D) instrument. Severity of HH was graded into four categories.
Multivariable regression analysis was performed to identify parameters associated with HSUV.
Results: Between November 2013 and November 2014, 221 people completed the survey. Increasing severity of
HH was negatively associated with utility. Mean (standard deviation) utilities were 0.76 (0.21), 0.81 (0.18), 0.60 (0.27),
and 0.50 (0.27) for categories 1–4 HH respectively. Lower mean utility was found for symptomatic participants
(categories 3 and 4) compared with asymptomatic participants (0.583 v. 0.796). Self-reported HH-related symptoms
were negatively associated with HSUV (r = −0.685).
Conclusions: Symptomatic stages of HH and presence of multiple self-reported symptoms were associated with
decreasing utility. Previous economic analyses have used higher utilities which likely resulted in underestimates of
the cost effectiveness of HH interventions. The utilities reported in this paper are the most robust available, and will
contribute to improving the validity of future economic models for HH.
Background
Hereditary hemochromatosis (HH) is a common auto-
somal recessive disorder in populations of northern
European heritage [1, 2]. It is characterised by increased
iron absorption caused by a defect in the HFE gene. Sev-
eral mutations have been identified: C282Y, H63D and
S56C [3–5]. C282Y homozygosity accounts for 80 to
90 % of people diagnosed with iron-overload, with the
other mutations uncommonly associated with iron over-
load [6, 7]. It has been hypothesised that HH is most
prevalent in northern European populations due to a
mutation occurring in Central Europe, hence the de-
scription ‘Celtic mutation” [8]. Prevalence of C282Y
homozygosity has been reported to be between 1 in 150
to 200 persons of Northern European ancestry. Amongst
populations of different heritage, prevalence is much
lower: 1 in 300 Hispanics; 1 in 1,000 Native Americans;
1 in 1,000, 000 Asians [9–13]. Whilst prevalence of other
genotypes is more common (1 in 50 C282Y/H63D com-
pound heterozygotes), the burden of disease associated
with these mutations is low [4, 14].
In a proportion of C282Y homozygotes, elevated hep-
cidin production increases the absorption of dietary iron,
which is stored in the parenchymal tissues of the heart,
liver and pancreas. If left untreated, iron overload can be
a cause of morbidity and mortality, including multiple
arthropathies, type 2 diabetes, liver disease and heart
disease [15–17]. HH and iron overload is commonly di-
agnosed by conducting iron studies (transferrin satur-
ation and serum ferritin) with confirmatory genotyping.
Treatment consists of regular therapeutic venesection.
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Rates of clinical penetrance (i.e. expression of disease)
reported in the literature vary, in part due to different
definitions. Some authors have defined penetrance as ir-
reversible organ damage, such as cirrhosis or hepatocel-
lular carcinoma, whilst other have included a spectrum
of health states, from elevated iron stores and serum
iron through to irreversible organ damage. Recent stud-
ies have reported rates of cirrhosis of the liver amongst
C282Y homozygotes to be between 2 and 6 % [10, 18,
19]. When penetrance is defined as elevated iron stores
and serum iron through to irreversible organ damage,
rates of 28.4 % for male and 1.2 % for female C282Y ho-
mozygotes have been recently reported [10].
Whilst diagnosis and prevention of iron overload in
genetically susceptible patients is relatively straightfor-
ward, the non-specific nature of early symptomatology,
in that this can be experienced by people with clinically
normal iron levels, contributes to some patients being
diagnosed only after irreversible organ damage has oc-
curred [20–23]. Effective treatment is readily available,
therefore early diagnosis and timely treatment leads to
substantial improvements in patient outcomes. Popula-
tion screening strategies have been proposed as an ap-
proach to increase early identification of people with
HH, thereby reducing the potential burden of disease as-
sociated with iron overload [24–28].
Whilst HH is a condition that fulfils several of the criteria
set out by the World Health Organisation for population
screening programs [29], a lack of robust health economic
data has been cited as a hurdle to implementing such a
program [24, 25, 30, 31]. Considerable limitations have
been identified in the economic evaluations of HH screen-
ing programs that have been published to date [32, 33].
Cost effectiveness analyses and cost utility analyses
give rise to a ratio of the difference in costs and effect-
iveness between two or more health interventions. The
cost of an intervention is measured in monetary units
and effectiveness may be measured unidimensionally for
cost effectiveness analyses (e.g. life years gained) or by
means of a multidimensional instrument (such as the
EQ-5D, SF-6, AQOL-4D) for cost utility analyses. Im-
portantly, multi-attribute utility instruments allow for
calculation of an individual’s utility (HSUV): a measure
of the strength of preference for a particular health state.
Utilities are measured on a scale of zero to one, with
one representing full health, and zero, death. Some in-
struments such as the AQOL-4D and the EQ-5D allow
for negative values, as certain states may be considered
worse than death [36, 37]. When a utility is combined with
life years gained (LYG), the outcome reflects both morbid-
ity and mortality: quality adjusted life years (QALYs). A
cost per QALY can then be reported, the preferred unit of
measurement of many decision makers, such as the UK’s
National Institute for Health and Care Excellence (NICE)
[34] and the Australian Pharmaceutical Benefits Advisory
Committee (PBAC) [35].
To date, just four cost utility studies of HH screening
programs have been published [33]. The studies did not
report the sources of the utilities used, and the estimates
employed for conditions such as healthy state, heart
disease and cirrhosis of the liver were markedly higher
than reported for comparable populations [33]. Such use
of elevated utility values is likely to result in underesti-
mates of the potential gains associated with screening
programs, which in turn may impact on policy decisions
regarding provision of HH screening programs.
The purpose of this study was to assess the utilities for a
sample of people with HH with different stages of disease
severity using a multi-attribute utility instrument.
Methods
A web-based cross-sectional study using convenience
sampling was conducted across Australia. Multiple re-
cruitment strategies were used: the national support
group, Hemochromatosis Australia (HA), sent emails to
all members on behalf of the researchers informing them
of the project and the web address; the link to the survey
was placed on HA’s website; flyers outlining the study
were sent to large Australian metropolitan hepatology,
haematology and gastroenterology clinics, along with
general practitioners sourced from HA’s referral network;
advertisements were placed on social media sites; and
newspaper articles about the condition and the study were
published. In addition, case finding was conducted in all
Tasmanian public hospitals. All patients admitted between
July 2009 and June 2014 with a diagnosis of HH, as identi-
fied in the International Statistical Classification of Dis-
eases and Related Health Problems, Tenth Revision,
Australian Modification (ICD-10-AM) by code E831:
Disorders of Iron Metabolism, were sent letters by the
research group, informing them of the study and inviting
them to participate. Only names and postal details were
supplied to the researchers. Eligibility criteria included a
diagnosis of haemochromatosis, residing in Australia, aged
18 or older and provision of written informed consent.
Ethical approval for the study was granted by the Tasman-
ian Health and Medical Research Ethics Committee
(H0013564).
Measurements
HSUV
Utility was measured using the Assessment of Quality of
Life 4D instrument (AQOL-4D) [38]. The AQOL-4D is a
12 item questionnaire that provides a global health state
utility value. It consists of four separate dimensions: inde-
pendent living, relationships, mental health and senses.
The HSUV is scored on a scale from −0.04 to 1.00. A
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score of one represents optimal health, a score of zero
represents a state equivalent to death, and scores less than
zero represent states worse than death [38]. This instru-
ment was chosen as it is sensitive to a broad range of
conditions and health states [39], Australian population
normative data were available for comparison [40], and
due to cost and software limitations associated with the
use of other instruments. AQOL HSUV were calculated
using syntax supplied by the AQOL Group [41].
HH-related health states
Stages of HH were categorised using the framework
published by the European Association for the Study of
the Liver (EASL) [16]. The expert panel identified a lack
of generalizability of much of the research into HH, in
part due to researchers and clinicians using different defi-
nitions or descriptions of HH, i.e. genetic mutation only,
through to organ damage. To address this, EASL recom-
mended using uniform categorisation of the different
stages of HH. These categories are described in Table 1.
Participants were provided with this matrix, and asked to
categorise their condition. These self-categorisations were
verified by cross-checking responses with regard to recent
experience of HH comorbidities. Just one discrepancy was
identified: recoding for the more conservative categorisa-
tion was carried out and comorbidities were assumed to
be unrelated to HH.
Lists of commonly reported HH-related comorbidities
and symptoms were compiled following a review of the lit-
erature. Comorbidities included osteoarthritis, liver diseases
(fibrosis, cirrhosis, hepatocellular carcinoma), heart failure,
cardiomyopathy, Type 2 diabetes and porphyria cutanea
tarda. Participants were asked if they had been diagnosed
with each condition and if it was a) related to HH, b) not
related to HH, or c) unsure if related to HH. Only condi-
tions for which the participant stated were related to HH
were included in analyses. In order to capture data on pos-
sible undiagnosed comorbidities and general symptoms of
iron overload, participants were asked if they had experi-
enced a range of symptoms in the last three months that
they considered were related to HH. Symptoms associated
with HH included the general effects of iron overload, such
as fatigue, along with symptoms of liver disease, heart
failure, cardiomyopathy, arthritis, porphyria cutanea tarda
and changes to the reproductive system (e.g. decreased
libido).
Statistical analyses
Statistical analyses were performed using SPSS version
20.0.0. Chi square and ANOVA were used for descriptive
statistics. Differences between HH utilities and data from
other population groups were analysed using T-tests and
Kruskal Wallis one way analysis of variance. Linear re-
gression was carried out to identify the association be-
tween co-morbidity count and utility. A Pearson
correlation coefficient was calculated for utility values
and severity of HH.
Results
Demographics
Two hundred and seventy participants self-completed a
web-based survey between November 2013 and November
2014 as part of a national cost of illness study for HH. Two
hundred and twenty one participants completed the
AQOL-4D. The demographic characteristics of participants
are presented in Table 2. The only notable difference
between participants who completed the AQOL-4D and
those who did not was that the former were more likely to
be employed full time (X2 = 4.254, p = 0.026) (Table 2).
Due to the sampling techniques, it is not possible to
quantify the number of people who viewed information
regarding the study, thus calculating a response rate.
However, for the case finding at all Tasmanian public
hospitals, a response rate of 20 % was observed (37 par-
ticipants from 189 letters).
AQOL-4D HSUV
The mean utility for all participants using the AQol-4D
was 0.66 (±0.26), with a range of −0.04 to 1.00 (95 % CI
0.63–0.70) (Table 3). This was lower than the Australian
population norm estimated using the AQoL-4D of 0.81
(n = 8839, SD = 0.22, 95 % CI 0.81–0.82) [40].
Univariate analyses were carried out to examine utilities
for age and sex (Table 3). This showed similar values for
males (0.69) and females (0.64) (p = 0.163). Utilities were
also examined by age deciles and sex. Whilst slightly
higher mean utility values were reported for males for
most age deciles, none of these differences were found to
be statistically significant. Overall, utility was highest for
participants aged between 30 and 39 (0.72), and lowest for
those aged 70–79 (0.61).
Reporting of utility by stages of severity of HH (Table 1)
can help mitigate any bias due to the sampling approach.
A trend of decreasing HSUV was identified with stages
three and four (Table 4). A Pearson correlation coefficient
was calculated to assess the relationship between mean
utility and stages of HH: a moderate negative correlation
was found (r = −0.366; p < 0.001). Whilst lower mean
Table 1 Categories of HH [11]
Category
1
Genetic mutation only (C282Y homozygotes, H63D
heterozygotes and compound heterozygotes)
Category
2
Genetic mutation and elevated iron studies, either transferrin
saturation or serum iron
Category
3
Genetic mutation, elevated iron levels and early symptoms,
including arthritis, fatigue
Category
4
Genetic mutation, elevated iron levels and organ damage
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HSUV were reported for female participants for each
category, these differences were not significant.
To investigate the impact of symptomatic HH on utility,
the four categories of HH were combined into asymptom-
atic (categories 1 and 2), and symptomatic (categories 3
and 4) participants. Utility was significantly lower for the
symptomatic group for males (0.85 v. 0.59: H = 25.36,
p < 0.001), females (0.75 v. 0.58: H = 14.90, p < 0.001)
and overall (0.80 v. 0.58: H = 38.79, p < 0.001) (Table 5).
In keeping with these findings, evaluation of the impact
of HH related comorbidities on utility found all comorbidi-
ties were related to lower mean utility than reported for
participants reporting no comorbidities (0.76) and the
entire HH cohort (0.66) (Table 6). Using the sample mean
utility value as the reference case (0.66), participants self-
reporting arthritis related to HH had a lower mean utility
(0.52: F(1,198) = 10.854, p = 0.001). Whilst lower mean
utility values were reported for fibrosis, cirrhosis, heart
Table 2 Demographic characteristics of the sample
AQol-4D completers AQoL-4D non-completers p value
n = 221 n = 47
Age, mean ± SD 52.7 ± 14.2 53.6 ± 13.2 0.694
Sex (male) 41.6 % 41.3 % 0.552
Relationship status:
currently married/defacto 79.6 % 68.1 % 0.066
Country of birth:
Australia 83.7 % 85.1 % 0.506
United Kingdom 9.0 % 8.5 % 0.584
Highest level of education completeda:
< yr 12 24.7 % 25.0 % 0.565
certificate, Trade etc. 31.7 % 39.4 % 0.245
yr 12 10.4 % 3.0 % 0.149
university 35.7 % 33.3 % 0.476
Labour force participation:
employed full time 32.1 % 17.0 % 0.026
employed part-time 15.4 % 14.9 % 0.568
self-employed 9.0 % 10.6 % 0.455
retired 25.3 % 19.1 % 0.242
Unemployed 5.4 % 4.3 % 0.542
aFor this question, n = 33 for the non-completer group
Table 3 Comparison of HH cohort and Australian population normative utility values [23]
Variables Mean
HSUV
95 % CI n Males Females Population
norm
HSUV
95 % CI
Mean HSUV 95 % CI n Mean HSUV 95 % CI n
Age group:
20–29 0.67 0.55–0.80 10 0.75 0.53–1.00 2 0.65 0.49–0.70 8 0.86 0.85–0.87
30–39 0.72 0.62–0.80 30 0.78 0.66–0.90 7 0.70 0.59–0.81 23 0.84 0.83–0.85
40–49 0.66 0.57–0.74 39 0.72 0.57–0.84 15 0.62 0.50–0.74 24 0.81 0.80–0.82
50–59 0.63 0.54–0.70 52 0.62 0.47–0.75 19 0.63 0.54–0.71 33 0.80 0.78–0.81
60–69 0.67 0.61–0.73 67 0.70 0.62–0.78 34 0.65 0.54–0.74 33 0.80 0.78–0.81
70–79 0.61 0.47–0.73 16 0.63 0.47–0.76 11 0.56 0.21–0.92 5 0.76 0.76–0.79
Sex
Male 0.69 0.64–0.75 92 0.82 0.81–0.83
Female 0.64 0.60–0.69 129 0.81 0.80–0.81
All 0.66 0.63–0.70 221 0.81 0.81–0.82
Note: HSUV refers to health state utility values; 95 % CI refers to the 95 % confidence interval
de Graaff et al. Health and Quality of Life Outcomes  (2016) 14:31 Page 4 of 9
failure, cardiomyopathy, diabetes and porphyria cutanea
tarda, only small numbers of participants reported these
co-morbidities, therefore these should be interpreted with
caution (Table 6).
Participants were also asked to report on experience of
symptoms related to HH and iron overload in the preced-
ing three months (Table 7). Participants were asked if they
thought these symptoms were related to HH, possibly
related or not related. Only participants reporting their
symptoms to be related to HH were included to minimise
over-reporting. Of a maximum of 20 symptoms and con-
ditions, the median number experienced by the sample
was 3 (SD = 3.8, range 0–15). When compared with the
reference HSUV, all symptoms were associated with lower
utility. A Pearson correlation coefficient was calculated to
assess the relationship between symptom count and
HSUV, and a strong negative correlation was found
(r = −0.685; p < 0.001) (Fig. 1).
Discussion
This is the first study that reports HSUV measured dir-
ectly from a cohort with HH. This is of importance, as a
lack of robust health economic data has been cited as a
barrier to implementing population screening programs
for HH [25, 30, 31, 42]. The utility values calculated in this
study provide robust estimates that can be used in future
economic models of screening interventions. Whilst the
sampling strategy may have introduced bias, this has been
mitigated by reporting utility values for categories of HH
rather than across the study population in general. These
values can then be used in combination with penetrance
rates in economic models for HH interventions.
Symptomatic stages of HH (categories three and four
[25]) were associated with lower utility than asymptom-
atic stages. The values for all four categories are useful,
as they incorporate all aspects of HH and related condi-
tions and can be used to populate health economic
models. Previous CUA models have only incorporated
specific comorbidities which are associated with signifi-
cant morbidity and mortality: cirrhosis, diabetes and
heart failure, with no consideration of common comor-
bidities such as arthritis, or symptoms such as fatigue.
This may be related to the relatively high prevalence of
both fatigue and arthritis amongst other populations,
Table 4 Mean utility values by categories of HH by sex
Categories of HH HSUV mean SD n 95 % CI
All participants
Category 1 0.76 0.21 20 0.67–0.85
Category 2 0.81 0.18 63 0.76–0.85
Category 3 0.60 0.27 115 0.55–0.66
Category 4 0.50 0.27 23 0.39–0.61
All categories 0.66 0.26 221 0.63–0.70
Males
Category 1 0.88 0.10 6 0.78–0.98
Category 2 0.85 0.12 29 0.80–0.89
Category 3 0.59 0.28 45 0.51–0.68
Category 4 0.59 0.23 12 0.44–0.74
All categories 0.69 0.27 92 0.64–0.75
Females
Category 1 0.71 0.24 14 0.58–0.84
Category 2 0.77 0.21 34 0.70–0.85
Category 3 0.60 0.26 70 0.54–0.66
Category 4 0.41 0.29 11 0.22–0.60
All categories 0.64 0.26 129 0.60–0.69
Note: HSUV refers to health state utility values; SD standard deviation; 95 % CI
refers to the 95 % confidence interval
Table 5 Mean utility values of symptomatic HH
Categories of HH HSUV mean SD n 95 % CI Between groupsa
All participants
Categories 1 & 2 0.80 0.19 83 0.76–0.84 H = 38.79, p < 0.001
Categories 3 & 4 0.58 0.27 138 0.54–0.63
All categories 0.66 0.26 221 0.63–0.70
Males
Categories 1 & 2 0.85 0.11 35 0.82–0.89 H = 25.36, p < 0.001
Categories 3 & 4 0.59 0.27 57 0.52–0.67
All categories 0.69 0.26 92 0.64–0.75
Females
Categories 1 &2 0.75 0.22 48 0.69–0.82 H = 14.90, p < 0.001
Categories 3 & 4 0.58 0.27 81 0.52–0.64
All categories 0.64 0.64 129 0.60–0.69
Note: HSUV refers to health state utility values; SD standard deviation; 95 % CI refers to the 95 % confidence interval
aKruskal Wallis one way analysis of variance was used for this test for significance
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and the difficulties surrounding the aetiologies of both,
however there is evidence suggesting that the prevalence
of both is higher amongst some groups of HH patients.
The prevalence of fatigue amongst general practice pa-
tients has been estimated to be between 1.4 and 7.0 % of
encounters [43–46]. Work by Allen and colleagues has
reported a much higher rate of 22 % for C282Y homozy-
gotes with elevated serum ferritin levels (greater than
1,000 μg/l) [10]. Similarly, arthritis, specifically osteo-
arthritis, is prevalent in Australia, with 9 % reporting
this condition [47]. Allen and colleagues reported use of
arthritis medication as a proxy measure for arthritis,
noting that 20 % of C282Y homozygotes with serum fer-
ritin greater than 1,000 μg/l reported use of these medi-
cations. In combination, these data guided the decision
to include arthritis and fatigue in the current study.
To date, just four cost utility analyses have been pub-
lished on HH screening programs, none of which cited
the sources of the utility values employed [7, 48–50].
Values were assigned for cirrhosis, diabetes and heart
failure, and in some cases, combinations of these. In a
Norwegian study [48], a basal utility value of 1.00 was
assumed for all HH conditions except cirrhosis, which
was assigned a utility of 0.95, values that are
substantially higher than those reported here. Two Can-
adian studies, by the same research group, used utilities
of 0.8 for cirrhosis, 0.9 for diabetes, 0.5 for heart failure,
0.72 for cirrhosis and diabetes, 0.78 for cirrhosis and
heart failure, 0.87 for diabetes and heart failure and 0.70
for a combination of cirrhosis, diabetes and heart failure
[7, 49]. A fourth study did not provide the utility values
used in the modelling [50]. Some concerns arise in re-
spect of these estimates. First, in comparing these utility
values to US population normative data, a disparity ap-
pears: the mean utility derived from the SF-6D ranged
from 0.79 to 0.81 for persons aged 35 to 74, and simi-
larly, using the EQ-5D, mean utility ranged between 0.87
and 0.89 [51]. The fact that the utility estimates that
were used in cost utility analyses for participants with
health conditions such as cirrhosis and diabetes are simi-
lar to or higher than those reported for the general US
population indicates these estimates may be incorrect.
The likely overestimates of HSUV for HH-related condi-
tions are likely to lead to underestimates of potential
utility gains associated with screening interventions.
Second, disease specific HSUV used in these cost util-
ity analyses are also higher than suggested in published
literature. A meta-analysis of utility values for liver
diseases using a range of approaches to measure utility
reported a mean of 0.75 for compensated cirrhosis
(range 0.65–0.90) and 0.67 for decompensated cirrhosis
(range 0.57–0.81) [52]. Whilst our study did not differ-
entiate cirrhosis in this manner, amongst the small num-
ber of participants reporting this condition (n = 5), the
mean utility (0.61) was slightly lower than reported for
decompensated cirrhosis but within the range reported.
In contrast, the published cost utility analyses used
values of 0.95 [48] and 0.8 [7, 49], higher than the mean
values reported for both compensated and decompen-
sated cirrhosis [52]. Similarly, a meta-analysis of utility
values for diabetes reported a mean of 0.76 (range 0.53–
0.88) [53]. In our study, a mean of 0.52 was reported (n
= 4), slightly lower than the lower range reported in this
meta-analysis. In the three HH cost utility analyses, one
used a utility value for diabetes of 1.00 [48], and two
used a value of 0.9 [7, 49], both notably higher than pub-
lished estimates.
Mean utility for heart failure varies depending on the
severity of the condition. From a large, multi-site trial
that used the EQ-5D, mean utility for different levels of
severity based on the New York Heart Association
(NYHA) classifications were: class I: 0.815, class II:
0.720, class III: 0.590, class IV: 0.508 [54]. Our study re-
ported a mean of 0.58, however data were available for
only three participants, and all were in different NYHA
classes. The two Canadian CUA models used a utility
value of 0.5 [7, 49], which is similar to the NYHA
class 4. In contrast, the Norwegian study assumed a
Table 6 Mean utility values by self-reported HH-related
comorbidities
HH-related comorbiditiesa mean HSUV SD n
All participants
no comorbidity 0.76 0.21 100
arthritis 0.52 0.25 35
fibrosis 0.53 0.29 7
cirrhosis 0.61 0.31 5
heart failure 0.58 0.24 3
cardiomyopathy 0.30 - 1
diabetes 0.52 0.33 4
porphyria cutanea tarda 0.02 - 1
Males
no comorbidity 0.76 0.25 39
arthritis 0.59 0.23 15
fibrosis 0.69 0.05 5
cirrhosis 0.74 0.16 3
Females
no comorbidity 0.76 0.19 61
arthritis 0.48 0.26 20
fibrosis 0.12 0.02 2
cirrhosis 0.42 0.45 2
Note: HSUV refers to health state utility values; SD standard deviation
aParticipants were asked if they had been diagnosed with these conditions
and that they were considered to be related to HH and iron overload.
Participants with these conditions, but were unsure if they were related to HH
were not included in this analysis
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utility of 1.00, which is not in keeping with estimates
in the current literature [48].
To date, no economic analysis has incorporated HSUV
related to arthritis. This is surprising as arthritis related to
iron overload is commonly reported amongst patients diag-
nosed with HH [10, 55–57]. Whilst HRQoL is not syn-
onymous with HSUV, it can serve as an indicator. A study
examining the effects of a range of HH-related comorbidi-
ties using the SF-36 found that, compared to cirrhosis and
diabetes, arthritis was the single strongest factor that im-
pacted on HRQoL [58]. Whilst the paper was published in
1996, no subsequent studies have incorporated utility
values for arthritis. Hawthorne and colleagues, using the
AQOL-4D, reported the Australian normative utility value
for arthritis as 0.69 (SD 0.26). Our study reported a lower
mean value of 0.52 (SD 0.25, n = 35). In the current study,
both self-reported diagnosis of arthritis related to HH and
symptoms suggestive of arthritis were associated with lower
Table 7 Mean utility values for HH related symptoms
Experienced in the last 3 months mean
HSUV
SD n Males Females
mean HSUV SD n mean HSUV SD n
General effects
Chronic fatigue 0.55 0.29 102 0.56 0.31 37 0.55 0.29 65
Weakness 0.49 0.26 87 0.51 0.28 33 0.48 0.26 54
Unexplained weight loss 0.42 0.40 10 1.00 - 1 0.35 0.36 9
Unexplained weight gain 0.50 0.26 30 0.37 0.31 8 0.55 0.23 22
Liver disease
Abdominal swelling 0.40 0.25 35 0.41 0.33 9 0.39 0.22 26
Abdominal pain/discomfort 0.47 0.26 47 0.51 0.31 12 0.46 0.25 35
Enlarged liver (hepatomegaly) 0.40 0.24 15 0.57 0.19 6 0.29 0.21 9
Cardiac-related problems
Swelling of feet and/or ankles 0.46 0.23 47 0.43 0.24 17 0.48 0.22 30
Shortness of breath- walking quickly or uphill 0.50 0.27 64 0.54 0.27 24 0.48 0.26 40
Shortness of breath- walking on level ground 0.36 0.26 29 0.39 0.26 14 0.33 0.27 15
Shortness of breath- resting in a chair 0.31 0.25 8 0.32 0.45 3 0.21 0.24 5
Heart failure or weak heart 0.30 - 1 0.30 - 1 - - -
Abnormal heart rhythm/ arrhythmia 0.55 0.23 25 0.61 0.17 8 0.52 0.26 17
Heart disease 0.52 0.27 6 0.49 0.28 5 0.71 - 1
Arthritis
Swollen/tender metacarpophalangeal joints (fingers/hands) 0.48 0.25 58 0.47 0.30 21 0.49 0.22 37
Other joint stiffness/pain/ache 0.55 0.26 96 0.6 0.26 39 0.51 0.24 57
Skin changes
Change in skin colour 0.45 0.29 25 0.50 0.35 8 0.43 0.27 17
Increased facial hair growth 0.32 0.21 14 - - - 0.32 0.21 14
Reproductive
Loss of libido and/or erectile dysfunction 0.49 0.27 49 0.48 0.27 17 0.49 0.28 32
Unexplained confusion and/or memory loss 0.40 0.24 53 0.39 0.25 18 0.41 0.24 35
Note: HSUV refers to health state utility values; SD standard deviation
Fig. 1 Linear regression of HSUV and symptom count related to HH
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mean utility than the sample mean (0.52, 0.48, 0.66
respectively).
Limitations of this study include cross-sectional design
and use of convenience sampling. Convenience sampling,
which was used as a result of available resourcing, may
limit the generalizability of these results. Further, the
majority of the respondents were female, despite higher
penetrance amongst males. To minimise sampling bias,
we have focused on utility values for categories of disease
and symptomatology for males and females separately.
Whilst an overall sample mean HSUV is likely to be
affected by under- or over-reporting from participants
with more health problems, the mean values for each
category are not affected. This allows for these values, in
combination with penetrance estimates from robust epi-
demiological studies, to be used in HH health economic
models.
A further limitation of this study was the reliance on
participants’ self-report regarding experience of HH re-
lated comorbidities and symptoms. Whilst participants
were asked if the comorbidities were related to HH, even
with clinical verification, it is difficult to be certain of the
aetiology of these. Whilst it can be argued that there may
be some over-reporting of symptoms and comorbidities
believed to be caused by HH, to minimise this possibility,
cases in which participants were unsure of the aetiology
have been excluded. Symptoms and comorbidities were
only included when participants stated that they were
related to HH. Lastly, the small number of participants
reporting HH-related comorbidities was also a limitation.
Whilst utility values were calculated wherever possible,
the small number of respondents means that these data
should be interpreted with caution and that no meaningful
comparisons can be made between these comorbidities.
Conclusions
In conclusion, this is the first study to report utility
values measured directly from people with HH. Despite
study limitations, these values are the best available to
date, and can be used to populate health economic
models investigating the cost utility of HH interventions.
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Haemochromatosis in Australia: A Cost of Illness study 
 
Date  ____/______/ 20___ 
 
Email address: _______________________________ 
Your email address will only be used to send you the link to the follow-up cost diaries. It will 
not be used for any other purpose. 
 
 
 
1a. What is your date of birth?    ____/____/________ 
1b. What is your sex?  
Male……………..0 
 Female………….1 
 
1c. What is your postcode?    _________ 
1d. What is your current relationship status? 
 Currently single, never married…………………..0 
 Currently married or defacto………………………1 
      Currently separated, divorced or widowed….2 
1e. What country were you born in?________________________ 
 
 
DEMOGRAPHICS 
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1f. What is your ancestry/ethnicity (mark all that apply)? 
We are interested in ethnicity as haemochromatosis mostly occurs in people of European 
ancestry. We would like to explore this in the current study. 
        Australian Aboriginal………………………0 
Australian (Caucasian)……………………1 
Chinese…………………………………………2 
Czech…………………………………………….3 
Danish…………………………………………..4 
Dutch…………………………………………….5 
English……………………………………………6 
Finnish…………………………………………..7 
French…………………………………………..8 
German………………………………………..9 
Greek……………………………………………10 
Torres Strait Islander……………………11 
Indian……………………………………………12 
Irish……………………………………………..13 
Italian………………………………………….14 
Kurdish………………………………………..15 
Lebanese……………………………………16 
Maori………………………………………….17 
New Zealand………………………………18        
Norwegian………………………………….19 
Polish………………………………………….20 
Scottish……………………………………..21 
  Spanish………………………………………22 
Vietnamese……………………………….23 
Welsh………………………………………..24 
Other (please specify)_______________________ 
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The following questions are to provide information on the support you have within your 
home and if other people are dependent on you for support 
2a. Which of the following best describes your usual residence? (Please mark one only) 
 I live with my spouse or partner without children…………………………………………………………..0 
 I live with my spouse or partner with children………………………………………………………………..1 
I live only with my children……………………………………..………………………………………………..2 
I live with one of my parents (without children of my own)………………………………………3 
I live with both of my parents (without children of my own)…………………………………….4 
I live with one of my parents with child(ren) of my own……………………………………………..5 
I live with both of my parents with child(ren) of my own…………….……………………………6 
I live with at least one friend, or other people like flatmates in a group household……7 
I live with other people in a hostel or nursing home environment……………………………..8 
I live on my own………………………………………………………………………………………………………..9 
I live with at least one family member (eg sibling, aunt, uncle)…………………………………10 
Other (please specify)______________________________......................................11 
 
2b. Please select the following option that best describes the living environment (Please 
mark one only) 
  Public rented house/unit…………………………………………..0 
Private rented house/unit………………………………………….1 
Family home………………………………………………………………2 
Own home/unit………………………………………………………….3 
Supported accommodation…………………………………..…..4 
No fixed address (i.e. homeless)………………………………..5 
Institution/hospital…………………………………………………….6 
Other (eg caravan), please specify:___________________________ 
 
2c. If you have people who rely on you (eg school children or elderly relatives), please write 
down the number of these people.      
 Children at home and/or still in education            ________ 
 Elderly relatives     ________ 
 Spouse/partner     ________ 
 
HOME ENVIRONMENT 
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The following questions are about your employment, and the impact haemochromatosis 
related health problems may have had on your employment. 
 
3a. Which of the following best describes you current employment status? (mark one only) 
 Employed full-time…………………………………………………………………………………………………………0 
Employed part-time……………………………………………….…………………………………………………1 
 How many hours per week on average do you work? _______hours  
 Self-employed……………………………………………………………………………………………………………….2 
How many hours per week on average do you work? _______hours  
 Unemployed, seeking full-time paid employment…………………………………………………………..3 
Unemployed, seeking part-time paid employment…………………………………………………….4 
Unemployed, not seeking paid employment……………………………………………………………..5 
Unpaid work only (eg home management work)………………………………………………………6 
Unpaid work only (eg volunteer work)……………………………………………………………………10 
Student…………………………………………………………………………………………………………………….7 
Retired, not on a government pension (ie self-funded retiree)………………………………….8 
  What age did you retire? _________years 
  Did you receive a disability payout?   (please circle)       Yes      No 
 Retired, on a government pension……………………………….………………………………………………9 
What age did you retire? _________years 
  Did you receive a disability payout?   (please circle)       Yes      No 
3ai). Do you currently receive any of these government pensions or allowances? (Which 
ones?)   
No……………………………………………………………………………………0 
Abstudy……………………………………………………………………………………1 
Age pension…………………………………………………………………………….2 
Austudy…………………………………………………………………………………..3 
Bereavement allowance………………………………………………………….4 
Carer allowance……………………………………………………………………….5 
Carer payment…………………………………………………………………………6 
CDEP participant supplement………………………………………………….7 
EMPLOYMENT 
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Child care benefit…………………………………………………………………….8 
Child care rebate……………………………………………………………………..9 
Dad and partner pay……………………………………………………………….10 
Disability support pension………………………………………………………11 
Family tax benefit part A…………………………………………………………12 
Family tax benefit part b…………………………………………………………13 
Income support bonus ……………………………………………………………14 
Jobs education and training child care fee assistance…………….15 
Low income family supplement……………………………………………..16 
Low income supplement…………………………………………………………17 
Mobility allowance………………………………………………………………….18 
Newstart allowance………………………………………………………………..19 
Parental leave pay ………………………………………………………………….20 
Parenting payment…………………………………………………………………21 
Partner allowance…………………………………………………………………..22 
Pensioner education supplement………………………………………….23 
Remote area allowance………………………………………………………….24 
Sickness allowance…………………………………………………………………26 
Single income family supplement………………………………………….27 
Special benefit……………………………………………………………………….28 
Widow allowance…………………………………………………………………..29 
Widow B pension…………………………………………………………………..30 
Wife pension………………………………………………………………………….31 
Youth allowance…………………………………………………………………….32 
 
 
3aii) Do you have a type of Concession or Health Care Card? (select all that apply) 
   No…………………………………………………………………………….……0 
  Yes, Pensioner Concession Card…………………………………….1 
  Yes, Commonwealth Seniors Health Card……………………..2 
  Yes, Low Income Health Care Card………………………………..3 
DVA Gold card……………………………………………………………….4 
DVA White card……………………………………………………………..5 
DVA Orange card……………………………………………………………6 
Yes, other (please specify)______________________...7 
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3b. Have you experienced any symptoms related to your haemochromatosis, including 
fatigue, arthritis, diabetes, heart disease, liver disease or any other health problems? 
Yes………….1 
    No…………..0 (skip to Q3c) 
 
3bi. Please state what your occupation is NOW and what it was BEFORE the onset of 
symptoms related to your haemochromatosis, even if it’s the same as now.  
Please complete this whether or not you are currently employed. 
 
Please note these are Australian Bureau of Statistics categories, please read carefully before 
choosing. 
 
 Now Before 
symptoms 
Managers or Administrators: 
Legislators and government appointed officials; general and specialist 
managers; farm managers; Commissioned Officers at management level 
  
Professionals: 
Professionals that are not managers or administrators; Such as: engineers, 
architects, doctors, research scientists, veterinarians, lawyers, registered 
nurses, accountants, auditors, analysts…. 
  
Associate professionals: 
Associates and technicians in engineering and science; dealers and traders in 
finance; shop, outlet or customer service managers; sales, real estate and 
travel agents; chefs; managers in hospitality; health, welfare and police 
officers; sports players and coaches or officials 
  
Trade persons and related workers: 
Skilled agricultural and horticultural workers; mechanical and fabrication 
engineering; tradespersons in automotive, electrical, electronics, 
construction, and food 
  
Advanced clerical and services workers: 
Secretaries, personal assistants and advanced clerical service workers…. 
  
Intermediate clerical, sales and service workers: 
Intermediate clerical, sales and service and related workers 
  
Intermediate production and transport workers: 
Intermediate plant operators, machine operators, road and rail transport 
drivers, other intermediate production 
  
Elementary clerical, sales and service workers: 
Elementary clerical, sales and service workers 
  
Labourers and related workers: 
Cleaners, factory labourers, other labourers and related workers 
  
Other: 
Home duties 
  
Student   
Retired   
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Voluntary work   
Unemployed   
Other (please specify)_________________________________   
 
3bii. If you indicated a change in occupation has occurred since you have experienced 
haemochromatosis-related health problems, was this change related to these? 
   Yes………….1 
   No…………..0 
 
3c. What is your main source of income? 
 Wage/salary…………………………0 
 Superannuation…………………..1 
 Government benefit…………….2 
 Other……………………………………3 (Please specify)__________________________ 
 
3ci. Which of the following is your current gross (before tax) personal income? (please mark 
only one) 
 nil income…………………………………………………………………………………10 
 $1  - $199 per week (less than $10,399 per year)……………………..0 
 $200 - $299 per week ($10,400 - $15,599 per year) ………………….1 
 $300 - $399 per week ($15,600 - $20,799 per year)………………….2 
 $400 - $599 per week ($20,800 - $31,199 per year)………………….3 
 $600 - $799 per week ($31,200 - $41,599 per year)………………….4 
 $800 - $999 per week ($41,600 - $51,999 per year)………………….5 
 $1,000 - $1,249 per week ($52,000 - $64,999 per year)…………….6 
 $1,250 - $1,499 per week ($65,000 - $77,999 per year)…………….7 
 $1,500 - $1,999 per week ($78,000 - $103,999 per year)……………8 
 $2,000 – or more per week ($104,000 or more per year)…………..9 
 
3cii.Which of the following is your current gross (before tax) combined household income? 
(please mark one only) 
 nil income…………………………………………………………………………………10 
 $1  - $199 per week (less than $10,399 per year)……………………..0 
 $200 - $299 per week ($10,400 - $15,599 per year) ………………….1 
 $300 - $399 per week ($15,600 - $20,799 per year)………………….2 
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 $400 - $599 per week ($20,800 - $31,199 per year)………………….3 
 $600 - $799 per week ($31,200 - $41,599 per year)………………….4 
 $800 - $999 per week ($41,600 - $51,999 per year)………………….5 
 $1,000 - $1,249 per week ($52,000 - $64,999 per year)…………….6 
 $1,250 - $1,499 per week ($65,000 - $77,999 per year)…………….7 
 $1,500 - $1,999 per week ($78,000 - $103,999 per year)……………8 
 $2,000 – or more per week ($104,000 or more per year)…………..9 
 
3d. What is the highest level of education you have completed? 
Did not go to school……………….0 
Year 8 or below……………………..1 
Year 9 or equivalent……………..2 
Year 10 or equivalent……………3 
Year 11 or equivalent…………..4 
Year 12 or equivalent……………5 
Trade certificate………………….6 
Certificate II…………………………7 
Associate diploma……………….8 
Advanced diploma ………………9 
Bachelor degree…………………10 
Postgraduate degree………….11 
 
3di. Has having haemochromatosis-related health problems made you leave your 
education? 
 Yes……………………………1 
 No…………………………….0 skip to 3e 
   3dii. If yes, in what year did you have to leave? ______________ 
 
3e. Has having haemochromatosis-related health problems made you leave your paid 
employment? 
Yes……………………………1 
  No…………………………….0 skip to 3f 
3ei. If yes, in what year did you have to leave? ______________ 
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3eii. What were the main reasons you left paid employment? (can mark more than one) 
 Organisational factors 
 Not allowed flexible work hours/work conditions (eg work from home)………………0 
 Not considered for promotion (perceived discrimination)…………………………………….1 
Ran out of paid sick leave………………………………………………………………………………………2 
More suitable work not able to be found within the same organisation ………………3 
Asked to leave/sacked…………………………………………………………………………………………..4 
Getting to/from work 
Unable to get to/from work…………………………………………………………………………………..5 
Unable to obtain appropriate parking (eg close to work)………………………………………6 
Unable to get up and dressed for work………………………………………………………………….7 
Unable to get dressed in time for work………………………………………………………………….8 
Getting around at work 
Architectural barriers (eg stairs)…………………………………………………………………………….9 
General area accessibility…………………………………………………………………………………….10 
Use of equipment at work 
Difficulty with use of necessary equipment…………………………………………………………11 
Difficulty in standing for long periods to use equipment………………………………….…12 
Chair/desk inappropriate for comfort and support……………………………………………..13 
Impact of physical symptoms 
Fatigue/tiredness………………………………………………………………………………………………..14 
Joint pain……………………………………………………………………………………………………………..15 
Abdominal pain……………………………………………………………………………………………………16 
Shortness of breath…………………………………………………………………………………………….17 
Swelling of feet and/or ankles…………………………………………………………………………….18 
Difficulty with performing work due to other symptoms 
Please specify _________________________________________.......................19 
Other reasons 
Feel the people at work are critical of unhelpful or unsympathetic…..…………….20 
Feel as if I’m not doing a good enough job according to my own standards…….21 
Feel as if I’m a burden to my colleagues…………………………………………………………..22 
Feel to stressed by the effort involved with maintain work……………………………..23 
Doctor or health professional advised……………………………………………………………..24 
  Other _____________________________________________________________ 
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3f. Has having haemochromatosis-related health problems made you reduce the hours of your paid 
employment? 
Yes……………………………1 
  No…………………………….0 (skip to Q4a) 
Not applicable………….2 (skip to Q4a) 
3fi. If yes, in which year did this occur? ________________ 
3fii. How many hours were you engaged in employment prior to reducing your hours?  
______hrs 
3fiii. How many hours are you engaged in paid employment now?  
______hrs 
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The following questions are about the assistance you may receive or need from people that you do not pay for yourself. The assistance you 
receive or need is because of your haemochromatosis related health conditions, such as fatigue, arthritis, diabetes, liver or heart disease.  
4a. Following is a list of items you may receive or need assistance for because of your haemochromatosis-related health problems. Please 
report an estimate for the hours of assistance you receive or need per week, for each item. 
  Do not pay for service Estimate the number of 
hours of additional 
support you need but do 
not receive 
  Report hours of assistance provided per week 
N/A Partner/ 
spouse 
Other 
relative 
Friend Volunteer Non-charging 
organisation 
Activities of daily living  (eg personal 
care, meal preparation, physical 
access to or within the home) 
       
Home and garden (eg essential 
household tasks; repairs and 
maintenance; bills and household 
paperwork; maintenance outside 
and garden) 
       
Essential transport        
Child care        
Other (please specify)        
PERSONAL SUPPORT  
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4b. Has someone (e.g. partner, friend) been absent from their paid employment to help you 
with your haemochromatosis related health problems (e.g. support with attending 
appointments or collecting medications, caring for you at home)? 
   Yes……………..1 
No……………….0 (skip to Q4c) 
4bi. In the last 4 weeks, how many hours/days has this person/s been absent for work to 
provide support to you, which was in relation to your haemochromatosis related health 
problems (e.g. arthritis, diabetes, liver disease, heart disease)? 
 _____________hours  
_____________days 
4c. Has someone (e.g. partner, friend) changed their employment situation or conditions to 
help you with your haemochromatosis-related health problems? 
  Yes……………….1 
  No………………..0 (skip to Q5a) 
4ci. If yes, who? (eg partner, child, parent)_________________________ 
 
4cii. Please complete for your support person’s change in employment: 
Average hours per week worked previously _________________hrs 
Average hours per week worked currently _________________hrs 
Average earnings per week previously    $__________ 
Average earnings per week currently   $__________ 
Other change in location or type of work (please specify) _____________________ 
4ciii. Does this person receive a carer’s payment or allowance from the government 
in relation to the care they provide you? 
  No………………………….……...0 
Yes, carer’s payment……..1 
Yes, carer’s allowance……2 
Don’t know…………………….3 
 
 
 
 
Appendix 3B: Survey 
  
118 | P a g e  
 
 
 
These next questions ask about any health insurance you may have, and changes to this due 
to your haemochromatosis. 
5a. Do you currently have Private Health insurance? 
  Yes……………….1 
  No………………..0(skip to Q5b) 
 5ai. If yes, what level of cover do you have: 
   Hospital only…………………………0 
Extras only……………………………1 
Hospital and extras ……………..2 
Other…………………………………..3  specify_________________________ 
5b. Have you changed your private health insurance cover because of your 
haemochromatosis-related health problems? 
  Yes……………….1 
  No………………..0 (skip to Q6a) 
5bi. If yes, what were the reason(s) 
   Can’t afford premiums so decreased level of cover………………….……...0 
Can’t afford premiums so stopped cover………………………………………….1 
Don’t believe the benefit is worth the cost of the premiums…………..2 
Don’t believe I need it now………………………………………………………………3 
Started cover so did not have to be on waiting list…………………………..4 
Increased level of cover so receive benefits for more services………..5 
Other (please specify)_________________________........................6 
 
5bii. What was the level of care you used to have? 
   No cover…………………………..0 
Hospital only…………………….1 
Extras only……………………….2 
Hospital and extras………….3 
Other……………………………….4 
 
INSURANCE  
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The next set of questions asks you about your health. 
 
6a. In what year were you told you had haemochromatosis? ___________ 
6b. How were you diagnosed with haemochromatosis? 
 Family member diagnosed, so I got tested………………………………………..0 
 GP tested because I had symptoms …………………………………………………1 
 GP tested, but I didn’t have symptoms……………………………………………..2 
 Specialist Dr tested because I had symptoms……………………………………3 
 Specialist Dr tested, but I didn’t have symptoms……………………………….4 
 Other specify_______________________________ 
 
6c  If you remember the result of you iron level blood tests when you were first diagnosed, 
please  
 specify what it was. 
 This may include transferrin, ferritin, iron levels and/or total iron-binding capacity. Please 
provide as much information as you can.  
___________________________________________________________________________
___________________________________________________________________________
______________ 
 
6d. Have you had a genetic test for haemochromatosis? 
Yes……………….1 
   No………………..0 (skip to Q6e) 
 6di. If yes, what was the result? 
  C282Y Homozygote…………………………………………0 
  C282Y/H63D compound heterozygote…………….1 
  H63D Homozygote…………………………………………2 
  S56C Homozygote………………………………………….3 
  S56C/C282Y compound heterozygote……………4 
HAEMOCHROMATOSIS RELATED 
HEALTH   
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  S56C/H63D compound heterozygote…………….5 
  Other……………………………………………………………..6 
  Declined………………………………………………………..8   
  Don’t know/can’t remember…………………………7 
 
6e. Some doctors and researchers have suggested there are 4 main categories/stages of 
haemochromatosis. Please indicate the category you would be in: 
Please note there is no evidence to suggest that people with haemochromatosis will progress 
through all of these stages. In fact, early treatment means haemochromatosis is unlikely to 
cause any health problems. 
1. Genetic mutation ONLY, no health problems related to haemochromatosis…………….0 
2. Iron overload ONLY (raised serum ferritin and/or transferrin saturation)…………………1 
3. Iron overload AND early symptoms (fatigue and arthritis)..……………………………….…….2 
4. Iron overload AND organ damage (such as diabetes, liver diseases, heart disease)….3 
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6f. The following questions will ask if you have ever been diagnosed with a range of health conditions, and if they were/are related to your 
haemochromatosis.  
 
 
 
 
 
Liver 
disease: 
 
 
 
 
 
 
 
 
 
 
Fibrosis 
 
No 
Yes, related to 
haemochromatosis 
Yes, but not related 
to 
haemochromatosis 
Yes, but not sure if 
this is related to 
haemochromatosis 
Year of 
diagnosis 
     
Cirrhosis      
Carcinoma (cancer)      
Heart 
disease 
 
 
 
Heart failure 
     
Cardiomyopathy      
Other (please specify)      
Arthritis       
Diabetes      
Porphyria cutanea tarda (Increased growth of 
hair on face) 
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6g. The list below includes several effects and complications of haemochromatosis and iron 
overload. Please indicate if you have experienced any of these in the past 3 months AND 
they were (or were likely to be) related to your haemochromatosis. 
 Experienced in the last 
3 months 
General effects 
Chronic fatigue 
 
Weakness  
Unexplained weight loss  
Unexplained weight gain  
Liver disease 
Abdominal swelling 
 
Abdominal pain/discomfort  
Enlarged liver (hepatomegaly)  
Diabetes  
Heart-related problems 
Swelling of your feet and/or ankles 
 
Shortness of breath- walking quickly or uphill  
Shortness of breath- walking on level ground  
Shortness of breath- resting in a chair  
Heart failure or weak heart  
Abnormal heart rhythm/ arrhythmia  
Heart disease  
Arthritis 
Swollen/tender metacarpophalangeal joints 
(fingers/hands) 
 
Other joint stiffness/pain/ache  
Skin changes 
Change in skin colour 
 
Increased facial hair growth  
Hypogonadism  
Loss of libido, erectile dysfunction 
 
Unexplained confusion and/or memory loss  
Other (please specify) 
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7a. As far as you know, do you have any of the following health conditions at the present 
time (tick all that apply): 
 Yes 
Asthma, emphysema, or chronic bronchitis  
Arthritis or rheumatism  
Cancer, diagnosed in the past 3 years  
Diabetes  
Digestive problems (such as ulcer, colitis, or 
gallbladder disease) 
 
Heart trouble (such as angina, congestive 
heart failure, or coronary artery disease) 
 
HIV illness or AIDS  
Kidney disease  
Liver problems (such as cirrhosis)  
Stroke  
 
 
 
 
 
 
 
 
 
 
 
Charlson Comorbidity Index 
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Q8. Have you ever been diagnosed with heart disease related to your haemochromatosis? 
  Yes…………1 
  No………….0 (skip to Arthritis section) 
Q8a. These questions are related to the impact heart disease has on your day to day health.   
         Please tick one box ONLY. 
 Tick ONE 
box only 
I can perform all physical activity without getting short of breath, tired or 
having palpitations 
 
I get short of breath or tired, or have palpitations when performing more 
strenuous  activities, eg walking on steep inclines or walking up several 
flights of steps 
 
I get short of breath or tired, or have palpitations when performing day to 
day activities, eg walking on the flat  
 
I feel breathless at rest and am mostly housebound. I am unable to carry 
out any physical activity without getting short of breath or tired, or having 
palpitations 
 
 
 
 
 
 
 
 
 
 
 
Heart Disease 
Appendix 3B: Survey 
  
125 | P a g e  
 
 
 
 
 
Q9. Have you ever been diagnosed with arthritis related to your haemochromatosis? 
  Yes…………1 
  No………….0 (skip to Diabetes section) 
Assessment of Pain 
Please answer the following question by placing a mark through the horizontal line. 
9a. On this line, in your left fingers, where would you rate your pain?  Use the last 30 days 
as a time frame. 
 
 
9b. On this line, in your left wrist, where would you rate your pain?  Use the last 30 days as 
a time frame. 
 
 
9c. On this line, in your left elbow, where would you rate your pain?  Use the last 30 days as 
a time frame. 
 
 
9d. On this line, in your left shoulder, where would you rate your pain?  Use the last 30 days 
as a time frame. 
 
 
9e. On this line, in your left hip, where would you rate your pain?  Use the last 30 days as a 
time frame. 
 
 
9f. On this line, in your left knee, where would you rate your pain?  Use the last 30 days as 
a time frame. 
 
9g. On this line, in your left ankle, where would you rate your pain?  Use the last 30 days as 
a time frame. 
 
 
Arthritis 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
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9h. On this line, in your left toes, where would you rate your pain?  Use the last 30 days as 
a time frame. 
 
 
9i. On this line, in your neck, where would you rate your pain?  Use the last 30 days as a time 
frame. 
 
 
9j. On this line, in your right fingers, where would you rate your pain?  Use the last 30 days 
as a time frame. 
 
 
9k. On this line, in your right wrist, where would you rate your pain?  Use the last 30 days 
as a time frame. 
 
 
9l. On this line, in your right elbow, where would you rate your pain?  Use the last 30 days 
as a time frame. 
 
 
9m. On this line, in your right shoulder, where would you rate your pain?  Use the last 30 
days as a time frame. 
 
 
9n. On this line, in your right hip, where would you rate your pain?  Use the last 30 days as 
a time frame. 
 
 
9o. On this line, in your right knee, where would you rate your pain?  Use the last 30 days 
as a time frame. 
 
 
9p. On this line, in your right ankle, where would you rate your pain?  Use the last 30 days 
as a time frame. 
 
 
 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
None Unbearable 
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9q. On this line, in your right toes, where would you rate your pain?  Use the last 30 days as 
a time frame. 
 
 
9r. On this line, in your back, where would you rate your pain?  Use the last 30 days as a 
time frame. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
None Unbearable 
None Unbearable 
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Q10. Have you ever been diagnosed with diabetes related to your haemochromatosis? 
  Yes…………1 
  No………….0 (skip to 11a) 
Diabetes related to HH:  
10a. In what year were you diagnosed with diabetes?  ________________ 
10b. Have you experienced any of the following complications due to diabetes: 
 Yes 
Eyes: 
Macular oedema 
 
Nonproliferative retinopathy  
Proliferative retinopathy  
Laser therapy  
Blindness  
Kidneys: 
                    Microalbuminuria  
 
Macroalbuminuria  
End stage renal disease (dialysis or kidney transplant)  
Neuropathy 
Peripheral neuropathy: 
Numbness/tingling or pain in toes, feet, legs, hands, arms 
or fingers 
 
Foot ulcers  
Autonomic neuropathy  
Proximal neuropathy  
Focal neuropathy  
 
 
Amputation: 
toe/s 
 
foot  
below knee  
above knee  
Diabetes 
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other  
Cardiovascular disease 
Coronary artery disease/angina 
 
Myocardial infarction  
Stroke/TIA  
 
 
 
 
11a.  Apart from any haemochromatosis related health problems, do you experience any 
other health problems? 
Yes……………….1 
  No………………..0 (skip to Quality of Life) 
If yes, please list below Year of 
diagnosis or 
onset 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11b. Do these conditions cause you any disability? 
Yes……………….1 
   No………………..0 (skip to Quality of Life) 
 11bi. Do these conditions cause you more disability than your haemochromatosis-
related health problems? 
  Yes……………….1 
  No………………..1  
OTHER HEALTH PROBLEMS 
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Tick the box next to the response that best fits your situation  
 
aqol1. Do you need any help looking after yourself? (For example: dressing, bathing, eating)  
☐I need no help at all.  
☐Occasionally I need some help with personal care tasks.  
☐I need help with the more difficult personal care tasks.  
☐I need daily help with most or all personal care tasks.  
 
aqol 2. When doing household tasks: (For example: cooking, cleaning the house, washing)  
☐I need no help at all.  
☐Occasionally I need some help with household tasks.  
☐I need help with the more difficult household tasks.  
☐I need daily help with most or all household tasks.  
 
aqol 3. Thinking about how easily you can get around your home and community:  
☐I get around my home and community by myself without any difficulty.  
☐I find it difficult to get around my home and community by myself.  
☐I cannot get around the community by myself, but I can get around my home with some 
difficulty.  
☐I cannot get around either the community or my home by myself.  
 
aqol 4. Because of your health, your relationships (for example: with your friends, partner 
or parents) generally:  
☐Are very close and warm.  
☐Are sometimes close and warm.  
☐Are seldom close and warm.  
☐I have no close and warm relationships.  
 
aqol 5. Thinking about your relationship with other people:  
☐I have plenty of friends, and am never lonely.  
☐Although I have friends, I am occasionally lonely.  
☐I have some friends, but am often lonely for company.  
☐I am socially isolated and feel lonely.  
QUALITY OF LIFE 
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aqol 6. Thinking about your health and my relationship with my family:  
☐My role in the family is unaffected by my health.  
☐There are some parts of my family role I cannot carry out.  
☐There are many parts of my family role I cannot carry out.  
☐I cannot carry out any part of my family role. 
 
aqol 7. Thinking about your vision, including when using your glasses or contact lenses if 
needed:  
☐I see normally  
☐I have some difficulty focusing on things, or I do not see them sharply.  
For example: small print, a newspaper or seeing objects in the distance.  
☐I have a lot of difficulty seeing things.  
My vision is blurred. For example: I can see just enough to get by with.  
☐I only see general shapes, or am blind.  
For example: I need a guide to move around.  
 
aqol 8. Thinking about your hearing, including using your hearing aid if needed:  
☐I hear normally  
☐I have some difficulty hearing or I do not hear clearly.  
For example: I ask people to speak up, or turn up the TV or radio volume.  
 
☐I have difficulty hearing things clearly.  
For example: Often I do not understand what is said. I usually do not take part in conversations 
because I cannot hear what is said.  
 
☐I hear very little indeed.  
For example: I cannot fully understand loud voices speaking directly to me.  
 
aqol 9. When you communicate with others: (For example: by talking, listening, writing or 
signing.)  
☐I have no trouble speaking to them or understanding what they are saying  
☐I have some difficulty being understood by people who do not know me. I have no trouble 
understanding what others are saying to me.  
☐I am only understood by people who know me well. I have great trouble understanding 
what others are saying to me.  
☐I cannot adequately communicate with others.  
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aqol 10. Thinking about how you sleep:  
☐I am able to sleep without difficulty most of the time.  
☐My sleep is interrupted some of the time, but I am usually able to go back to sleep without 
difficulty.  
☐My sleep is interrupted most nights, but I am usually able to go back to sleep without 
difficulty.  
☐I sleep in short bursts only. I am awake most of the night.  
 
aqol 11. Thinking about how you generally feel:  
☐I do not feel anxious, worried or depressed.  
☐I am slightly anxious, worried or depressed.  
☐I feel moderately anxious, worried or depressed.  
☐I am extremely anxious, worried or depressed.  
 
aqol 12. How much pain or discomfort do you experience:  
☐None at all.  
☐I have moderate pain.  
☐I suffer from severe pain.  
☐I suffer unbearable pain.  
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Chapter 4: Costs associated with hereditary 
haemochromatosis in Australia: A cost of illness study 
4.1  Preface 
In the systematic review presented in Chapter 2, no literature was identified that quantified 
the quality of life or economic burdens associated with haemochromatosis. In the preceding 
chapter, data on the health state utility values were presented, clearly establishing that more 
severe stages of haemochromatosis are correlated with poorer quality of life, evidenced by 
the significantly lower utility values for these groups. 
Chapter 4 presents data on the economic burden associated with haemochromatosis in 
Australia. A national cost of illness study was conducted to quantify the costs from the patient, 
government and societal perspectives. Costs included those arising from the health sector, 
other sector and time/productivity losses. These data establish the economic burden 
associated with the haemochromatosis, and can be used to populate future health economic 
models for haemochromatosis interventions. 
 
This chapter has been accepted by Australian Health Review (Appendix 4A)  
de Graaff, B., Neil, A. Sanderson K, Yee, K.C. & Palmer AJ. “Costs associated with hereditary 
haemochromatosis in Australia: A cost of illness study” Australian Health Review. Accepted 
for publication. 
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4.2  Abstract 
Objective: To assess health sector, other sector and time-related (productivity) costs 
associated with hereditary haemochromatosis from societal, government and patient 
perspectives for the Australian setting. 
Methods: A national web-based survey of people with haemochromatosis was conducted 
between November 2013 and February 2015. Participants completed a health survey and 
resource-use diaries.  Costs were calculated using a bottom-up approach and calculated in 
2015 Australian dollars. 
Results: Cost data were available for 157 participants. From a societal perspective, the 
estimated annual cost of haemochromatosis was AUD274 million. Mean cost for symptomatic 
patients (AUD10,030: 95%CI 7,705-12,670) was almost three times that of asymptomatic 
patients (AUD3,701: 95%CI 2,423-5,296). Health sector and productivity-related time-loss 
were the main cost drivers. When extrapolating costs to the Australian population level, 
asymptomatic haemochromatosis accounted for higher costs than symptomatic 
haemochromatosis (AUD183 million versus 91 million), reflecting the low clinical penetrance 
estimate used. Total costs increased when higher clinical penetrance estimates were used. 
Conclusion: This cost of illness study, the first to be published for haemochromatosis, found 
that whilst costs were substantial, they could be decreased by reducing clinical penetrance. 
Development of cost effective strategies to increase early diagnosis is likely to result in 
better health outcomes for patients and lower total costs.  
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4.3  Introduction  
Hereditary haemochromatosis is a common autosomal recessive disorder amongst people of 
northern European ancestry [1-3]. Clinically, haemochromatosis is characterised by increased 
absorption of dietary iron, which is stored in the parenchymal tissues of the liver, heart and 
pancreas. If untreated, this can be the cause of morbidity, including type 2 diabetes, heart 
disease and liver disease. 
Whilst several mutations of the HFE gene have been identified, C282Y homozygotes account 
for between 80 and 90% of morbidity and mortality [4, 5]. Other mutations are rarely 
observed to cause comorbidity related to iron overload [6, 7]. Between 1 in 150 to 200 people 
of northern European ancestry are estimated to be C282Y homozygotes; in other populations 
this is considerably lower to non-existent [7-12]. 
As iron stores increase, symptoms may progress from lethargy and arthropathy of the 
metacarpophalangeal joints to Type 2 diabetes, liver disease and heart disease. Symptoms of 
iron overload are most commonly reported in male patients aged over 30 years; symptom 
onset is typically later in females as menstruation reduces iron stores [7, 13, 14]. 
Clinical penetrance (individuals exhibiting symptoms) is incomplete and widely differing rates 
have been reported. For C282Y homozygotes, reported rates have varied between 2% and 
76% [4, 5, 7, 8, 15-26]. This variance can in part be explained by use of  different definitions 
of penetrance: iron studies with different iron elevation cut-off points, clinically assessed 
symptoms or self-reported symptoms [27]. For other common genotypes such as the H63D 
and S56C mutations, clinical penetrance is much lower, with some authors noting no 
association between the S56C allele and elevated transferrin saturation [28].  
This issue of differing definitions of clinical penetrance and the resulting lack of 
generalizability of much of this body of research was recognised by the European Association 
for the Study of the Liver (EASL). In 2000, a consensus document was published outlining four 
categories of disease (Table 1) [27]. These categories have been adopted by a small number 
of other studies. One study reported penetrance of C282Y homozygosity, defined as 
categories 2 through to 4, as 15.8%; 12.1% for categories 3 and 4; and 2.9% for category 4 
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[29]. Similarly, an Australian study of a random sample of participants reported a penetrance 
rate, defined as categories 3 and 4, of 13.9% amongst C282Y homozygotes [8].  
Table 1: Categories of haemochromatosis [27] 
Category 1 Genetic mutation only (C282Y homozygotes, H63D heterozygotes and compound 
heterozygotes) 
Category 2 Genetic mutation and elevated iron studies, either transferrin saturation or serum 
iron 
Category 3 Genetic mutation, elevated iron levels and early symptoms, including arthritis, 
fatigue 
Category 4 Genetic mutation, elevated iron levels and organ damage 
 
Diagnosis and treatment of haemochromatosis are relatively straightforward. Diagnosis 
involves conducting serum iron studies (transferrin saturation and serum ferritin) followed by 
confirmatory HFE genotyping. Treatment consists of regular therapeutic venesection [30].  
When treatment is commenced prior to irreversible organ damage, the patient retains normal 
life expectancy [2, 30]. As early symptoms of iron overload are non-specific, in some cases 
diagnosis occurs subsequent to organ damage [31, 32]. Population screening programs have 
been suggested to increase the rate of early diagnosis, thereby reducing morbidity and 
mortality associated with haemochromatosis [27, 33-35]. To date, no quantification of the 
costs of haemochromatosis has been published. A cost of illness (COI) study estimates all 
relevant costs from the perspectives of the patient, government and/or society. The preferred 
method is a bottom-up COI analysis that incorporates observational data [36]. This study 
sought to calculate the health sector, other sector and time-loss costs of haemochromatosis 
from the societal, government and patient perspectives for the Australian setting.  
4.4  Methods 
A web-based cross-sectional COI study using convenience sampling was conducted across 
Australia between November 2013 and February 2015. Multiple recruitment strategies were 
used to maximise participation: emails were sent to all members of the national 
haemochromatosis support group (Haemochromatosis Australia, HA) informing them of the 
project and the web address; a link to the survey was placed on HA’s website; flyers were sent 
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to large Australian metropolitan hepatology, haematology and gastroenterology clinics, along 
with general practitioners sourced from HA’s referral network. In addition, advertisements 
were placed on social media sites and newspaper articles about the condition and the study 
were published. To augment recruitment, case finding was conducted in all Tasmanian public 
hospitals. All patients admitted between July 2009 and June 2014 with a diagnosis of 
haemochromatosis, as identified in the ICD-10-AM by code E831, were sent letters by the 
research group, informing them of the study and inviting them to participate. Ethical approval 
for the study was granted by the Tasmanian Health and Medical Research Ethics Committee 
(H0013564).  
Participants initially completed a survey on health, income, employment and health-related 
quality of life. This survey was followed by resource-use diaries. Participants were requested 
to complete the diary retrospectively for the preceding four weeks at monthly intervals  over 
a three month period i.e. three diaries in total. The resource-use diary asked participants to 
only record resources used that were directly related to haemochromatosis-related health 
conditions, such as arthropathies, type 2 diabetes, heart disease and liver disease. For each 
condition, participants were then asked if it was a) related to iron overload; b) not related to 
iron overload; or c) unsure. Cost data were excluded if participants gave responses b or c. 
Resources included prescribed and non-prescribed drugs, supplements, medical 
appointments, medical investigations and procedures, hospitalisations (inpatient and 
outpatient), purchase of specialised equipment and transport costs. Data on time-related 
impacts, such as absenteeism, presenteeism and transfer payments related to 
haemochromatosis, were also collected. 
4.4.1 Costing 
The annual costs of haemochromatosis in Australia in 2015 have been estimated from a 
bottom-up, prevalence-based analysis, based on previously-reported methodologies [37, 
38]. Costs were estimated by calculating an average monthly cost for each category of 
resource and extrapolating this to 12 months. Costs from the perspectives of the patient, 
government and society by EASL categories were assessed.  All costs were calculated in 
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2015 Australian dollars (1AUD=0.75USD).  An overview of the costing methodology is 
presented below and a full description is included in Appendix 4B. 
 
Health sector costs 
Prescribed and non-prescribed medications, supplements 
Unit costs for prescribed drugs were calculated using the 2015 Pharmaceutical Benefits 
Scheme (PBS) Price Schedule of January 1, 2015 [39]. Frequency and dosage data were used 
to estimate an annual cost per participant. These costs were summed and safety net 
thresholds and costs were calculated based on concession card status.  
 
Costs for non-prescribed medications and supplements were estimated by calculating the 
mean cost for each item based on the prices reported by three large online Australian 
pharmacies during January 2015 (Pharmacy Direct, Pharmacy Online, Chemist Warehouse).  
 
Medical appointments, investigations and interventions 
Costs of medical appointments (general practitioner and specialist) were calculated based 
on the length of the appointment, with unit costs derived from the Medicare Benefits 
Schedule (MBS) Book (January 1, 2015) [40]. Unit costs for all investigations were also 
derived from this resource. For each participant, annual expenditure was calculated, MBS 
safety net thresholds applied and costs calculated by perspective.  
 
Hospitalisations 
Hospitalisation costs were broken up into public and private; inpatient, outpatient and 
emergency only presentations. For public inpatient admissions, prices were assigned using 
the National Hospital Cost Data Collection cost weights for Australian Refined Diagnosis-
Related Group (AR-DRG) version 6.0x, round 16 (2011-12) [41]. These costs were then 
adjusted for inflation using the price index for Government final consumption expenditure on 
hospitals and nursing homes, 2012/13 [42]. Costs for public outpatient admissions were taken 
from the Independent Hospital Pricing Authority [43]. For attendance at a private hospital 
emergency department (ED), costs were calculated by taking a sample of published costs from 
private hospitals and calculating the mean (no participants reported attendances at public 
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ED, private outpatients clinic or inpatient admissions). 
Specialised equipment 
Specialised equipment included use of equipment specific to haemochromatosis-related 
conditions, such as domestic tools for assistance with arthritis. Unit costs for these items were 
estimated by calculating the mean cost obtained from the three online pharmacies and 
specialist suppliers of equipment in February 2015. Amortisation of costs of goods with a life 
expectancy greater than one year was carried out [44].  
Other sector costs 
Transport 
Transport costs were estimated by asking participants to record the distance travelled in the 
preceding month for haemochromatosis-related treatment. Fuel consumption was calculated 
using average fuel consumption for a private vehicle data from the Australian Bureau of 
Statistics [45]. The average national fuel price was taken from the Australian Institute of 
Petroleum, on April 5, 2015 [46]. 
Time-loss costs 
Time-loss costs incorporated productivity losses from the societal perspective, and transfer 
costs from the government perspective [38]. Time-loss costs were not calculated from the 
patient perspective.  A modified human capital approach was used to value time-loss costs 
[44]. Absenteeism was costed using questions adapted from the World Health Organization 
Health and Work Performance Questionnaire [47].  Mean annual number of days absent was 
calculated for each participant, and mean weekly earnings were taken from the Australian 
Bureau of Statistics for age and sex for 2013 [48]. Weekly earnings were adjusted for inflation 
using the Consumer Price Index (CPI) for June 2013 as the base year (102.8) and for March 
2015 (106.8) [49]. Annual days absent were costed using this wage data and reported in 2015 
AUD. Appendix 4B provides further explanation regarding the methodology employed.   
Presenteeism (attending work when unwell) is associated with a loss of productivity and 
therefore incurs a cost. Participants were asked to report the number of days in the preceding 
month that they had attended work whilst suffering a health problem related to 
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haemochromatosis. Participants then provided a subjective rating of their productivity by 
indicating the percentage of time they were as productive as usual [50, 51]. Presenteeism was 
converted to days absent, with costs calculated using the same methodology for absenteeism. 
Carer’s time-loss costs were calculated by converting hours and/or days lost in provision of 
care or support for a haemochromatosis-related event to days lost. The unit cost was the 
mean Australian wage (2013) inflated using the March 2015 CPI [48, 49].  
Transfer payments (government welfare, e.g. Disability Support Pension) to participants for 
haemochromatosis-related conditions were costed. Payments comprised those related to 
their haemochromatosis condition, cross-checked with the self-reported health conditions. 
Similarly, transfer payments to carers were costed depending on the form of payment 
received (Carer’s Payment, Carer’s Allowance).  
4.4.2 Population cost estimates 
As convenience sampling was used for this study, the sample may not be representative of 
all people in Australia with haemochromatosis. Assumptions used in the base case costing 
extrapolations were taken from the most robust datasets and studies available. Table 2 
provides an overview of these.  
 
The profile of clinical penetrance that Allen and colleagues report is comparable to EASL’s 
categories 3 and 4 (Table 1) and used in the current study. Costs were calculated from 
patient, government and societal perspectives and extrapolated to the population based on 
these prevalence and penetrance estimates.  Initially, costs were only assigned to 31% of 
C282Y homozygotes in Australia: an estimate of the proportion of C282Y homozygotes likely 
to be diagnosed through current approaches to diagnosis (cascade screening or incidental 
diagnosis) (L. Gurrin, Principal Investigator, HealthIron study, personal communication, 
March 16 2015).  
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Table 2: Assumptions used in base case costing calculations 
Base-case assumptions   Assumptions n 
Australian population aged 20 or older [52] 
Of northern European ancestry [53] 
Prevalence of C282Y homozygotes * [8] 
Diagnosed as C282Y homozygote ~ 
Penetrance  (categories 3 and 4) [54] 
- 
66% 
0.68% 
31% 
13.9% 
16,652,952 
10,990,948 
74,738 
23,3169 
3,220 
* Amongst people identifying as having Northern European ancestry 
~ Either through cascade screening or incidental diagnosis (L. Gurrin, personal communication, March 16 2015). 
 
To provide a more accurate estimate of total costs associated with haemochromatosis in 
Australia, costs were also estimated for the 69% of undiagnosed homozygotes. Raw cost data 
were recalculated by subtracting all costs for therapeutic venesection, and all costs for 
category 1 patients were set at zero.  Other costs were maintained as it was assumed that 
resources would be consumed irrespective of a formal diagnosis. Assumptions in Table 2 were 
retained. 
4.4.3 Sensitivity analyses 
To reflect the variable penetrance rates reported in the literature, a sensitivity analysis 
around this was conducted.  Penetrance estimates were varied between 1% and 50% [8, 25, 
26, 52, 53] to understand how this impacts on total costs. Both diagnosed and undiagnosed 
C282Y homozygotes were included. 
 
4.4.4 Statistical analysis 
Simple descriptive statistics were assessed. Demographic characteristics were analysed using 
ANOVA and chi square.  As cost data were not normally distributed, bootstrapping (x1,000) 
was employed to calculate 95% confidence intervals [54, 55]. Comparisons between costs are 
considered to be statistically significant when there is no overlap between confidence 
intervals. This is considered to be a conservative approach [56].  Analysis was conducted using 
SPSS version 22.0.0.0 and Excel for Windows. 
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4.5  Results  
4.5.1 Demographic characteristics 
Two hundred and sixty-six participants completed at least one part of the four elements of 
this survey: 157 completed the initial health questionnaire and at least one resource use diary, 
and 109 participants completed only the initial health questionnaire. Participants completing 
the initial survey and at least one resource use diary were included in the cost analysis.  
Demographic differences between participants completing at least one resource use diary (in 
addition to the initial survey) and those who did not complete this were examined (Table 3). 
Diary-completers were older (56 yrs v. 48 yrs, p<0.001), and more likely to be retired from the 
workforce (33.6% v. 17.9%, p=0.014).  
For participants included in the cost analysis, demographic characteristics were compared 
across EASL categories. Participants in category 4 were older than participants in the other 
categories (63 years v. 55-56 years, p=0.011) and were more likely to report being retired 
(62% v. 27%, p=0.002) (Table 3).  
In comparison with the HealthIron study, which recruited a large representative sample of 
Australian adults with haemochromatosis, our cohort consisted of a lower percentage of 
males (41% v. 47%) and a higher rate of clinical penetrance (categories 3 and 4: 63% v. 24%) 
[8]. In addition the median age of HealthIron participants at follow-up by genotype ranged 
between 63.2 and 66.6years (no mean age reported), older than the median age of our cohort 
(57 years). Our study thus recruited a more severely affected population on average. 
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Table 3: Demographic characteristics  
 diary completers (n=157) diary non-completers 
(n=109) 
p value 
Mean age (range, SD) 
Male 
Employment status: 
employed full-time 
employed part-time 
 retired 
other 
Category of haemochromatosis 
 category 1 
category 2 
category 3 
category 4 
56yrs (19-83, SD=13.16) 
41.4% (65) 
 
29.3% (46) 
14.0% (22) 
33.6% (46) 
27.0% (43) 
 
7.6% (12) 
29.3% (46) 
49.7% (78) 
13.4% (21) 
48yrs (18-73, SD=13.75) 
42.2% (46) 
 
30.6% (33) 
15.7% (17) 
17.9% (12) 
57.0% (62) 
 
11.4% (10) 
26.1% (23) 
51.1% (45) 
9.1% (8) 
p<0.001 
0.498 
 
0.466 
0.413 
0.014 
- 
 
0.226 
0.354 
0.466 
0.217 
Diary completers (n=157)    
 Category 1 (n=12) Category 2 (n=46) Category 3 (n=78) Category 4 (n=21) 
Mean age (range, SD) 
 
Male 
Employment status: 
employed full-time 
employed part-time 
self-employed 
 retired 
other 
56 (SD=7.9,41-69) 
 
25% (3) 
 
8% (1) 
33% (4) 
17% (2) 
25% (3) 
17% (2) 
55 (SD=14.2,28-81) 
 
48% (22) 
 
30% (14) 
17% (8) 
11% (5) 
28% (13) 
13% (6) 
55 (SD=13.8,19-83) 
 
36% (28) 
 
37% (29) 
13% (10) 
8% (6) 
27% (21) 
15% (12) 
63 (SD=8.7,46-79) 
 
57% (12) 
 
10% (2) 
0% 
14% (3) 
62% (13) 
14% (3) 
 
4.5.2 Base-case results 
Mean and 95% confidence intervals for health sector, other sector and time-loss costs 
associated with the categories of (diagnosed) haemochromatosis are displayed in Table 4. A 
breakdown of these costs is displayed in Appendix 4C.  The mean costs for each perspective 
increased as severity of disease increased. From the societal perspective, mean annual costs 
per patient in category 1 were AUD1,431 as compared to AUD11,882 in category 4. The main 
drivers of this increase were health sector and productivity costs. Similarly, mean costs from 
the government perspective increased from AUD824 for category 1 to AUD10,393 for 
category 4, with health sector and transfer costs being the main drivers. Mean costs from the 
patient perspective increased from AUD607 in category 1 to AUD2,066 in category 4. This 
increase was largely driven by health sector costs. 
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Table 4: Costs of haemochromatosis by category 
 Patient perspective 
(AUD/person) 
Government perspective 
(AUD/person) 
Societal perspective 
(AUD/person) 
 mean cost 
(95%CI) 
Median costs 
[IQR] 
mean cost  
(95%CI) 
Median costs 
[IQR] 
mean cost  
95%CI) 
Median costs  
[IQR] 
Category 1 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
 
560 (165-989) 
47 (0-136) 
n/a 
607 (209-1041) 
 
197 [6-1201] 
0 [0-23] 
n/a 
250 [6-1314] 
 
824 (278-1454) 
n/a 
0 
824 (287-1441) 
 
552 [0-1440] 
n/a 
0 
552 [0-14404] 
 
1384 (546-2308) 
47 (0-136) 
0 
1431 (643-2262) 
 
1498 [14-2138] 
47 [0-23] 
0 
1559 [14-2212] 
Category 2 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
 
765 (497-1098) 
54 (32-80) 
n/a 
819 (544-1154) 
 
341 [131-1129] 
13 [0-93] 
n/a 
463 [147-1244] 
 
1949 (1162-3018) 
n/a 
0 
1949 (1162-3018) 
 
899 [247-2305] 
n/a 
0 
8994 [247-2305] 
 
2722 (1761-3867) 
54 (32-80) 
1517 (572-2852) 
4293 (2754-6110) 
 
1805 [488-3771] 
13 [0-93] 
0 [0-1775] 
1993 [488-6391] 
Category 3 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
 
1464 (1197-1796) 
94 (62-137) 
n/a 
1558 (1268-1913) 
 
1140 [611-2133] 
34 [0-107] 
n/a 
1149 [425-2234] 
 
2638 (2061-3287) 
n/a 
1043 (239-2140) 
3681 (2557-5109) 
 
1978 [745-3558] 
n/a 
0 
2064 [819-3640] 
 
4126 (3336-5036) 
94 (62-137) 
5311 (3304-7837) 
9531 (7169-12609) 
 
3505 [1335-5174] 
34  [0-107] 
0 [0-5329] 
5185 [2043-12523] 
Category 4 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
 
1904 (1078-2859) 
162 (67-281) 
n/a 
2066 (1208-3028) 
 
1149 [28-2404] 
41 [0-345] 
n/a 
1432 [628-2872] 
 
4583 (2242-7861) 
n/a 
5811 (1849-10169) 
10393 (5172-16558) 
 
2519 [939-4816] 
n/a 
0 
4732 [996-20976] 
 
6518 (3576-10354) 
162 (67-281) 
5202 (1086-10576) 
11882 (5750-19707) 
 
3699 [1706-7691] 
41 [0-345] 
0 [0-3526] 
5410 [1891-14208] 
Asymptomatic (categories 1 & 2) 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
 
723 (480-1017) 
53 (30-79) 
n/a 
775 (528-1078) 
 
327 [54-1129] 
0 
n/a 
388 [54-1244] 
 
1716 (1125-2604) 
n/a 
0 
1716 (1125-2604) 
 
844 [134-1941] 
n/a 
0 
844 [134-1941] 
 
2445 (1719-3422) 
53 (30-79) 
1203 (454-2269) 
3701 (2423-5296) 
 
1670 [191-2953] 
0 [0-76] 
0 
1960 [191-4471] 
Symptomatic (categories 3 & 4) 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
 
1557 (1289-1856) 
109 (76-149) 
n/a 
1666 (1384-1996) 
 
1149 [613-2185] 
34 [0-121] 
n/a 
1163 [648-2440] 
 
3051 (2356-3937) 
n/a 
2054 (1007-3231) 
5105 (3853-6720) 
 
2130 [844-3620] 
n/a 
0 
2416 [864-4117] 
 
4633 (3752-5672) 
109 (76-149) 
5288 (3313-7423) 
10030 (7705-12670) 
 
3567 [1407-5528] 
34 [0-121] 
0 [0-5160] 
5294 [2033-12344] 
IQR: interquartile range 
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These groups were further analysed by comparing the mean costs for diagnosed 
asymptomatic haemochromatosis patients (categories 1 and 2) with diagnosed symptomatic 
patients (categories 3 and 4) (Table 4). From the societal perspective, the mean cost per 
symptomatic patient was almost three-fold higher than an asymptomatic patient (AUD3,701 
and AUD10,030 respectively). Health sector costs accounted for 66% of costs for 
asymptomatic patients, whereas for symptomatic patients, 53% of costs were attributable 
to productivity losses and 46% to health sector costs. 
 
From the government perspective, the mean annual cost per symptomatic patient was 
almost three times higher than for an asymptomatic patient (AUD1,716 v. AUD5,105). All 
costs for asymptomatic patients were attributable to health sector costs, whereas for 
symptomatic patients, 60% of costs were related to health sector costs and 40% to transfer 
payments. 
 
From the patient perspective, the mean annual cost for a symptomatic patient was double 
that of an asymptomatic patient (AUD1,666 v. AUD775 respectively). For both groups, 
almost all costs were attributable to health sector costs (93% respectively), with just 7% 
respectively accounted for by other sector costs, i.e. transport. 
 
4.5.3 Population cost estimates 
To estimate costs associated with diagnosed haemochromatosis for Australia, these costs 
were extrapolated to the Australian population, adjusted for age and ancestry (Table 2).  The 
overall cost attributable to diagnosed haemochromatosis from a societal perspective was 
AUD106 million, with 60% of this related to health sector costs and 39% to productivity losses 
(Table 5). At a penetrance of 13.9%, asymptomatic patients accounted for a higher proportion 
of total costs than symptomatic patients (AUD74million v. AUD32 million). The main driver of 
costs for asymptomatic patients were health sector costs (66%), whereas for symptomatic 
patients, both productivity losses (53%) and health sector costs (46%) were the main drivers.  
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From the government perspective, the total estimated costs of diagnosed haemochromatosis 
were AUD51 million. For asymptomatic patients, all costs were associated with health sector 
costs; for symptomatic patients, 60% were attributable to health sector costs and 40% to 
transfer payments. Across all diagnosed patients with haemochromatosis, health sector costs 
accounted for 87% of costs, with transfer payments, accounting for the balance.   
 
From the patient perspective, the majority of costs for all patients arose from health sector 
costs (93%). Other sector costs, which consisted entirely of costs attributable to transport, 
were relatively minor (7%). At a penetrance of 13.9%, asymptomatic patients accounted for 
higher costs than symptomatic patients (AUD15 million v. AUD5 million).  
 
Table 5: Estimated total costs (AUD) for the Australian population from patient, 
government and societal perspectives, based on 31% of HMZ being diagnosed 
 Patient perspective Government 
perspective 
Societal perspective 
Asymptomatic (Categories 1 and 2) 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
14,416,937 
1,049,088 
0 
15,466,025 
34,240,100 
0 
0 
34,240,100 
48,778,323 
1,049,088 
24,004,356 
73,831,767 
Symptomatic (CATEGORIES 3 and 4: 13.9% penetrance) 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
5,014,126 
350,388 
0 
5,364,514 
9,825,201 
0 
6,615,703 
16,440,903 
14,921,578 
350,388 
17,029,897 
32,301,863 
ALL (based on 13.9% clinical penetrance) 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
19,431,063 
1,399,477 
0 
20,830,539 
44,065,300 
0 
6,615,703 
50,681,003 
63,699,900.41 
1,399,476.62 
41,034,252.90 
106,133,629.93 
 
 
 
As the costs reported in Table 5 only include 31% of C282Y homozygotes (i.e. those who are 
assumed to be diagnosed), costs were also calculated for the estimated 69% of undiagnosed 
homozygotes.   Total combined costs were estimated to be AUD274 million, with the 
undiagnosed group accounting for 61% of this (Table 6). Health sector costs were estimated 
to be AUD137 million overall, and time-loss costs AUD132 million.  For the undiagnosed 
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group, the total costs were estimated to be AUD168million, with asymptomatic patients 
accounting for almost two-thirds of this. Undiagnosed symptomatic patients were estimated 
to cost AUD58 million, with two-thirds of this attributed to time-loss costs. Due to the low 
penetrance estimate used, the asymptomatic group accounted for greater total costs than 
the symptomatic group (AUD183 million v. AUD91 million). 
 
Table 6: Estimated total costs (AUD) for diagnosed and undiagnosed C282Y homozygotes 
in the Australian population from the societal perspective 
 Diagnosed (31%) Undiagnosed (69%) 
Asymptomatic (Categories 1 and 2) 
Health sector costs 
Other sector costs 
Time-loss costs 
SUB-TOTAL 
48,778,323 
1,049,088 
24,004,356 
73,831,767 
53,703,895 
2,335,068 
53,429,050 
109,468,013 
TOTAL 183,299,780 
Symptomatic (Categories 3 and 4) 
Health sector costs 
Other sector costs 
Time-loss costs 
SUB-OTAL 
14,921,578 
350,388 
17,029,897 
32,301,863 
19,570,021 
779,896 
37,905,254 
58,255,172 
TOTAL 90,557,035 
ALL 
Health sector costs 
Other sector costs 
Time-loss costs 
SUB-TOTAL 
63,699,900 
1,399,477 
41,034,253 
106,133,630 
73,273,916 
3,114,964 
91,334,305 
167,723,185 
TOTAL  273,856,815 
 
 
As clinical penetrance has been shown to be higher in males than females [7, 8, 13, 14, 57], 
societal costs were also calculated based on sex (Table 7). These estimates were taken from 
Allen and colleagues’ work (28.4% of males and 1.2% of female homozygotes) [8].  Overall, 
the total estimated cost for both diagnosed and undiagnosed C282Y homozygotes was 
AUD278 million. Males accounted for 60% of these costs. For diagnosed males, health sector 
costs were the main driver (AUD35 million), whereas for undiagnosed males, time-loss costs 
were the main contributor (AUD61 million).  Female C282Y homozygotes (diagnosed and 
undiagnosed) were estimated to cost AUD110 million. Due to the low penetrance estimate 
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used (1.2%), symptomatic females accounted for a small proportion of costs (4%) in 
comparison with asymptomatic females. 
 
Table 7: Estimated total costs (AUD) for the male and female Australian populations 
(societal perspective) 
 Male 
28.4% penetrance 
Female 
1.2% penetrance 
Asymptomatic (Categories 1 and 2) 
 
Diagnosed 
Undiagnosed 
Diagnosed Undiagnosed 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
19,972,179 
429,547 
9,828,532 
30,230,258 
22,329,842 
970,911 
22,215,563 
45,516,317 
28,413,891 
611,015 
13,982,792 
43,007,788 
30,802,688 
1,339,749 
30,654,995 
62,807,431 
 
Symptomatic (CATEGORIES 3 and 4) 
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
15,010,910 
352,486 
17,131,851 
32,495,246 
19,992,369 
796,729 
38,723,353 
59,512,478 
653,930 
15,356 
746,326 
1,415,611 
844,749 
33,665 
1,636,198 
2,514,612 
ALL  
Health sector costs 
Other sector costs 
Time-loss costs 
TOTAL 
34,983,089 
782,033 
26,960,383 
62,725,505 
42,322,238 
1,767,639 
60,938,917 
105,028,795 
29,067,820 
626,461 
14,729,118 
44,423,400 
31,657,437 
1,373,413 
32,291,193 
65,322,043 
Total for sexes 167,754,300 109,745,443 
Total costs combined 277,499,743 
  
 
The impact of penetrance estimates on costs was analysed by varying penetrance from 1% 
to 50% [8, 25, 26, 52, 53] (ceteris paribus) (Figure 1). This analysis showed that increased 
penetrance resulted in increased cost. At 1% penetrance, total costs were estimated to be 
AUD215 million; when penetrance was increased to 50%, total estimated costs increased to 
AUD459 million [7].  
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Figure 1: Sensitivity analysis of penetrance rate on estimated cost 
 
4.6 Discussion 
This cost of illness study, which includes health sector, other sector and time-loss costs, is 
the first to be published for hereditary haemochromatosis.  Costs have been reported from 
the societal, government and patient perspectives using the most robust prevalence and 
penetrance estimates available for the Australian population.  From the societal perspective 
the mean cost per diagnosed haemochromatosis patient was significantly lower for 
asymptomatic patients (AUD3,701) than for symptomatic patients (AUD10,303). However, 
due to the low penetrance rate used in the base case analysis (13.9%), the asymptomatic 
group accounted for the majority of costs at the population level.  
 
From the societal perspective, the total estimated costs of haemochromatosis in Australia 
were AUD274 million in 2015, consisting of AUD137 million for health sector costs and 
AUD132 million for time-loss costs. This estimate was based on several assumptions from a 
robust Australian study [8] and included diagnosed and undiagnosed C282Y homozygotes.  
Whilst these assumptions add uncertainty to cost estimates, they were all based on the 
most robust data available to-date.  
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The sensitivity analysis of varying penetrance rates showed that lower penetrance likely 
leads to lower costs. As haemochromatosis is relatively straightforward to diagnose and 
treat, reducing clinical penetrance should be achievable. Early diagnosis could be 
accomplished through awareness raising campaigns targeting the public and/or medical 
practitioners, or through a population screening program. Whether these interventions are 
cost-effective or not is beyond the scope of this study. Importantly, reducing penetrance is 
likely to lead to improved health and quality of life amongst people with haemochromatosis.  
A recent study reported quality of life utility to be negatively correlated with the number of 
haemochromatosis-related symptoms [58]. It is likely that increasing the rate of early 
diagnosis and treatment is likely to improve haemochromatosis patients’ utility. 
 
There are several limitations to this study. First, use of a convenience sample may introduce 
bias, with possible questions of generalizability. To mitigate this, prevalence and penetrance 
estimates were taken from a robust Australian epidemiological study, and total costs were 
based on these data. Second, the small sample size resulted in large confidence intervals 
around the cost estimates. Lastly, several assumptions were adopted when extrapolating 
costs to the population level. Whilst this was unavoidable, increased uncertainty around the 
cost estimates resulted, although this was explored in sensitivity analysis. The results of this 
study should be viewed as indicative cost estimates.  A strength of this study is the bottom-
up approach to costing, which combines resource utilization data and unit costs at an 
individual level [59].  
 
Whilst the costs associated with haemochromatosis in Australia are not as substantial as 
those reported for conditions such as psychosis (AUD4.9 billion in 2010) [38], multiple 
sclerosis (AUD1.04 billion in 2010) [37], and diabetes (AUD1.4 billion in 2008/09) [60], they 
are sizeable and incur an opportunity cost. Unlike these other disorders, symptomatic 
haemochromatosis could feasibly be substantially reduced by increasing early diagnosis. The 
cost data reported in this paper can be used to populate cost-effectiveness models of 
haemochromatosis to identify optimal screening and intervention strategies. Such 
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interventions would likely result in reduced opportunity costs related to haemochromatosis, 
and importantly, reduce the morbidity and mortality due to this condition. 
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Health sector costs 
Prescribed and non-prescribed medications, supplements 
Mean annual cost per participant was calculated by summing all annual costs and applying 
the relevant safety net threshold. For pharmaceuticals, the Australian health system 
incorporates a safety net for all holders of the national health insurer Medicare card (all 
permanent citizens and holders of permanent residency visas are eligible). The maximum cost 
of medication listed on the Pharmaceutical Benefits Scheme (PBS) is AUD37.70 (as of January 
1, 2015).  Any cost above this is borne by the government. When a patient has reached the 
threshold of AUD1,453.90, all PBS prescription costs are capped at AUD6.10 for the patient, 
with the government paying the balance. Alternately, for holders of both a Medicare card and 
government-issued concession card, the maximum cost for all PBS-listed prescriptions is 
AUD6.10. When the threshold of AUD366.00 is reached, all PBS prescriptions are cost free to 
the patient with the government paying the balance. 
Medical appointments, investigations and interventions 
Similar to the PBS, the Australian health system incorporates a safety net for medical 
services for all holders of the Medicare card: the Medicare Benefits Scheme (MBS). In 2015, 
when a patient’s expenditure on medical items reached AUD2,000 (excluding medications), 
Medicare paid 80% of all further costs under the MBS, and the patient paid the remaining 
20%. In the case where a patient was also a holder of a government issued concession card, 
the MBS safety net of AUD638.40 applied. Thereafter, Medicare would pay 80% of any 
further costs and the patient 20%.  
 
Time-loss  
Presenteeism and absenteeism were costed using questions adapted from the World Health 
Organization Health and Work Performance Questionnaire [1]. Absenteeism was measured 
by asking participants who were employed at the time of the interview ‘How many days in 
the last four weeks have you stayed away from work for more than half the day because of 
haemochromatosis related health problems?’. A mean number of days absent was calculated 
for each participant and multiplied by 12 to derive an annual figure. Mean weekly earnings 
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were taken from the Australian Bureau of Statistics for age and sex for 2013 [2]. These were 
adjusted for inflation using the Consumer Price Index (CPI) for June 2013 as the base year 
(102.8) and for March 2015 (106.8) [3]. Annual days absent were then costed using this wage 
data and reported in 2015 AUD. 
Presenteeism was measured by asking participants ‘How many days in the last four weeks did 
you go to work while suffering from such (HH) health problems?’, and ‘On these days, what 
percentage of the time were you as productive as usual?’. Participants were asked to mark a 
scale of 0 to 100 indicating their response. Presenteeism was calculated by dividing 
productivity (0-100 scale) by 100 and multiplying this by the number of days attended 
employment when unwell due to HH-related symptoms by. This figure was then subtracted 
from the number of days employment was attended when the participant was unwell. This 
provided the number of days lost to presenteeism per month. A mean number of days over 
the three monthly cost diaries was calculated and multiplied by 12 to derive an annual figure. 
Costs associated with this loss were calculated in the same was as described for absenteeism, 
using ABS wage data. 
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Table 1: Mean and median costs per patient in 2015 AUD 
 Patient perspective Government perspective Societal perspective 
 Mean cost (95%CI) Median cost (IQR) Mean cost (95%CI) Median cost (IQR) Mean cost (95%CI) Median cost (IQR) 
category 1 (n=12) 
Medications & supplements 
Medical appointments, investigations, 
interventions 
Hospital admissions 
Specialised equipment 
Transport 
Productivity: absenteeism 
Productivity: presenteeism 
Productivity: HH patients 
Productivity: carers 
Transfer payments: HH patients 
Transfer payments: carers 
TOTAL 
 
24.62 (0-77.45) 
521.79 (169.82-951.56) 
 
0 
13.48 (2.59-27.62) 
46.76 (0.00-140.49) 
- 
- 
- 
- 
- 
- 
606.66 (228.50-1039.82) 
 
0 
146.70 (0-1110.30) 
 
0 
0 (0-30.24) 
0 (0-22.61) 
- 
- 
- 
- 
- 
- 
250.37 (6.00-1314.48) 
 
7.75 (0-23.26) 
816.71 (296.80-1434.13) 
 
0 
- 
- 
0 
- 
- 
- 
0 
0 
824.46 (303.27-1427.60) 
 
0 
551.94 (0-1439.94) 
 
0 
- 
- 
- 
- 
- 
- 
0 
0 
551.94 (0-1439.94) 
 
32.38 (0-84.63) 
1338.50 (574.92-2133.48) 
 
0 
13.49 (3.11-27.63) 
46.76 (0.00-140.49) 
0 
0 
0 
0 
- 
- 
1431.12 (553.80-2374.63) 
 
0 
1497.60 (0-1923.03) 
 
0 
0 (0-30.24) 
0 (0-22.61) 
0 
0 
0 
0 
- 
- 
1559.04 (13.86-2211.71) 
category 2 (n=46) 
Medications & supplements 
Medical appointments, investigations, 
interventions 
Hospital admissions 
Specialised equipment 
Transport 
Productivity: absenteeism 
Productivity: presenteeism 
Productivity: carers 
Transfer payments: HH patients 
Transfer payments: carers 
TOTAL 
 
86.22 (39.05-152.93) 
558.35 (388.92-736.67) 
 
82.17 (0-263.72) 
38.45 (6.42-85.66) 
54.11 (32.05-77.74) 
- 
- 
- 
- 
- 
819.30 (543.12-1170.52) 
 
0 (0-120.37) 
267.00 (49.20-863.50) 
 
0 
0 
12.92 (0-92.76) 
- 
- 
- 
- 
- 
462.51 (146.72-1244.36) 
 
18.98 (2.52-45.01) 
1509.84 (1059.15-2033.35) 
 
420.31 (0-1263.74) 
- 
- 
- 
- 
- 
0 
0 
1949.13 (1192.00-3042.93) 
 
0 
868.35 (172.95-1940.58) 
 
0 
- 
- 
- 
- 
- 
0 
0 
898.35 (247.20-2304.69) 
 
112.85 (51.40-186.53) 
2068.19 (1414.97-2727.69) 
 
502.49 (0-1338.88) 
38.45 (6.42-85.66) 
54.11 (32.05-77.74) 
216.66 (22.05-482.45) 
246.70 (8.78-562.82) 
1053.86 (215.12-2403.56) 
- 
- 
4293.31 (2853.24-6198.65) 
 
0 (0-150.24) 
1224.30 (487.80-3017.94) 
 
0 
0 
12.92 (0-92.76) 
0 
0 
0 
- 
- 
1993.18 (487.80-6391.47) 
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category 3 (n=78) 
Medications & supplements 
Medical appointments, investigations, 
interventions 
Hospital admissions 
Specialised equipment 
Transport 
Productivity: absenteeism 
Productivity: presenteeism 
Productivity: carers 
Transfer payments: HH patients 
Transfer payments: carers 
TOTAL 
 
195.31 (145.55-249.36) 
990.83 (801.63-1190.36) 
 
96.92 (0-242.31) 
180.51 (84.82-299.79) 
94.41 (59.47-135.87) 
- 
- 
  - 
- 
- 
1557.99 (1268.27-1905.82) 
 
121.70 (0-310.20) 
823.20 (164.85-1434.15) 
 
0 
0 (0-98.62) 
34.45 (0-106.80) 
- 
- 
- 
- 
- 
1148.58 (642.35-2233.89) 
 
98.49 (49.90-158.80) 
2500.35 (2009.34-3092.18) 
 
39.58 (0-132.32) 
- 
- 
 
- 
- 
1042.93 (242.11-2112.96) 
0 
3681.36 (2523.90-4962.16) 
 
0 (0-20.88) 
1892.04 (744.60-3511.20) 
 
0 
- 
- 
- 
- 
- 
0 
0 
2064.30 (818.85-3639.56) 
 
317.34 (230.04-404.68) 
3491.18 (2837.18-4236.45) 
 
136.51 (0-301.02) 
180.51 (84.82-299.79) 
94.41 (59.47-135.87) 
1155.51 (606.09-1772.85) 
3212.08 (1638.09-5235.51) 
943.56 (91.76-2062.44) 
- 
- 
9531.10 (7060.49-12320.70) 
 
150.24 (0-471.122) 
2682.90 (0-4715.25) 
 
0 
0 (0-98.62) 
34.45 (0-106.80) 
0 (0-1035.59) 
0 (0-2139.45) 
0 
- 
- 
5185.32 (2043.02-12523.09) 
category 4 (n=21) 
Medications & supplements 
Medical appointments, investigations, 
interventions 
Hospital admissions 
Specialised equipment 
Transport 
Productivity: absenteeism 
Productivity: presenteeism 
Productivity: carers 
Transfer payments: HH patients 
Transfer payments: carers 
TOTAL 
 
378.72 (211.16-582.62) 
1187.78 (632.28-1968.47) 
 
0 
337.26 (113.94-601.34) 
162.28 (62.64-276.00) 
- 
- 
- 
- 
- 
2066.03 (1219.70-3118.82) 
 
219.60 (51.07-473.25) 
798.36 (322.20-1117.48) 
 
0 
51.03 (0-381.04) 
41.34 (0-344.53) 
- 
- 
- 
- 
- 
1432.28 (628.15-2871.98) 
 
590.70 (94.91-1505.37) 
2623.80 (1711.11-3577.33) 
 
1368.21 (0-3318.08) 
- 
- 
- 
- 
- 
3873.75 (884.23-7744.43) 
1936.88 (0-5084.30) 
10393.34 (5416.29-16751.23) 
 
57.60 (0-372.51) 
2260 (939.00-4559.82) 
 
0 
- 
- 
- 
- 
- 
0 
0 
4731.80 (996.48-20976.20) 
 
1000.98 (378.82-1954.42) 
3811.58 (2557.68-5162.23) 
 
1368.21 (0-3318.08) 
337.25 (113.94-601.34) 
162.28 (62.64-276.00) 
1132.21 (0-2456.89) 
2852.62 (0-6370.48) 
1217.19 (0-3485.48) 
- 
- 
11882.32 (5336.46-19167.23) 
 
443.52 (51.07-1042.59) 
1391.40 (1057.92-5875.90) 
 
0 
51.03 (0-381.04) 
41.34 (0-344.53) 
0 
0 
0 
- 
- 
5410.16 (1891.39-14208.27) 
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Asymptomatic patients: 
Categories 1 and 2 (n=58) 
Medications & supplements 
Medical appointments, investigations, 
interventions 
Hospital admissions 
Specialised equipment 
Transport 
Productivity: absenteeism 
Productivity: presenteeism 
Productivity: carers 
Transfer payments: HH patients 
Transfer payments: carers 
TOTAL 
 
 
73.47 (31.98-128.49) 
550.79 (392.83-714.06) 
 
65.17 (0-213.86) 
33.28 (7.78-73.23) 
52.59 (30.86-77.72) 
- 
- 
- 
- 
- 
775.31 (533.62-1052.38) 
 
 
0 (0-68.96) 
202.80 (25.56-863.50) 
 
0 
0 
0 (0-76.23) 
- 
- 
- 
- 
- 
387.59 (53.93-1244.36) 
 
 
16.69 (1.90-36.26) 
1366.43 (976.10-1786.13) 
 
333.35 (0-977.81) 
- 
- 
- 
- 
- 
0 
0 
1716.44 (1061.19-2600.52) 
 
 
0 
843.60 (133.77-1853.85) 
 
0 
- 
- 
- 
- 
- 
0 
0 
843.60 (133.77-1940.58) 
 
 
96.20 (46.36-158.33) 
1917.22 (1441.69-2453.93) 
 
398.52 (0-1046.38) 
33.28 (7.78-73.23) 
52.59 (30.86-77.72) 
171.84 (19.19-367.91) 
195.66 (5.67-464.91) 
835.82 (159.23-1836.13) 
- 
- 
3701.13 (2378.10-5123.92) 
 
 
0 (0-112.15) 
1340.10 (173.03-2732.19) 
 
0 
0 
0 (0-76.23) 
0 
0 
0 
- 
- 
1959.13 (190.51-4471.40) 
Symptomatic patients 
Categories 3 and 4 (n=99) 
Medications & supplements 
Medical appointments, investigations, 
interventions 
Hospital admissions 
Specialised equipment 
Transport 
Productivity: absenteeism 
Productivity: presenteeism 
Productivity: carers 
Transfer payments: HH patients 
Transfer payments: carers 
TOTAL 
 
 
234.22 (177.25-296.42) 
1032.61 (840.29-1243.22) 
 
76.36 (0-198.95) 
213.76 (119.18-315.61) 
108.80 (71.65-149.43) 
- 
- 
- 
- 
 
1665.75 (1355.78-008.67) 
 
 
150.24 (0-364.26) 
798.36 (171.60-1362.00) 
 
0 
0 (0-132.29) 
34.45 (0-120.58) 
- 
- 
- 
- 
- 
1163.14 (647.52-2439.91) 
 
 
202.90 (80.19-413.34) 
2526.54 (2036.47-3029.61) 
 
321.41 (0-794.45) 
- 
- 
- 
- 
- 
1643.41 (610.27-2873.06) 
410.85  (0-1026.87) 
5105.11 (3611.80-6971.61) 
 
 
 
0 (0-129.78) 
1956 (744.60-3591.36) 
 
0 
- 
- 
- 
- 
- 
0 
0 
2416.04 (864.00-4117.46) 
 
 
 
462.65 (306.48-701.19) 
3559.15 (2938.20-4204.57) 
 
397.78 (63.02-887.20) 
213.76 (119.18-315.61) 
108.80 (71.65-149.43) 
1150.57 (686.17-1719.70) 
3135.83 (1669.35-4808.05) 
1001.60 (281.91-1921.94) 
- 
- 
8950.91 (6604.63-11599.97) 
 
 
183.58 (0-605.52) 
2733.20 (1016.40-4827.60) 
 
0 
0 (0-132.29) 
34.45 (0-120.58_ 
0 
0 (0-1137.73) 
0 
- 
- 
5294.02 (2033.38-12344.49) 
Appendix 4D: Cost and resource use diary 
  
174 | P a g e  
 
 
Haemochromatosis in Australia: A Cost of Illness study 
Haemochromatosis Cost diary 
Over the next three months, we would like you to record all the resources (goods and 
services) that you used in the treatment, care and/or support of your haemochromatosis 
related health problems, regardless of whether you paid for them or not. We will need to 
know the amount of each type of resource you used, and if at all possible, how much it cost. 
To record this information we request that you complete a Haemochromatosis Cost Diary at 
the end of each month over this three month period. 
Please note: People with haemochromatosis come from all lifestyles and experience a range 
of health problems of varying severity. For some people, these problems may impact their 
financial and/or employment situations. This cost diary may therefore contain questions and 
items that currently do not, and perhaps never will, apply to you. Please read the various 
sections carefully and then complete these as best you can. 
 
 
 
 
 
Date: _____/______/ 20___  
 
1a. Date of birth  ___/___/_______ 
 
1b. Sex : 
 Male……………..0 
 Female………….1 
 
1c. What is your postcode?  _________ 
 
 
Please remember, only include cost for medications, treatments and services for 
health problems that are associated with your haemochromatosis 
Appendix 4D: Cost and resource use diary 
  
175 | P a g e  
 
 
 
 
2a. Prompt question: Have you used any medications for haemochromatosis related health problems in the last 4 weeks? 
 Yes…………….1 
 No…………….0 (skip to Non-prescription medications) 
2b. Please complete the table below, with regard to medications that have you have used in the last 4 weeks that are for your 
haemochromatosis related health problems (e.g. arthritis, diabetes, heart disease). 
 
Name of medication Please tick one Strength (in mg, 
gm etc) 
How many 
tablets do you 
usually take in a 
day? 
Out of the last 30 
days, how many days 
have you taken this 
medication? 
Total paid by you 
(please leave blank 
if you don’t 
remember) 
Did you use a 
script for this 
medications? 
Regular Periodic 
A        
Abisart (irbesartan)        
Accupril (quinapril)        
Aclin (sulindac        
Actos (Pioglitazone)        
Advil (ibuprofen)       Y/N 
Aldactone (spironolactone)        
Amaryl (glimepiride)        
Amlo (amlodipine)        
MEDICATIONS 
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Amlodipine        
Arthrexin (indomethacin)        
Arthrotec (diclofenac & misoprostol)        
Aspirin (e.g. Aspro)        
Atacand (candesartan)        
Atenolol        
Avandamet (metformin & rosiglitazone)        
Avapro (irbesartan)        
Aylide (glimepiride)        
B       
 
Barbloc (pindolol)        
Betaloc (metopolol)        
Bicor (bisoprolol)        
Bispro (bisoprolol)        
Bisoprolol        
Brufen (ibuprofen)        
Burinex (bumetanide)        
Byetta (exenatide)        
C       
  
Cadatin (amlodipine & atorvastatin)        
Captopril        
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Capoten (captopril)        
Cartia (aspirin)        
Carvedilol        
Celebrex (celecoxib)        
Co-Diovan (valsartan & 
hydrochlorothiazide) 
       
Corbeton (oxprenolol)        
Cozavan (losartan)        
D       
  
Daonil (glibenclamide)        
Dapa-tabs (indapamide)        
Deralin (propranolol)        
Diabex (metformin)        
Diabex XR (metformin)        
Diaformin (metformin)        
Diaformin XR (metformin)        
Diamicron (gliclazide)        
Dicarz (carvedilol)        
Diclofenac        
Dilatrend (carvedilol)        
Dimirel (glimepiride)        
Diovan (valsartan)        
Dithiazide (hydrochlorothiazide)        
Dolapril (trandolapril)        
E        
Enalapril        
Exforge (valsartan & amlodipine)        
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F        
Feldene (piroxicam)        
Formet (metformin)        
Fosinopril        
Frusemide        
G        
Galvumet (metformin & vildagliptin)        
Galvus (vildagliptin)        
Gliclazide        
Glimel (glibenclamide)        
Glimepiride        
Glucobete (metformin)        
Glucovance (metformin & glibenclamide)        
Glyade (gliclazide)        
Gopten (trandolapril)        
H        
Humalog (insulin lispro)        
Humulin (isophane insulin)        
Hydrene (hydrochlorothiazide & 
triamterene) 
       
Hygroton (chlorthalidone)        
Hypurin Isophane (isophane insulin)        
Hypurin Neutral (neutral insulin)        
I        
Ibuprofen       Y/N 
Imflac (diclofenac)       Y/N 
Indapamide        
Inderal (propranolol)        
Indocid (indomethacin)        
Insig (indapamide)        
Inspra (eplerenone)        
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Inza (naproxen)        
Irbesartan        
J        
Janumet (metformin & sitagliptin)        
Januvia (sitagliptin)        
Juvicor (sitagliptin & simvastin)        
K        
Kaluril (amiloride)        
L        
Lantus (insulin glargine)        
Lasix (frusemide)        
Lisodur (lisinopril)        
Lisinopril        
Lopressor (metopolol)        
M        
Melizide (glipizide)        
Meloxibell (meloxicam)        
Meloxicam        
Metformin        
Metformin XR        
Metex XR (metformin)        
Metopolol        
Minidiab (glipizide)        
Mixtard (isophane insulin)        
Mobic (meloxicam)        
Mobilis (piroxicam)        
Monopril (fosinopril)        
N        
Naprosyn (Naproxen)        
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Natrilix (indapamide)        
Nebilet (nebivolol)        
Nidem (gliclazide)        
Noten (atenolol)        
Novomix (insulin aspart)        
Nurofen (ibuprofen)       Y/N 
Nurofen Plus (ibuprofen & codeine)       Y/N 
O        
Olmetec Plus (olmesartan & 
hydrochlorothiazide) 
       
Onglyza (saxagliptin)        
Orudis (ketoprofen)        
Oruvail (ketoprofen)        
Oziclide (gliclazide)        
P        
Panadeine (paracetamol & codeine)       Y/N 
Panadeine Forte (paracetamol & codeine)        
Paracetamol (e.g. Panadol, Panadol Osteo)       Y/N 
                                                 Pioglitazone        
Piroxicam        
Presolol (labetalol)        
Prilace (ramipril)        
Protophane (isophane insulin)        
Q        
Quinapril        
R        
Rafen (ibuprofen)       Y/N 
Ramipril        
Renitec (enalapril)        
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S        
Sevikar (olmesartan & amlodipine)        
Spiractin (spironolactone)        
T        
Tranjenta (linagliptin)        
Tenormin (atenolol)        
Tensig (atenolol)        
Teveten (Eprosartan)        
Toprol-XL (metopolol)        
Toradol (ketorolac)        
Trandate (labetalol)        
Triace (ramipril)        
Trandolapril        
Tryzan (ramipril)        
Twynsta (telmisartan & amlodipine)        
U        
Uremide (frusemide)        
V        
Visken (pindolol)        
Volirop (carvedilol)        
Voltaren (diclofenac)        
Z        
Zestril (lisinopril)        
Other (please specify)       Y/N 
Other (please specify)       Y/N 
Other (please specify)       Y/N 
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3a. Prompt question: Have you used any supplements (including fish oil, vitamin supplements) or other medicinal preparations for your 
haemochromatosis related health problems in the last four weeks? 
 Yes…………….1 
 No…………….0 (skip to Health Services) 
3b. Please complete the table below, for non-prescribed medications that you used for symptoms/effects of haemochromatosis (including, 
but not limited to, arthritis) in the last 4 weeks.   
Name of non-prescription 
medication/ 
treatment 
Please tick one Strength (in mg, 
mls, grams etc) 
How many tablets 
do you usually 
take in a day? 
Out of the last 30 
days, how many 
days have you 
taken this 
medication? 
Total paid by you 
(please leave 
blank if you don’t 
remember) 
Regular Periodic 
Vitamin supplements       
Mineral supplements       
Fish oil/omega 3/krill oil/algae 
oil 
      
Other (please specify) 
 
      
 
 
 
SUPPLEMENTS/OTHER PREPARATIONS 
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4a. Please complete the table below with regard to visits to GPs, private specialists and other health providers for haemochromatosis related 
health problems in the community in the last 4 weeks.  (Please note, this does NOT include visits to an outpatients clinic) 
 Number of 
visits 
Average length 
of visit 
(minutes) 
Total fee 
charged (If 
known) 
$ 
How much did you 
pay 
$ 
How much did you get back 
(e.g. reimbursed by 
Medicare or a  private 
health fund) 
$ 
GP, local doctor      
Gastroenterologist      
Haematologist      
Rheumatologist      
Cardiologist      
Ophthalmologist      
Other medical specialist (please 
specify) 
     
Community nurse      
Physiotherapist      
Social worker      
GP, PRIVATE SPECIALISTS AND OTHER HEALTH 
PROVIDER VISITS  
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Psychologist      
Dietician/nutritionist      
Optometrist      
Acupuncturist      
Naturopath      
Other (please specify) 
 
     
Other (please specify) 
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5a. Please complete the table below with regard to medical tests/investigations/procedures that you have had for haemochromatosis related 
health problems in the last 4 weeks. 
 
Health professional visits for 
your haemochromatosis 
related health problems 
Number 
of visits 
Average 
length of 
visit 
(minutes) 
 Total fee 
charged (If 
known) 
$ 
How much did you pay 
$ 
How much did you get back (e.g. reimbursed 
by Medicare or a  private health fund)  
Therapeutic venepuncture (i.e. 
blood taken to remove iron) 
     
In the last 4 weeks, where did you usually have blood taken: 
                            Hospital outpatients (public hospital)………………….0 
                            Hospital outpatients (private hospital)………………..1 
                            Red Cross…………………………………………………………….2 
                            Pathology service………………………………………………..3 
                            GP/medical clinic…………………………………………………4 
                            Community health centre……………………………………5 
                           Other (please specify)  …………………………………………6  
 
5b. What is the total number of times you have had a blood test (for testing purposes) in the last 4 weeks (i.e. this does not include therapeutic 
venepuncture)? __________ 
 
MEDICAL PROCEDURES, TESTS & INVESTIGATIONS 
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5c. Please complete the table below with regard to medical tests/investigations/procedures that you have had for haemochromatosis related 
health problems in the last 4 weeks. 
 
Medical tests for your haemochromatosis 
related health problems 
Number of tests Total fee 
charged  
(If known) 
$ 
How much did 
you pay 
$ 
How much did you get back (e.g. 
reimbursed by Medicare or a  
private health fund) 
$  
Blood test: Iron studies     
Blood test: Liver function test     
Blood test: Full blood count     
Blood test: HbA1c (glycosylated 
haemoglobin) 
    
Blood test: lipids (triglyceride, cholesterols)     
Other blood tests: please specify:     
X-ray: specify what sort, area of your body:     
Liver biopsy     
Liver ultrasound     
Endoscopy     
ECG (electrocardiogram)     
Urine test     
Other (please specify) 
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6a. Prompt question: Have you attended hospital for health problems related to your haemochromatosis related health problems in the last 
4 weeks, excluding outpatient visits for venepuncture? 
  Yes…………….1 
  No…………….0 (skip to Specialised equipment) 
6b. Please complete the table below with regard to hospitalisation attendances for your haemochromatosis related health problems in the 
last 4 weeks. 
Please DO NOT include outpatient visits for venepuncture. 
1. Whether it was an outpatient, emergency department and/patient inpatient admission 
2. The reason  
3. The length of the stay. If you were an Outpatient, enter the length of stay as ‘0’ (zero) days. If you can’t remember, just write don’t 
know in the box, however an approximate duration would be sufficient. PLEASE do not include outpatient visits for venepuncture. 
4. The total cost of the stay, if known 
5. Total cost per visit/admission (before reimbursement) 
6. The total cost to you in dollars 
Hospital visits for your 
haemochromatosis related 
health problems 
Outpatient 
attendances 
(number) 
Emergency 
department visits 
(number) 
Admissions 
last 4 weeks 
(number) 
Reason(s) for each 
admission  
Total length of 
stay(s)(days) 
Total cost per 
visit/admission 
(before 
reimbursement) 
Total 
cost to 
you ($) 
Public hospital  
 
      
Private hospital  
 
      
Other (please specify) 
 
       
HOSPITAL ADMISSION/ATTENDANCES 
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7a Related to you haemochromatosis and related health problems over the last 5 years. As people with haemochromatosis have highly 
variable health problems, there is equipment in this list you may never need to use. We would like to know if you have purchased any of the 
following: 
Special equipment for your 
haemochromatosis related health 
problems 
How many of 
this item have 
you purchased in 
the last 4 weeks 
How long does 
this last you 
Total cost to you 
(subtract any 
rebates, 
reimbursements) 
Who paid the 
balance or 
remainder 
Blood glucose sticks     
Pen-needles and syringes     
Urine testing strips/tablets     
Other (please specify) 
 
    
 
 
 
 
 
 
SPECIALISED EQUIPMENT 
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7b. Related to you haemochromatosis and related health problems over the last 5 years. If you have purchased any assistive devices, we 
would like to know: 
1. The month or year the equipment was purchased  
2. The total cost of the equipment, if known 
3. The total cost to you, in dollars 
4. Who paid for the balance or remainder (e.g. government, private health insurance, friend or family) 
5. Expected life of the item in years 
Special equipment for your 
haemochromatosis related health 
problems 
Month or year 
purchased 
Total cost of 
item 
Total cost to you 
(subtract any 
rebates, 
reimbursements) 
Who paid the 
balance or 
remainder 
Expected life 
of item 
(years) 
  
Heat pack/s      
Walking stick      
Walking frame      
Shower chair/stool      
Bath grab rails      
Non-slip bath mat      
Assistive devices for the household 
(e.g. can opener specifically for hand 
arthritis) 
     
Other (please specify) 
 
     
Other (please specify) 
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7c. Related to you haemochromatosis and related health problems over the last 5 years. If you have hired any assistive devices, we would 
like to know: 
1. The month or year the equipment was hired 
2. The total cost of the hiring this equipment 
3. The total cost to you, in dollars 
4. Who paid for the balance or remainder (e.g. government, private health insurance, friend or family) 
5. Expected life of the item in years 
Special equipment for your 
haemochromatosis related health problems 
Month or year 
hired 
Cost of hire  
(please circle the frequency of 
this hire payment) 
$ 
Total cost to you 
(subtract any 
rebates, 
reimbursements) 
Who paid the 
balance or 
remainder 
Expected life of 
item (years) 
  
Walking stick   Weekly 
Monthly 
Annually 
   
Walking frame   Weekly 
Monthly 
Annually 
   
Shower chair/stool   Weekly 
Monthly 
Annually 
   
Bath grab rails   Weekly 
Monthly 
Annually 
   
Non-slip bath mat   Weekly 
Monthly 
Annually 
   
Assistive devices for the household (e.g. can 
opener specifically for hand arthritis) 
  Weekly 
Monthly 
Annually 
   
Other (please specify) 
 
  Weekly 
Monthly 
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Annually 
Other (please specify) 
 
  Weekly 
Monthly 
Annually 
   
 
 
 
8a. Please complete the table below, with regard to community services that you have used because of your haemochromatosis related 
health problems in the last 4 weeks. 
 
Community services for your 
haemochromatosis related health problems 
Number of visits Average length of 
visit (minutes) 
Total fee charged (If 
known) 
$ 
How much did you get back (e.g. 
reimbursed by Medicare or a  
private health fund)  $ 
 
Support groups (for haemochromatosis and for 
any of the related health conditions) 
    
Meals on Wheels     
Home and Community Care (HACC)     
Welfare organisation     
Housing organisation     
Other (please specify) 
 
    
Other (please specify) 
 
    
COMMUNITY SERVICES 
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We would like to know if, in the last 4 weeks, you incurred any out-of-pocket costs for travel 
that was specifically for haemochromatosis and related health conditions (e.g. therapeutic 
venepuncture, Drs appointments, etc). 
 
9a. In the last 4 weeks, did you use a car/motorbike for such purposes?   
  Yes………1 
  No……….0 (skip to Q9b) 
 9ai. If yes: please estimate how many kilometres you travelled for this purpose/s 
______kms 
 9aii. Please specify any parking costs incurred   $_______ 
 
9b. In the last 4 weeks, did you incur any out-of-pocket costs for travel (that was specifically 
for haemochromatosis and related health conditions) from any of the following: 
  Public transport $_______ 
  Taxi $_________ 
  Patient transport service $________ 
 
 
10. Are you currently employed? 
   Yes…….…1 
   No………..0 (finished) 
10a. How many days in the last 4 WEEKS have you stayed away from your work for more 
than half the day because of haemochromatosis related health problems?  
   days 
10b. How many days in the last 4 weeks did you go to work while suffering from such health 
problems?  
   days 
IMPACT ON EMPLOYMENT 
TRANSPORT 
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10c. On these days when you went to work suffering from health problems, what 
percentage of your time were you as productive as usual?  
 For example, if you were exactly as productive as usual please mark ‘100 %’. 
 Please indicate the percentage with a vertical line on the scale below. 
 
10d. Did you take paid sick leave in the last 4 weeks for haemochromatosis related health 
problems? 
  No……………………….0  
  Yes………………………1 
  Not applicable…….2  
 
10d1. If answered yes, how many days in the last 4 weeks have you taken sick leave?         
              ______ days 
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Chapter 5: Population screening for hereditary 
haemochromatosis in Australia: construction and 
validation of a state-transition cost-effectiveness model  
 
5.1  Preface 
In Chapters 3 and 4, the scope of the quality of life and economic impacts associated with 
haemochromatosis have been presented. These studies have provided evidence that the 
more severe stages of haemochromatosis are associated with higher costs and poorer quality 
of life. Chapters 5 and 6 are focused on evaluating screening interventions to identify the 
most cost-effective approach to reduce these burdens. 
Chapter 5 presents a detailed overview of the construction and validation of a health 
economic model for screening for haemochromatosis. In order to validate the model and 
maximise model transparency, the International Society for Pharmacoeconomics and 
Outcomes Research guidelines for model transparency were followed. A state-transition 
Markov model was constructed and validated for Australian males aged 30 and females aged 
45, both of northern European ancestry. The status quo approach to screening in Australia, 
(i.e. incidental and cascade screening) was used in the model simulation. 
This chapter has been submitted to Applied Health Economics and Health Policy.  
de Graaff, B., Lei, S., Neil, A., Yee, K.C., Sanderson, K., Gurrin, L.C. & Palmer AJ. “Population 
screening for hereditary haemochromatosis in Australia: construction and validation of a 
state-transition cost-effectiveness model”.  
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5.2  Abstract 
Introduction: HFE-associated haemochromatosis, the most common monogenic disorder 
amongst populations of northern European ancestry, is characterised by iron-overload. 
Excess iron is stored in parenchymal tissues, leading to morbidity and mortality. Population 
screening programs are likely to improve early diagnosis, thereby decreasing associated 
disease. Our aim was to develop and validate a health economics model of screening using 
utilities and costs from a haemochromatosis cohort.  
Methods: A state-transition model was developed with Markov states based on disease 
severity. Australian males (aged 30) and females (aged 45) of northern European ancestry 
were the target populations.  The screening strategy was the status quo approach in Australia; 
the model was run over a lifetime horizon. Costs were estimated from the government 
perspective; costs and QALYs were discounted at 5% annually.  Model validity was assessed 
using goodness-of-fit analyses. Second-order Monte Carlo simulation was used to account for 
uncertainty in multiple parameters.  
Results: For validity, the model reproduced mortality, life expectancy (LE) and prevalence 
rates in line with published data. LE for C282Y homozygote males and females were 49.9 and 
40.2 respectively, slightly lower than population rates. Mean (95%CI) QALYS were 15.7 (7.7-
23.7) for males and 14.4 (6.7-22.1) for females. Mean discounted lifetime costs for C282Y 
homozygotes were AUD22,737 (3,670-75,793) for males and AUD13,840 (1,335-67,377) for 
females.  Sensitivity analyses revealed discount rates and prevalence had the greatest impacts 
on outcomes.  
Conclusion: We have developed a transparent, validated health economics model of C282Y 
homozygote haemochromatosis. The model will be useful to decision-makers to identify cost-
effective screening strategies. 
 
 
 
 
Chapter 5: Population screening for hereditary haemochromatosis in Australia: construction and 
validation of a state-transition cost-effectiveness model 
 
196 | P a g e  
 
5.3  Introduction 
HFE-associated hereditary haemochromatosis is the most common monogenic disorder 
amongst populations of northern European ancestry [1-3]. Whilst several mutations of the 
HFE gene have been identified, C282Y homozygotes account for between 80% and 90% of the 
burden of disease [4, 5]. The prevalence of this genotype has been estimated to be between 
1 in 150, to 1 in 200 in populations of northern European ancestry [6-8]. Prevalence in 
populations of other ancestries is far lower, with estimates in the range of 1 in 1,000 for both 
Native and African Americans [9] and 1 in 1 million amongst Asian populations [10]. 
Clinically, haemochromatosis is characterised by iron overload, with excess iron stored in the 
parenchymal tissues of the liver, heart and pancreas [2, 11, 12]. Early symptoms of iron 
overload are non-specific, including fatigue, lethargy and arthropathy of the 
metacarpophalangeal joints. As iron overload progresses, liver disease, heart disease and type 
2 diabetes can occur. Clinical penetrance is incomplete: a further genetic mutation is thought 
to play a role in this process [13, 14].  Whilst age of onset of iron overload varies, males 
typically develop overload at an earlier age, as menstruation assists in reducing iron stores in 
females [6]. 
Both diagnosis and treatment of haemochromatosis are straightforward. The former involves 
iron studies, most importantly transferrin saturation and ferritin, with confirmatory HFE 
genotyping. Treatment involves regular therapeutic venesection. When treatment is 
commenced prior to organ damage and maintained, the patient will not experience any long-
term health problems related to haemochromatosis and retains normal life expectancy. 
However, as the early symptoms of haemochromatosis are non-specific, timely diagnosis is 
often missed until organ damage has occurred [15, 16]. In order to increase early diagnosis, 
population screening programs have been suggested [17-20]. 
Screening programs are typically resource intensive, therefore decision makers need to be 
confident that such interventions are likely to be cost-effective prior to their introduction. 
Economic modelling is a method that assists decision makers to evaluate the cost-
effectiveness of a given intervention [21].  Long-term costs and consequences of the disorder 
with or without screening can be predicted by using existing clinical, epidemiological and cost 
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data combined in a suitable model.  To date, no health economic model based on costs and 
utilities from a haemochromatosis cohort has been published. To address this lack of 
evidence, we have developed a model to assess screening strategies for the Australian setting 
for people homozygous for the C282Y mutation. The aim of this paper is to describe the 
construction and validation of our haemochromatosis screening model and to present model 
predictions for life expectancy, quality adjusted life years and total lifetime costs associated 
with haemochromatosis.  
5.4  Methods 
5.4.1 Model structure 
We constructed a cost-effectiveness model using a Markov approach allowing for modelling 
of multiple disease states over a lifetime horizon.  The cycle length was one year, which 
continued to run until the death of all simulated subjects. A lifetime horizon was selected to 
reflect the chronic nature of haemochromatosis.  The perspective taken was that of the 
government. This perspective was adopted as funding decisions are based, in part, on these 
government costs.  Both costs and effectiveness were discounted by 5%, in line with the 
Australian guidelines [22]. The structure of the model is detailed in Appendix 5A.  The model 
was constructed using TreeAge Pro Suite 2014 (TreeAge Software, Williamstown, 
Massachusetts). Validation was conducted using TreeAge Pro and SPSS version 22.0.0.0. 
Modelled output data were exported into SPSS allowing for calculation of correlation 
coefficients and fitting linear curves for goodness-of-fit analyses. 
Markov states were categorised according to the European Association for the Study of the 
Liver’s (EASL) recommendations (Table 1) [17]. The four categories represent increasing 
severity of haemochromatosis and iron overload. For the Markov model, an absorbing ‘Death’ 
state was also included. Figure 1 provides an overview of the possible transitions between 
these states. Simulated participants could move between categories in either direction for all 
disease states except Category 4, as this included irreversible organ damage, and the 
absorbing state of ‘Death’. The model was designed by an experienced clinician (KY) and 
health economists (AP, BdG, LS, AN). 
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Table 1: Categories of haemochromatosis [17] 
Category 1 Genetic mutation only (C282Y homozygotes, H63D heterozygotes and compound 
heterozygotes) 
Category 2 Genetic mutation and elevated iron studies, either transferrin saturation or serum 
iron 
Category 3 Genetic mutation, elevated iron levels and early symptoms (e.g. arthritis, fatigue, 
lethargy) 
Category 4 Genetic mutation, elevated iron levels and organ damage (e.g. liver cirrhosis, 
hepatocellular carcinoma, heart disease, Type 2 diabetes) 
 
 
Figure 1: Structure of the Markov model. For C282Y homozygotes, simulated patients can 
move between the Markov states in the direction of the arrows 
 
 
 
 
 
 
 
 
5.4.2 Base case populations 
Two base-case populations were selected for analysis: males 30 years of age and females 45 
years of age, both of northern European ancestry. The rationale for this decision was based 
on prevalence and penetrance estimates.  Northern European ancestry was chosen as the 
prevalence of C282Y homozygosity is far higher than reported for populations of other 
ancestries [6, 9]. Amongst males, iron overload and related complications typically occur from 
the age of 30 onwards, and this has been the preferred age in other haemochromatosis 
models [23-25]. The second base-case population consisted of females 45 years of age, as 
Category 2 Category 3 
Category 1 
Death 
Category 4 
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females tend to experience iron-overload following commencement of menopause [26].  
5.4.3 Screening 
The screening strategy was based on the status quo approach in Australia. Screening occurs 
either through a cascade approach, in which first degree relatives of a homozygote are 
offered genotyping and iron studies reimbursed by the Medical Benefits Scheme (MBS). 
Alternatively, screening occurs incidentally, consisting of a three step process:  two 
consecutive elevated transferrin saturation (TfS) tests followed by HFE genotyping. In our 
model, when a participant tested negative to the genotype test, a referral to a specialist 
medical practitioner for further investigation was assumed (Appendix 5A). At present, this 
combined approach is estimated to diagnose 31% of C282Y homozygotes in Australia (L. 
Gurrin, Principal Investigator, HealthIron study, personal communication, March 16 2015).  
5.4.4 Costs 
Costs were reported from the government perspective, and were limited to direct medical 
costs, although other costs (indirect and direct non-medical costs) can also be included in the 
model. The costs were screening and state (Category) costs, both of which were reported in 
2015 AUD (USD 0.75). Costs were deflated to constant prices using the price index for 
Government final consumption expenditure on hospitals and nursing homes, 2013/14 [27].  
Direct medical costs associated with screening were sourced from the 2015 MBS [28].  The 
costs associated with haemochromatosis states were sourced from our previous cost of illness 
study [29].  This study estimated the costs of haemochromatosis on the basis of a national 
survey using a bottom-up approach. To date, these are the only published cost estimates for 
haemochromatosis. Costs were reported for each of the four EASL categories of 
haemochromatosis and are defined in Table 2. These costs were used for hypothetical 
participants who were diagnosed and received treatment. For participants either not 
diagnosed or not adhering to treatment, treatment costs, i.e.  therapeutic venesection, were 
subtracted from the total costs for each category.  Further, costs for undiagnosed Category 1 
patients (either not screened or a false negative test) were set a zero. A brief description of 
the costing methodology is included here, but readers are directed to the original paper for a 
more detailed description.  
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Costs included were limited to resources funded by federal or state and territory 
governments. Pharmaceutical costs were based on the subsidy  from the 2015 Pharmaceutical 
Benefits Scheme (PBS) Price Schedule of January 1, 2015 [30] – the difference between the 
dispensed price and the co-payment, if the dispensed price is greater.  Unit costs for medical 
consultations and investigations (blood tests, liver biopsies, X-rays etc.) were derived from 
the MBS Book [28]. The National Hospital Cost Data Collection cost weights for Australian 
Refined Diagnosis-Related Group (AR-DRG) version 6.0x (2011-12) were used to estimate 
public hospital events [31]. Costs for public outpatient admissions were costed as reported 
by the Independent Hospital Pricing Authority [32].  
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Table 2: Key model parameters  
Parameter Base case Range for SA Distribution Source 
Prevalence of C282Y homozygotesb 0.0068 0.0044-0.0074 Triangular [6, 8, 56, 
57] 
Probabilities for categories of 
haemochromatosis 
Category 1 
Category 2 
Category 3 
Category 4 
Males Females Males Females  
 
Triangular 
Triangular 
- 
- 
 
 
[6, 58] 
 
 
0.8 
0.2 
0 
0 
 
0.95 
0.05 
0 
0 
 
0.64-0.096a 
0.16-0.24 a 
- 
- 
 
0.76-1.00 a 
0.04-0.06 a 
- 
- 
Annual transition probabilities:  
With treatment:                                            
Category 1 to 2 
Category 2 to 1 
Category 2 to 3 
Category 3 to 2 
Category 3 to 4 
Category 4 to die 
      Without screening and/or treatment: 
Category 1 to 2 
Category 2 to 1 
Category 2 to 3 
Category 3 to 4 
Category 4 to die 
 
 
0 
1-(mortality#) 
0 
0.0083 
0 
0.0167 
 
0.071 
0 
0.0625 
0.0083 
0.0167 
 
 
0 
1-(mortality#) 
0 
0.0083 
0 
0.0167 
 
0.0542 
0 
0.0167 
0.0083 
0.0167 
 
 
- 
- 
- 
0.0064-0.0096 a 
- 
0.0134-0.0200 a 
 
0.0568-0.0852 a 
- 
    0.050-0.075 a 
0.0064-0.0096 a 
0.0134-0.0200 a 
 
 
- 
- 
- 
0.0064-0.0096 a 
- 
0.0134-0.0200 a 
 
  0.04336-0.0650 a 
- 
0.0134-0.0200 a 
0.0064-0.0096 a 
0.0134-0.0200 a 
 
 
- 
- 
- 
Triangular 
- 
Triangular 
- 
Triangular 
- 
Triangular 
Triangular 
Triangular 
 
 
 
 
 
 
 
[6, 59] 
Adherence to therapeutic venesection 
(3-4 times annually)                Year 1 
Year 2 
Year 3 
Year 4 
Year 5 
Year 6 
 
0.905 
0.837 
0.769 
0.701 
0.633 
0.565 
 
0.724-1.000 a 
0.670-1.000 a 
0.615-0.923 a 
0.561-0.841 a 
0.506-0.760 a 
0.452-0.678 a 
 
Triangular 
Triangular 
Triangular 
Triangular 
Triangular 
Triangular 
 
 
 
[51] 
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Year 7 
Year 8 
Year 9 
Year 10 and thereafter 
0.497 
0.429 
0.361 
0.293 
0.398-0.596 a 
0.343-0.515 a 
0.289-0.433 a 
0.234-0.352 a 
Triangular 
Triangular 
Triangular 
Triangular 
Government costs incurred in categories 
of haemochromatosis* 
Category 1 
Category 2 
Category 3 
Category 4 
     
 
LogNormal 
LogNormal 
LogNormal 
LogNormal 
 
 
 
[32] 
 
 
824 
1,949 
3,681 
10,393 
 
       434-1,213 a 
1,162-3,018 a 
2,945-4,417 a 
8,313-12,472 a 
Unit costs of screening strategies 
elements*  
GP Level A 
GP Level B 
Iron studies 
HFE genotype: blood 
Initial medical specialist appointment 
   
 
n/a* 
n/a* 
n/a* 
n/a* 
n/a* 
 
 
LogNormal 
LogNormal 
LogNormal 
LogNormal 
LogNormal 
 
 
[29, 30] 
[29, 30] 
[29] 
[29] 
[29, 30] 
 
16.95 
37.05 
27.70 
31.00 
72.75 
 
Sensitivity: 
HFE genotype  
First transferrin saturation 
Second transferrin saturation 
 
Specificity: 
HFE genotype 
First transferrin saturation 
Second transferrin saturation 
Males Females Males Females  
 
Triangular 
Triangular 
Triangular 
 
 
Triangular 
Triangular 
Triangular 
 
 
Genotype 
[60]; 
transferrin 
saturation 
[44] 
 
0.92 
0.938 
0.90 
 
 
0.994 
0.981 
0.996 
 
0.92 
0.546 
0.55 
 
 
0.994 
0.981 
        0.994 
 
0.736-1.00 a 
0.750-1.00 a 
0.72-1.00 a 
 
 
0.795-1.00 a 
0.785-1.00 a 
0.797-1.00 a 
 
0.736-1.00 a 
0.437-0.655 a 
0.44-0.66 a 
 
 
0.795-1.00 a 
0.785-1.00 a 
0.795-1.00 a 
Uptake of screening: 
Population b 
                                    Of these: 
Cascade screening 
Incidental screening 
 
0.05 
 
0.50 
0.50 
 
0.025-0.075~ 
 
- 
- 
 
Triangular 
 
Triangular 
Triangular 
 
Estimatesc 
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Utilities 
Category 1 
Category 2 
Category 3 
Category 4 
Male Female Male Female  
Beta 
Beta 
Beta 
Beta 
 
[41] 
[41] 
[41] 
[41] 
0.88 
0.85 
0.59 
0.59 
0.71 
0.77 
0.60 
0.41 
0.70-1.00 a 
0.68-1.00 a 
0.47-0.71 a 
0.47-0.71 a 
0.57-0.85 a 
0.62-0.92 a 
0.48-0.72 a 
0.33-0.49 a 
Annual discount rate 
Costs 
Effectiveness 
 
0.05 
0.05 
 
0.00-0.07 
0.00-0.07 
 
- 
- 
 
[23] 
* All costs are in 2015 AUD; a One-way sensitivity analysis values ±20% of base-case value; ~ One-way sensitivity analysis values ±50% of base-case value; b This 
refers to persons of northern European ancestry; c These estimates were based on expert opinion as no data was available;# mortality rates used were age 
and sex specific, and obtained from the Australian Bureau of Statistics [47]; *Sensitivity analysis was carried out on total screening costs, not unit costs .   
GP refers to general practitioner 
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5.4.5 Effectiveness 
Health state utility values (HSUVs) were used to calculate quality adjusted life years (QALYs). 
Utility values were taken from a recently published study by our group,  the only study date 
that has assessed  utility values directly in people with haemochromatosis [33]. This study 
reported HSUVs amongst a sample of Australian adults with haemochromatosis, using the 
Assessment of Quality of Life 4D (AQOL-4D) instrument [33]. Mean utilities and their 
distributions were calculated for each of the four EASL categories (Tables 1 and 2).  
5.4.6 Mortality 
Mortality associated with haemochromatosis was assumed to be the same as the Australian 
population age and sex adjusted rates, with the exception of Category 4. Age and sex adjusted 
mortality was sourced from Australian life tables [34] (Table 2).  For Category 4, as irreversible 
organ damage (e.g. liver cirrhosis, heart disease) characterises this category, an elevated 
probability of death was assigned to this state reflecting current literature.  A multiplier of 
2.45 (95%CI of 2.27 and 2.64) was applied to the age and sex-specific mortality rates for the 
Australian population, based on an estimate from an epidemiological study [35]. 
5.4.7 Bayes’ revision 
Bayes’ revision 
As with almost all diagnostic tests, the sensitivity and specificity of transferrin saturation and 
HFE genotyping as diagnostic tools for haemochromatosis are imperfect, that is, both less 
than 100%. To address this, the Bayes’ revision function within the TreeAge model structure 
was used. This function, based on Bayes’ theorem [36], combines prior and posterior 
probabilities (or, alternatively, combines a prior odds with a likelihood ratio to generate a 
posterior odds for a given hypothesis) as per the formula: 
P(Hypothesis | Evidence)  = P(Evidence|Hypothesis) × P (Hypothesis)P (Evidence)  
Where P(Hypothesis) is the prior probability of the hypothesis of disease (usually taken to be 
the unadjusted population prevalence if we are considering a diagnostic test for a binary 
outcome) and P(Evidence) is the marginal probability of the evidence given that the 
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hypothesis is true, usually derived from a “sampling model” for the probability of the 
observed data given values of the sensitivity and specificity consistent with the hypothesis. 
The decision tree incorporated four posterior probabilities in both the incidental and cascade 
screening sub-branches, specific to the tests ordered.  The estimates of sensitivity and 
specificity for genotyping [37] and transferrin saturation tests [38] are displayed in Table 2.  
5.4.8 Sensitivity analyses 
Probabilistic decision analysis with simultaneous sampling from distributions of key input 
parameters was used to address uncertainty. Tornado diagrams were produced for both 
populations to identify parameters with the greatest individual impact on costs and 
effectiveness. Prevalence of C282Y homozygosity, adherence to treatment, transition 
probabilities, Category 4 mortality rates, utility values and costs were varied by ±20% of the 
values used in the base-case analysis  [39].  Screening uptake was varied by ±50% of the values 
used in the base-case analysis, reflecting the greater uncertainty given reliance on expert 
opinion.  Discounting of both costs and effectiveness was varied between zero and 7%, from 
the base-case of 5%.  Based on these results, one-way sensitivity analysis of all key input 
parameters was performed. For variables that were defined by a distribution, probabilistic 
sensitivity analysis was conducted to incorporate multiple parameter uncertainties 
simultaneously.  
5.4.9 Model validity 
Validation of the model followed the recommendations of the International Society of 
Pharmacoeconomics and Outcomes Research Task-Force 7 [40]. Face validity, internal validity 
and external validity were addressed. Face validity is a subjective approach involving people 
with clinical expertise in the disease area, thus ensuring the model incorporates the highest 
level of clinical evidence. The overall structure of the model, population, screening 
approaches, outcomes and assumptions were reviewed and validated by a hepatologist (KCY), 
biostatistician (LG) and four health economists (AP, LS, BdG, AN).  
Internal validity involved assessments to ensure the correct mathematical calculations were 
implemented. This was conducted by validating equations and parameters against their 
sources (BdG, LS).  Screening was modelled to predict mortality rates for males and females 
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at various ages. These estimates were compared with the mortality data that was used to 
populate the model [34]. One-way sensitivity analyses were conducted, as previously 
discussed, to ensure the results changed as expected when input parameter values were 
varied.  
Assessing external validity involved comparing the predictions generated by our model with 
other published epidemiological and clinical data that were not used in our model. External 
validity was tested by estimating the life expectancy (LE) of 30 year old males and 45 year old 
females, and prevalence of C282Y homozygosity, and comparing to published data [34]. 
5.5 Results  
5.5.1 Validity assessment 
Face validity and internal validation 
For face validity, the model structure was found to correctly represent all clinical aspects of 
haemochromatosis [7, 16, 41, 42]. To assess internal validity, mortality rates generated by the 
model were compared to the published rates used to build the model (Table 3) [34]. 
Specifically, the modelled predictions for mortality rates for males (at ages 30, 40, 50, 60, 70 
and 80) and females (ages 45, 55, 65, 75 and 85) were plotted against the published rates and 
the goodness of fit for the linear relationship assessed (Figure 2). The correlation coefficient 
(R2) was 1.00, indicating the model accurately reproduced the inputted mortality rates.  
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Table 3: Annual mortality rate for males and females from model predictions and inputs  
Age (years) 
Annual mortality 
rate from model 
predictions  
Annual mortality 
rate from 
literature[47] 
Males 
30 
40 
50 
60 
70 
80 
 
0.00079 
0.00134 
0.00291 
0.00678 
0.01690 
0.05126 
 
0.00079 
0.00134 
0.00291 
0.00678 
0.01691 
0.05126 
Females 
45 
55 
65 
75 
85 
 
0.00121 
0.00270 
0.00626 
0.01783 
0.06603 
 
0.00121 
0.00270 
0.00626 
0.01783 
0.06603 
 
Figure 2: Goodness-of-fit test for model internal validation 
 
External validity 
For the overall hypothetical cohort, the model predicted a life expectancy (LE) of 30 year old 
males of 51.0 years, identical to the data reported in the ABS Life Tables (51.0 years) (Table 
4) [34]. Similarly, for females aged 45, the model predicted life expectancy (LE) of 40.4 years, 
consistent with the data from the ABS Life Tables (40.4 years).  These findings were as 
expected, given the relatively low prevalence of C282Y homozygotes. Further, the penetrance 
of Category 4 – the only state with elevated mortality rates – is very low, ranging between 0 
and 0.01% (Figures 4 and 5). External validation analyses were also conducted for the 
prevalence of C282Y homozygosity (Table 4). Our model predicted a prevalence rate of 0.62%, 
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falling within the range established by two large, robust studies of 0.44% C282Y homozygosity 
for a population of ‘white’ North Americans and [43]  and 0.75%  for a Norwegian sample [38].  
Table 4: External validity 
Parameters Model predictions  
Data from 
literature 
Life expectancy  
male aged 30 
female aged 45 
 
51.0  
40.4  
 
51.0 [47] 
40.4 [47] 
Prevalence of C282Y homozygotes amongst 
persons of northern European ancestry* (%): 
males 
females 
 
 
0.62 (0.0006) 
0.62 (0.0006) 
 
 
 
0.75 [44]; 0.44 
[50] 
 
 
Note: * Whilst the prevalence of C282Y homozygosity is the same for both sexes, the model was run separately 
for males and females. As a result, they are reported separately. 
 
To further assess external validity, the strength of the linear relationship between modelled 
LE and prevalence estimates with the respective published rates (Table 4) was assessed 
(Figure 3). The correlation coefficient (R2) was 1.00, indicating the model accurately 
reproduced the published rates.  
Figure 3: Goodness-of-fit test for model external validation 
 
 
0
10
20
30
40
50
60
0 10 20 30 40 50 60
Va
lu
es
 fr
om
 m
od
el
 
pr
ed
ic
tio
ns
Values from published data
R2=1.00
Chapter 5: Population screening for hereditary haemochromatosis in Australia: construction and 
validation of a state-transition cost-effectiveness model 
 
209 | P a g e  
 
5.5.2 Model predictions 
Table 5 displays the results of the base-case Monte Carlo simulations, calculated from age 30 
years for males and 45 years for females. Life expectancy was estimated specifically for C282Y 
homozygotes: for 30-year old males, LE (standard deviation) was estimated to be 49.9 years 
(0.04), 1.1 years less than the Australian LE for 30 year old males (51.0 years). The projected 
LE for female C282Y homozygotes aged 45 was 40.2 years (0.01), 0.3 years less than the 
Australian LE for females of the same age (40.4 years). The mean (95% CI) discounted QALYs 
associated with screening were 15.7 (7.7-23.7) for males and 14.4 (6.7-22.1) for females. The 
model also predicted mean lifetime direct medical costs (95%CI) for male C282Y homozygotes 
as AUD22,737 (AUD3,670-85,793) and AUD13,840 (AUD1,335-67,377) for females.  
Table 5: Results of base-case analyses  
 
Males 
(age 30 years) 
(SD) 
Females 
(age 45 years) 
(SD) 
Life expectancy (C282Y homozygotes) 49.9 (0.04) 40.2 (0.01) 
 
Population* C282Y homozygotes  
Costs  
(2015 AUD) 
Effectiveness 
(QALYs) 
Costs 
(2015 AUD) 
LE 
(years) 
Males  
Mean  
Standard deviation 
95% CI 
 
145 
148 
29-498 
 
15.654 
4.062 
7.694-23.668 
 
22,737 
25,104 
3,670-85,793 
 
49.91 
0.04 
- 
Females 
Mean  
Standard deviation 
95% CI 
 
91 
135 
15-414 
 
14.390 
3.955 
6.660-22.142 
 
13,840 
22,696 
1,335-67,377 
 
40.15 
0.01 
- 
 
Time (years) in disease states 
 
Category 1 
Category 2 
Category 3 
Category 4 
C282Y homozygotes   
Males (SD) Females (SD) 
10.42 (0.00) 
13.53 (0.00) 
23.19 (0.00) 
2.79 (0.04) 
14.77 (0.00) 
19.54 (0.00) 
5.51 (0.00) 
0.41 (0.01) 
* Population refers to the entire hypothetical cohort of males or females of northern European 
ancestry; 95% CI, 95% confidence interval 
Time in states 
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The model projected the time spent in each disease state (Table 5). The low rates of uptake 
of screening and adherence to treatment were the drivers of transition to Categories 3 and 4: 
the states in which co-morbidities related to iron overload occur. Males spent a mean of 
23years in Category 3 and three years in Category 4, whilst females, with lower clinical 
penetrance, spent a projected mean of six years in Category 3 and less than one year in 
Category 4. 
The model predicted the probabilities of both the male and female cohorts being in each of 
the five Markov states for each stage of the model, until all hypothetical participants were in 
the absorbing Dead state (Figures 4 and 5). For both sexes, the probability of being in Category 
1 increased between the first two stages, and conversely, the probability of being in Category 
2 decreased. This result is a function of screening, in that 90.5% of Category 2 patients access 
treatment subsequent to screening. Therefore, most Category 2 participants transition to 
Category 1, the impacts of haemochromatosis being potentially reversible until Category 4. 
This effect is less dramatic for females as fewer females than males are in Category 2 at the 
time of screening (80% and 95% respectively).   
For both sexes, the probability of being in Category 1 decreased over time reflecting reduced 
adherence to treatment; 90.5% in the first year to 29.3% in the tenth year and thereafter [44]. 
In turn, the probability of being in Categories 2, 3 or 4 increased. Participants in Category 4 
had a higher probability of moving into the ‘Death’ state than other participants. In addition, 
the probability of transitioning into the ‘Death’ state increased with the advancing age of the 
cohort, in line with population data [34].  
 
 
 
 
 
 
Figure 4: State probabilities for male C282Y homozygotes 
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Figure 5: State probabilities for female C282Y homozygotes 
 
5.5.3 Sensitivity analysis 
One-way sensitivity analyses were carried out by varying the value by ±20% for all key 
parameters, with the exception of uptake of screening (±50%) and discounting (varied 
between 0 and 7%) (Appendix 5B). Tornado diagrams were constructed to identify 
parameters with the greatest effect on costs and effectiveness. The five parameters with the 
greatest impact (discount rate, prevalence, probability of starting in Category 1, transition 
from Category 1 to 2 and costs associated with Categories 2 and 3) are included in Appendix 
5B.  
For males, varying the discount rate had the most notable effect on both costs and 
effectiveness. With no discounting, mean costs increased from the base-case estimate of 
AUD145 to AUD497 and effectiveness increased from 15.7 to 42.2 QALYs. When the discount 
rate was set at 7%, mean costs decreased to AUD101 and effectiveness reduced to 11.9 
QALYs. Varying the prevalence also had an impact on costs: increased the estimate by 20% 
increased mean costs to AUD185, and decreasing the estimated by 20% reduced costs to 
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AUD126. Varying uptake of screening (±50%) marginally impacted costs and effectiveness. 
Decreasing uptake reduced costs to AUD143, and increasing uptake increased costs to 
AUD146.  No notable impact on effectiveness was observed (<0.001QALY).  Varying the 
mortality multiplier had negligible effects on cost and effectiveness for males, (<AUD1 and 
<0.001 QALY respectively).  For LE, varying the multiplier for mortality by ±20% (1.96 to 2.94) 
resulted in small changes. For males aged 30, from a base-case LE estimate of 40.1 years, 
decreasing the multiplier increased LE to 50.2years, and conversely, increasing the multiplier 
decreased LE to 49.7 years. One-way sensitivity analysis on other variables showed small 
impacts on costs and effectiveness (Appendix 5B).  
For females, the parameter with the most effect on costs and effectiveness was the discount 
rate. Decreasing this to zero resulted in costs increasing to AUD264 from the base-case 
estimate of AUD91, and increasing this rate to 7% decreased costs to AUD64. Similarly, 
effectiveness increased from the base-case estimate of 14.4 to 33.1 QALY gained with no 
discounting and decreased to 11.3 QALY gained when the discount rate was set at 7%. 
Increasing the prevalence estimate increased costs to AUD114; when this was decreased, cost 
reduced to AUD79. Decreasing the uptake estimate by 50% reduced costs to AUD89, and 
increasing this estimate increased costs to AUD93. No notable change in effectiveness was 
observed (<0.001QALY).  Similar to males, varying the mortality multiplier had negligible 
effects on costs and effectiveness (<AUD1 and <0.001 QALY gained respectively).  The LE of 
females aged 45 increased by <0.01 years when the multiplier was decreased by 20% 
(40.2years), and conversely, LE decreased to 40.1 years when the multiplier was increased. 
All other sensitivity analyses revealed minor changes from the base-case estimate (Appendix 
5B) 
5.6 Discussion 
This is the first economic model to be published using utility and cost data from a 
haemochromatosis cohort to populate a Markov model with probabilistic decision analysis: 
the approach best suited to this chronic, progressive disease. Just one other model has 
evaluated the cost-effectiveness of population screening for haemochromatosis, using a 
Markov model with probabilistic decision analysis. Our model has built on this previously 
published model by incorporating multiple disease states as recommended by the European 
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Association for the Study of the Liver, along with disease-specific cost and utility data derived 
from people living with haemochromatosis. Previous models used estimates of costs and 
utilities based on expert opinion.  
The number of health technology assessments being conducted has increased over the past 
two decades and, with an increasing focus on value in health care, this is likely to continue. 
Whilst clinical studies are ideally placed to assess the short- to medium-term costs and 
effectiveness of interventions, long-term costs and effectiveness are most feasibly and 
efficiently assessed through modelling. Important considerations for modelling studies 
include use of the highest quality clinical and epidemiological data available, transparency, 
and acceptability to patient groups, expert clinicians, decision makers and healthcare payers. 
The model for haemochromatosis that we have constructed has aimed to address all of these 
issues. 
The model was assessed for internal and external validity, returning correlation coefficients 
of 1.00 for goodness-of-fit analyses. These findings provide a level of confidence that the 
model correctly reproduces published data. All key input parameters, results of one-way 
sensitivity analyses and the structure of the model have been provided to enhance 
transparency.  
The base-case analyses estimated the mean direct medical costs associated with screening 
and consequential treatment for those identified was AUD145 for males and AUD91 for 
females. The higher costs incurred by males than females are expected given the higher rate 
of clinical penetrance for males. One-way sensitivity analysis identified no parameters which 
altered this. Increasing the penetrance for females by increasing the probability of 
commencing in Category 2 (rather than Category 1) had a negligible effect on costs and 
effectiveness in comparison to the base-case results. Another factor contributing to the lower 
costs for females is the low sensitivity of transferrin saturation as a screening test for females. 
This results in missed diagnoses and lower total screening costs (two consecutive elevated 
transferrin saturation tests followed by confirmatory genotype), as fewer females than males 
will go on to have the second transferrin saturation test and genotype.  In turn, potential 
venesection treatment costs are not accrued. Whilst in our model female C282Y homozygotes 
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who are not diagnosed, and therefore not receiving treatment, still accrue costs (with the 
exception of Category 1), these costs are smaller as venesection costs are excluded. Further, 
treatment costs accrue in the future, and are thus subject to discounting. Overall, the trade-
off for this lower cost screening strategy is the reduced identification of female homozygotes.  
The trade-off between any cost savings versus the greater burden of disease generated is an 
issue which requires careful consideration. 
Our model, consistent with other published studies, reported relatively high levels of 
uncertainty as evidenced by large standard deviations and 95%CI reported in the base-case 
analyses [4, 23, 45-47].  However, these uncertainties were addressed in our one-way 
sensitivity analyses and, with the exception of discounting, were found to have little impact 
on the base-case results. Our primary avenue to minimise uncertainty was by utilising patient 
derived information on costs and utilities associated with EASL categorisations.  
Projected life expectancy for C282Y homozygotes was marginally lower than for the general 
population. The mortality multiplier applied to Category 4 of 2.45 [35], was in-line with other 
recent epidemiological work on mortality associated with haemochromatosis [48]. Whilst 
higher mortality rates were adopted for Category 4, the low penetrance rate for this category 
resulted in marginal impacts on overall mortality in both the base-case and sensitivity 
analyses.  
Our model has been developed to allow for comparisons between the status quo approach 
of screening for haemochromatosis and alternatives, such as population level genetic or 
neonatal screening.  In our accompanying paper in this issue, we report on an expansion of 
this model to compare several screening strategies for both adults and neonates and the 
assessment of the comparative cost-effectiveness [49].  Our model is well placed to assist 
decision makers in Australia to assess different screening strategies for haemochromatosis. 
Further, it is flexible enough that alternative parameters may be used to allow for cost-
effectiveness analyses in different jurisdictions.  
A transparent and validated health economics model of screening for C282Y homozygote 
haemochromatosis based on Australian economic, epidemiological and clinical data has been 
developed. The model will be useful to decision makers to identify cost-effective screening 
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and treatment strategies for C282Y homozygote haemochromatosis. 
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One-way sensitivity analyses: males and females 
 
Parameters 
 
Government perspective 
Costs a Effectiveness b 
Males  
Discount rate: 0% 
Discount rate: 7% 
Prevalence: -20%  
Prevalence: +20%  
Probability of starting in category 1:  -20%  
Probability of starting in category 1:  +20%  
Transition from category 1 to 2~: -20%  
Transition from category 1 to 2~: +20%  
Costs: category 3(no treatment): -20%* 
Costs: category 3(no treatment): +20%* 
 
497 
101 
126 
185 
158 
127 
133 
151 
129 
156 
 
42.246 
11.903 
15.453 
15.451 
15.451 
15.454 
15.453 
15.453 
15.453 
15.453 
 
Parameters 
Government perspective 
Costs a Effectiveness b 
Females 
Discount rate: 0% 
Discount rate: 7% 
Prevalence: -20%  
Prevalence: +20%  
Costs: category 2(no treatment): -20%  
Costs: category 2(no treatment): +20%  
Probability of starting in category 1:  -20%  
Probability of starting in category 1:  +20%  
Transition from category 1 to 2~: -20%  
Transition from category 1 to 2~: +20% 
 
264 
64 
79 
114 
76 
101 
107 
84 
79 
97 
 
33.124 
11.286 
14.281 
14.277 
14.280 
14.280 
14.280 
14.280 
14.280 
14.280 
* At time of diagnosis, in the base-case this is assumed to be 0; a costs are lifetime costs reported in 2015 AUD; b 
effectiveness is presented in quality adjusted life years (QALYs) 
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Chapter 6: Cost-effectiveness of different population 
screening strategies for hereditary haemochromatosis in 
Australia 
6.1 Preface 
Chapter 3 and 4 presented evidence of the quality of life and economic impacts associated 
with haemochromatosis. Chapter 5 was concerned with presenting the construction and 
validation of a cost-effectiveness model for haemochromatosis. In Chapter 6, the application 
of the haemochromatosis health economics model is presented.   
Four screening strategies were modelled: HFE genotyping using a blood sample, HFE 
genotyping with a buccal cell sample, sequential screening with two consecutive iron studies 
and confirmatory HFE genotyping, and the status quo was included as the comparator.  The 
target populations for all strategies were males aged 30 years and females aged 45 years, 
both of northern European ancestry. In addition, HFE genotyping of neonates using Guthrie 
cards, irrespective of ancestry, was modelled, again using the status quo as the comparator.  
 From the government perspective, genotyping with a blood sample was the most cost-
effective strategy for adult males; for adult females, the sequential approach was considered 
to be the most cost-effective. For male and female neonates, screening dominated the status 
quo. The results of this model can be used by decision-makers when considering resource 
allocation in relation to haemochromatosis screening interventions. 
This chapter has been submitted to Applied Health Economics and Health Policy.  
de Graaff, B., Neil, A., Lei, S., Yee, K.C., Sanderson, K., Gurrin, L.C. & Palmer AJ. “Cost-
effectiveness of different population screening strategies for hereditary haemochromatosis 
in Australia”. 
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6.2  Abstract 
Introduction: Amongst populations of northern European ancestry, HFE-associated 
haemochromatosis is a common genetic disorder characterised by iron overload. In the 
absence of treatment, excess iron is stored in parenchymal tissues, causing morbidity and 
mortality. Population screening programs may increase early diagnosis and reduce associated 
disease. No contemporary health economic evaluation has been published for Australia. 
Methods: A Markov model using probabilistic decision analysis was developed comparing 
four adult screening strategies: the status quo (cascade and incidental screening), genotyping 
with blood and buccal samples and transferrin saturation followed by genotyping (TfS); and 
two neonatal strategies: genetic screening and the status quo. Target populations were males 
(30 years) and females (45 years) of northern European ancestry, and neonates irrespective 
of ancestry. Cost-effectiveness was estimated from the government perspective over a 
lifetime horizon. 
Results: All strategies for adult males were cost-effective compared to the status quo. The 
incremental costs (standard deviation) associated with genotyping (blood) were AUD7 (56), 
TfS AUD15 (45) and genotyping (buccal) AUD63 (56), producing ICERs of AUD1,673; 4,103; 
and 15,233/QALY gained respectively.  For females, only the TfS strategy was cost-effective, 
producing an ICER of AUD10,195/QALY gained. Neonatal screening dominated the status quo 
for both sexes. Approximately 3% of C282Y homozygotes were estimated to be identified with 
the status quo approach, compared with 40% and 92% for adult and neonatal strategies 
respectively.  
Conclusion: This model estimated that genotyping and TfS strategies are likely to be more 
cost-effective screening strategies than the status quo.  
6.3  Introduction 
HFE-associated hereditary haemochromatosis is the most common single-gene autosomal 
recessive disorder among populations of northern European ancestry [1-3]. People 
homozygous for the C282Y mutation in the HFE gene account for between 80% and 90% of 
clinical cases of iron overload [4, 5]. The prevalence of this genotype has been estimated from 
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population studies to be between 1 in 150 and 1 in 200 in populations of northern European 
ancestry [6-8]. Haemochromatosis is characterised by iron overload; treatment involves 
regular therapeutic venesection. Clinical penetrance is incomplete: a further genetic mutation 
is thought to play a role in this process [9, 10].  When treatment is delayed, morbidity and 
mortality can occur [2, 11, 12]. As diagnosis is often delayed until organ damage has occurred, 
population screening programs have been suggested to increase early diagnosis [13-18].  
Modelled cost-effectiveness studies provide a pragmatic approach to assess the costs and 
effectiveness associated with various interventions in chronic diseases [19]. A clinical trial of 
population-based screening for haemochromatosis is unlikely, due to the high costs and long 
follow-up period required to comprehensively capture outcomes.  Several studies have been 
published on the cost-effectiveness of screening for haemochromatosis, however a recent 
systematic review identified methodological issues with many of these, limiting their 
robustness and generalisability [20]. Assumptions regarding rates of prevalence, penetrance, 
screening uptake, adherence to treatment and utility values were highly variable, reflecting a 
paucity of data from high quality epidemiological and clinical studies at the time they were 
conducted. Most studies of screening interventions used cost/case detected or cost/life year 
gained (LYG) as outcome measures. Long-term outcomes for haemochromatosis – which have 
substantial effects on quality of life – may be better measured using quality adjusted life years 
(QALYs) [21, 22]. To date, just four cost-effectiveness studies reporting QALYs have been 
published [5, 23-25]. For the most part, the utility values used to calculate QALYs were notably 
higher than reported for relevant population norms [26], disease-specific utilities for 
comparable comorbidities [27-29] and for a recently reported cohort of people with 
haemochromatosis [22]. Use of elevated utility values may contribute to underestimates of 
QALY gains. The aim of this study was to assess the cost-effectiveness of adult and neonatal 
screening strategies for the Australian setting to identify people homozygous for the C282Y 
mutation, using the most robust clinical, epidemiological and health economic data available.  
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6.4  Methods 
6.4.1 Model structure 
We constructed a cost-effectiveness model that has been described in detail in our 
accompanying paper in this issue [30].  A brief description is provided here. A state-transition 
model utilising a Markov approach over a lifetime horizon was developed, with four Markov 
states based on disease severity along with the absorbing state ‘Death’ (Figure 1) [31].  
Markov states were based on disease categories as recommended by the European 
Association for the Study of the Liver (EASL) (Table 1) [31]. At the time of diagnosis, it was 
assumed that no participants were in Categories 3 or 4; the probability of being in Categories 
1 and 2 were 0.8 and 0.2 respectively for males, and 0.95 and 0.05 respectively for females. 
State transition probabilities were taken from a large Australian epidemiological study, and 
were dependent upon adherence to treatment (i.e. non-adherence resulted in a higher 
probability of transition to the next category of disease  [6, 32, 33] (Table 2). 
Figure 1: Structure of the Markov model. For C282Y homozygotes, simulated patients can 
move between the Markov states in the direction of the arrows. ‘Categories 1,2 3 and 4’ are 
temporary states and ‘Death’ is an absorbing state. 
 
 
 
 
 
 
 
 
 
 
Category 2 Category 3 
Category 1 
Death 
Category 4 
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Table 1: Categories of haemochromatosis [25] 
Category 1 Genetic mutation only (C282Y homozygotes, H63D heterozygotes and compound 
heterozygotes) 
Category 2 Genetic mutation and elevated iron studies, either transferrin saturation or serum 
iron 
Category 3 Genetic mutation, elevated iron levels and early symptoms (e.g. arthritis, fatigue, 
lethargy) 
Category 4 Genetic mutation, elevated iron levels and organ damage (e.g. liver cirrhosis, 
hepatocellular carcinoma, heart disease, Type 2 diabetes) 
 
Age and sex adjusted mortality was sourced from Australian life tables [34] (Table 2). 
Mortality for disease states was assumed to be the same as the Australian population age and 
sex adjusted rates with the exception of Category 4. As irreversible organ damage (e.g. liver 
cirrhosis, heart disease) characterises this category, a multiplier of 2.45 (95%CI 2.27-2.64) was 
applied to age and sex specific mortality based on recently published mortality estimates [35, 
36].  
Second order Monte Carlo simulation (probabilistic sensitivity analysis) was conducted by 
simultaneously sampling from multiple distributions around key inputs to address parameter 
uncertainty. When defining the distributions of model parameters, where insufficient data 
from the literature was available, triangular distributions were adopted. The model was 
constructed using TreeAge Pro Suite 2014 (TreeAge Software, Williamstown, Massachusetts).    
6.4.2 Base case populations 
Adults 
Two base-case populations were selected: 30 year old males and 45 year old females, both of 
northern European ancestry. The sex-specific ages were selected as they reflect typical ages 
for iron-overload to commence [23, 37, 38], and northern European ancestry as the 
prevalence of C282Y homozygosity is notably higher amongst this group than for populations 
of other ancestries [6, 39].  
Neonates 
Two base-case populations of male and female neonates irrespective of ancestry were also 
selected. This strategy reflects the existence of universal neonatal genetic screening in 
Australia, therefore avoiding additional infrastructure requirements.  
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Table 2: Key model parameters  
Parameter Base case Range for SA Distribution Source 
Prevalence of C282Y homozygotes 
 Of northern European ancestry 
Australian population 
 
0.0068 
0.0039 
 
0.0044-0.0074 
0.00312-0.00468 
 
Triangular 
Triangular 
 
[2-4] 
[5] 
Probabilities for categories of 
haemochromatosis 
                                        Category 1 
Category 2 
Category 3 
Category 4 
Males Females Males Females  
 
Triangular 
Triangular 
- 
- 
 
[6] 0.8 
0.2 
0 
0 
0.95 
0.05 
0 
0 
0.64-0.096a 
0.16-0.24 a 
- 
- 
0.76-1.00 a 
0.04-0.06 a 
Annual transition probabilities:  
with treatment:                                            
Category 1 to 2 
Category 2 to 1 
Category 2 to 3 
Category 3 to 2 
Category 3 to 4 
Category 4 to die 
        without screening and/or treatment: 
Category 1 to 2 
Category 2 to 1 
Category 2 to 3 
Category 3 to 4 
Category 4 to die 
Category 4 mortality multiplier b 
 
 
0 
1-(mortality#) 
0 
0.0083 
0 
0.0167 
 
0.071 
0 
0.0625 
0.0083 
0.0167 
2.45 
 
 
0 
1-(mortality#) 
0 
0.0083 
0 
0.0167 
 
0.0542 
0 
0.0167 
0.0083 
0.0167 
2.45 
 
 
- 
- 
- 
0.0064-0.0096a 
- 
0.0134-0.0200a 
 
0.0568-0.0852a 
- 
     0.050-0.075 a 
0.0064-0.0096 a 
0.0134-0.0200 a 
1.96-2.94 a 
 
 
- 
- 
- 
0.0064-0.0096a 
- 
0.0134-0.0200a 
 
   0.04336-0.0650a 
- 
0.0134-0.0200a 
0.0064-0.0096a 
0.0134-0.0200a 
1.96-2.94 a 
 
 
- 
- 
- 
Triangular 
- 
Triangular 
- 
Triangular 
- 
Triangular 
Triangular 
Triangular 
Triangular 
 
 
[6, 7]  
 
 
 
 
 
 
 
 
 
 
 
[8] 
Adherence to therapeutic 
venesection (3-4 times annually) 
                       Year 1 
 
0.905 
 
0.724-1.000 a 
 
Triangular 
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Year 2 
Year 3 
Year 4 
Year 5 
Year 6 
Year 7 
Year 8 
Year 9 
Year 10 and thereafter 
 
0.837 
0.769 
0.701 
0.633 
0.565 
0.497 
0.429 
0.361 
0.293 
0.670-1.000 a 
0.615-0.923 a 
0.561-0.841 a 
0.506-0.760 a 
0.452-0.678 a 
0.398-0.596 a 
0.343-0.515 a 
0.289-0.433 a 
0.234-0.352 a 
Triangular 
Triangular 
Triangular 
Triangular 
Triangular 
Triangular 
Triangular 
Triangular 
Triangular 
 
 
[9] 
Costs incurred in categories of 
haemochromatosis * 
Category 1 
Category 2 
Category 3 
Category 4 
    
 
LogNormal 
LogNormal 
LogNormal 
LogNormal 
 
 
[10] 
[10] 
[10] 
[10] 
 
824 
1,949 
3,681 
10,393 
  
   434-1,213 a 
1,162-3,018 a 
2,945-4,417 a 
8,313-12,472 a 
Unit costs of screening strategies 
elements*                              
GP Level A c 
GP Level B c 
Iron studies c 
Genotype: blood c 
Genotype: buccal c 
Initial medical specialist consultation c 
Information pamphlet c 
Neonatal heel prick screen c 
 
 
 
16.95 
37.05 
27.70 
31.00 
150 
72.75 
0.38 
0.88 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
[11, 12] 
[11, 12] 
[11] 
[11] 
Estimate d 
[11, 12] 
Estimate e 
[13] 
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Sensitivity: 
First genotype test 
First transferrin saturation 
Second transferrin saturation 
Specificity: 
First genotype test 
First transferrin saturation 
Second transferrin saturation 
Males Females Males Females  
Triangular 
Triangular 
Triangular 
 
Triangular 
Triangular 
Triangular 
 
Genotype 
[14]; TfS 
[15] 
0.92 
0.938 
0.90 
 
0.994 
0.981 
0.996 
0.92 
0.546 
0.55 
 
0.994 
0.981 
       0.994 
0.74-1.00 a 
0.75-1.00 a 
0.72-1.00 a 
 
0.80-1.00 a 
0.78-1.00 a 
0.80-1.00 a 
0.74-1.00 a 
0.44-0.66 a 
0.44-0.66 a 
 
0.80-1.00 a 
0.78-1.00 a 
0.80-1.00 a 
Uptake of screening: 
Status quo 
      Of these:             Cascade screening  
Incidental screening 
Genotype  
Neonatal heelprick 
Adult state iron studies 
 
0.05 
0.50 
0.50 
0.469 
1.00 
0.50 
 
0.025-0.075~ 
- 
- 
0.23-0.70~ 
- 
0.025-0.075~ 
 
Triangular 
Triangular 
Triangular 
Triangular 
Triangular 
Triangular 
 
Estimate d 
[16, 17] 
[16, 17] 
[16, 17] 
[13, 18, 19] 
Estimate d 
Utilities 
Category 1 
Category 2 
Category 3 
Category 4 
Male Female Male Female  
Beta 
Beta 
Beta 
Beta 
 
[20] 
[20] 
[20] 
[20] 
0.88 
0.85 
0.59 
0.59 
0.71 
0.77 
0.60 
0.41 
0.70-1.00 
0.68-1.00 
0.47-0.71 
0.47-0.71 
0.57-0.85 
0.62-0.92 
0.48-0.72 
0.33-0.49 
Annual discount rate 
Costs 
Effectiveness 
 
0.05 
0.05 
 
 
0.00-0.07 
 
- 
- 
 
 
[21] 
* All costs are in 2015 AUD; a One-way sensitivity analysis values ±20% of base-case value; ~ One-way sensitivity analysis values ±50% of base-case value; # mortality rates used 
were age and sex specific, from the Australian Bureau of Statistics [54]; c Sensitivity analysis was carried out on total screening costs, not unit costs; d this estimate is based 
on expert opinion, as no cost data was available; e this estimate was based on production and dissemination costs from a large printing agency and Australia Post postage 
charges.  GP refers to general practitioner
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6.4.3 Interventions 
Adults 
Four screening interventions were modelled that reflect current practice, literature and 
available technology. All interventions were subject to variable uptake and adherence rates 
(Table 2), and all adult strategies were assumed to be performed through initial contact with 
a general practitioner (GP). 
Strategy 1  
Strategy 1 was based on the status quo approach in Australia. Current guidelines recommend 
screening either through a cascade approach in which first-degree relatives of a C282Y 
homozygote are offered concurrent genotyping and iron studies, or through incidental 
screening. This latter approach consists of three stages: two consecutive elevated TfS results 
followed by HFE genotyping. In our model, when a participant tested positive as a C282Y 
homozygote with either strategy, they moved into Markov states Category 1 or Category 2. 
For a patient who tested negative for C282Y homozygosity and had elevated transferrin 
saturation, a consultation with a specialist medical practitioner for further investigations was 
assumed. Apart from the cost of this consultation, no other consequences were considered. 
Strategy 2 
The second strategy was a population-based approach to screening, in that all 30 year old 
males and 45 year old females of northern European ancestry were offered HFE genotyping 
via a blood sample. Following a positive result, iron studies were conducted with a follow-up 
appointment with a GP.  
Strategy 3 
This strategy entailed HFE genotyping via a buccal cell sample obtained through a painless 
cheek-brush procedure. The benefits of this approach are that it is non-invasive, and in 
laboratory and screening studies, has been shown to have high sensitivity and specificity [40-
43].  This strategy replicated Strategy 2 with the exception that instead of a blood sample for 
genotyping, a buccal cell sample was used.  
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Strategy 4 
The fourth strategy was based in part on the status quo. Screening was assumed to be offered 
to all adults of northern European ancestry, and consisted of two consecutive iron studies, 
specifically TfS, which if elevated, were followed by a confirmatory HFE genotype.  
Neonates 
Strategy 5 
The neonatal screening intervention involved HFE genotyping as an add-on to the existing 
newborn screening program [44]. Following birth, all neonates, irrespective of ancestry, were 
assumed to be offered genetic screening for a range of disorders, including 
haemochromatosis.  This screening strategy assumed that 50% of adult C282Y homozygotes 
(males aged 30 and females aged 45 years) would have iron studies conducted with a GP and 
commence treatment if required. As neonates from all ancestries were included, a lower 
prevalence rate of 0.39% was adopted [45].   
Strategy 6 
The comparator for this strategy was the status quo (i.e. Strategy 1 for adult screening 
strategies), however, participants were simulated from birth. At age 30 for males and 45 for 
females, the screening approaches and assumptions described for Strategy 1 commenced. 
6.4.4 Estimates of screening uptake 
As no data on uptake of cascade and incidental screening in Australia were available, an 
estimate was made based on values used in other studies and expert opinion, and these 
estimates were thoroughly tested in univariate sensitivity analysis. The probability of being 
screened was set at 0.05 [45], and a probability of 0.5 was used for screening via cascade and 
incidental approaches respectively.  
Similarly, as no population screening programs for haemochromatosis have been introduced 
internationally, an uptake rate was estimated. Uptake rates of two Australian screening 
programs were identified (bowel cancer screening: 36.0% [46] and cervical cancer: 
57.8%[47]), and a mean of 0.469 was calculated and varied in sensitivity analyses by ±50%.  
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For neonatal screening, as this is close to being universal in Australia, the probability of uptake  
was assumed to be 1.0 [48-50]. The probability of having iron studies conducted as an adult 
was set at 0.5, based on expert opinion. To reflect the uncertainty around the estimate, this 
was varied by ±50% in one-way sensitivity analyses. 
6.4.5 Adherence to treatment 
The probabilities of adherence to treatment were taken from a longitudinal study following 
haemochromatosis patients over a nine year period [51]. From a baseline adherence rate of 
90.5%, an annual linear decrease of 6.8% was reported. For our model, the probability of 
adherence in years 10+ plateaued at 29.3% (Table 2). 
6.4.6 Sensitivity and specificity of screening tests 
The model incorporated sensitivity and specificity estimates for the two consecutive TfS tests 
based on sex, and for HFE genotyping (Table 2). These estimates, in combination with 
prevalence estimates, were built into the model using Bayes’ revision function, as detailed in 
our accompanying paper.  
6.4.7 Costs 
As the Australian Government would be the potential payer of a population screening 
program, the perspective of the government was taken. Total government costs included 
direct medical costs and transfer payments, with both reported separately. Transfer 
payments were included as they were found to contribute substantially to the overall costs 
associated with haemochromatosis [52].  All costs were reported in 2015 AUD (USD 0.75). 
Cost calculations and methodology have been reported in detail elsewhere [52], however a 
brief description is provided here .  
Direct medical costs included medical consultations, procedures, investigations, prescribed 
medications and public hospital admissions.  Costs were taken from the 2015 Medical Benefits 
Scheme (MBS), Pharmaceutical Benefits Scheme (PBS) and the National Hospital Cost Data 
Collection cost weights for Australian Refined Diagnosis-Related Group (AR-DRG) [53-55]. No 
cost data were available for HFE-genotyping with buccal swabs, so estimates were based on 
comparable investigations. Unit costs are displayed in Table 2. All costs associated with EASL 
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haemochromatosis disease states were sourced from our recently published cost of illness 
study (Table 2) [52].  
Transfer payments, in the form of government welfare (Disability Support Pension, Carer’s 
Allowance) were costed based on patients’ and carers’ reports from our cost of illness study 
[52].  
As recommended by the Australian Medical Services Advisory Committee, costs and 
effectiveness were discounted by 5% annually [56]. The model was validated following the 
recommendations of the International Society of Pharmacoeconomics and Outcomes 
Research Task-Force 7 [57], described in detail in our accompanying paper [30].   
6.4.8 Effectiveness 
QALYs were used as a measure of effectiveness. Utility values for each category of disease 
severity were sourced from a recently published study [22]. QALYs were calculated by 
adjusting the time spent in a health state by the utility score assigned to that state. 
6.4.9 Sensitivity analyses 
Tornado diagrams were produced for each strategy, by sex for total government costs. These 
were used to identify the parameters with the greatest impact on outcomes when varied 
through plausible ranges.  Prevalence, adherence to treatment,  transition probabilities, utility 
values, the Category 4 mortality multiplier and costs were varied by ±20% of the values used 
in the base-case analyses [58].  For all model parameters that were informed by expert 
opinion, the estimates were varied ±50%, reflecting the greater uncertainty around these 
estimates. [58].  Discounting of costs and effectiveness was varied from zero to 7%. For 
variables that were defined by a distribution, probabilistic sensitivity analysis was conducted 
to incorporate multiple parameter uncertainties simultaneously.  
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6.5 Results  
6.5.1 Adult strategies 
Males 
From the government perspective (direct medical costs and transfer payments) all three 
screening strategies were cost effective compared to the status quo (Table 3). The most cost-
effective approach was genotyping (blood), which produced an ICER of AUD1,673/QALY 
gained, followed by the TfS strategy (AUD4,103/QALY gained) and genotyping (buccal) 
(AUD15,233/QALY gained). To address uncertainty, cost-effectiveness acceptability curves 
(CEACs) were produced. Whilst a willingness to pay (WTP) threshold has not been explicitly 
specified for the Australian context, an implicit threshold of AUD50,000/QALY gained is 
commonly used [59, 60].  In comparison with the status quo, the probability of genotyping 
(blood) being cost-effective at a WTP of AUD50,000 was 82%, for TfS screening 81%, and for 
genotyping (buccal) 74% (Figures 2a, c and b respectively). Ranking of the comparative cost-
effectiveness of all strategies showed genotyping (blood) to be the dominant strategy (Table 
4). 
Similarly, when the analysis was limited to direct medical costs, all strategies for males were 
cost-effective when compared with the status quo (Table 3).  The most cost-effective 
approach was genotyping (blood), with an ICER of AUD1,810/QALY gained, followed by TfS 
screening (AUD4,225/QALY gained) and genotyping (buccal) (AUD15,371/QALY gained). All 
three strategies returned ICERs below this threshold.  
Females 
All three screening strategies for females incurred greater costs than the status quo. For both 
genotyping strategies, the incremental gains in effectiveness were marginal (i.e. <0.001QALY), 
resulting in ICERs of AUD552,964 for genotyping (blood) and AUD1,872,055/QALY gained for 
genotyping (buccal). The incremental gain in effectiveness related to the TfS strategy was 
0.002QALY, producing an ICER of AUD10,195/QALY gained. Applying the WTP threshold of 
AUD50,000, only the TfS strategy was considered to be cost-effective. The CEAC showed a 
61% probability of this strategy being cost-effective with this WTP threshold (Figure 2f). 
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Ranking of the comparative cost-effectiveness for all strategies showed TfS to be the 
dominant strategy (Table 4). 
When the analysis was limited to direct medical costs, similar results were produced (Table 
3). For both genotyping strategies, ICERs of AUD559,675 for genotyping (blood) and 
AUD1,887,171/QALY gained for genotyping (buccal) were produced. The ICER associated with 
the TfS strategy was AUD10,253/QALY gained, below the WTP threshold of AUD50,000.  
6.5.2 Neonatal strategies 
Neonatal screening of both males and females resulted in cost savings and increased 
effectiveness, thereby dominating the status quo (Table 3). For males, the estimated cost 
savings associated with neonatal screening were AUD8 (6) and the incremental gain in 
effectiveness was 0.07 (0.020) QALY. For females, the cost savings associated with screening 
were AUD2 (2) and the incremental gain in effectiveness was 0.06 (0.02) QALY. Applying the 
WTP threshold, there was a 100% probability for both males and females that this strategy 
would be cost-effective (Figures 2g and 2h respectively). These results were unchanged when 
the analysis was limited to direct medical costs. 
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Table 3: Results of base-case cost effectiveness analyses: status quo vs alternate strategies for direct medical, transfer and total government 
costs 
 
Cost 
(SD) 
Incremental cost 
(SD) 
Effectiveness 
(QALY) 
(SD) 
Incremental 
effectiveness 
(SD) 
ICER  
($/QALY gained) 
Direct medical costs      
Adult males 
Status quo 
Genotype screening (blood) 
Genotype screening (buccal) 
Transferrin saturation 
 
145 (149) 
152 (99) 
208 (99) 
160 (110) 
 
- 
7 (55) 
63 (55) 
15 (44) 
 
15.654 (4.062) 
15.658 (4.062) 
15.658 (4.062) 
15.657 (4.060) 
 
- 
0.004 (0.004) 
0.004 (0.004) 
0.003 (0.004) 
 
- 
1,810 
15,371 
4,225 
Adult females 
Status quo 
Genotype screening (blood) 
Genotype screening (buccal) 
Transferrin saturation 
 
91 (135) 
115 (88) 
170 (89) 
108 (101) 
 
- 
24 (52) 
79 (52) 
17 (35) 
 
14.290 (3.955) 
14.390 (3.955) 
14.390 (3.955) 
14.392 (3.958) 
 
-- 
<0.001 (0.005) 
<0.001 (0.005) 
0.002 (0.005) 
 
- 
559,675 
1,887,171 
10,253 
Neonate males 
Status quo 
Genetic screen 
 
17.3 (11.2) 
9.5 (6.1) 
 
- 
-7.8 (5.5) 
 
16.830 (4.386) 
16.900 (4.406) 
 
- 
0.070 (0.020) 
 
- 
DOMINANT 
Neonate females 
Status quo 
Genetic screen 
 
5.3 (3.8) 
3.4 (2.2) 
 
- 
-1.9 (1.8) 
 
16.667 (4.619) 
16.723 (4.619) 
 
- 
0.055 (0.016) 
 
- 
DOMINANT 
Transfer payments      
Adult males 
Status quo 
Genotype screening (blood) 
Genotype screening (buccal) 
Transferrin saturation 
 
1.8 (23.1) 
1.2 (14.5) 
1.2 (14.5) 
1.3 (16.2) 
 
- 
-0.6 (8.7) 
-0.6 (8.7) 
-0.4 (7.1) 
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Adult females 
Status quo 
Genotype screening (blood) 
Genotype screening (buccal) 
Transferrin saturation 
 
0.4 (5.6) 
0.3 (3.5) 
0.3 (3.5) 
0.3 (4.1) 
 
- 
-0.1 (2.2) 
-0.1 (2.2) 
-0.1 (1.6) 
   
Neonate males 
Status quo 
Genetic screen 
 
0.2 (1.4) 
<0.01 (0.7) 
 
- 
-<0.01 (0.8) 
   
Neonate females 
Status quo 
Genetic screen 
 
<0.1 (0.1) 
<0.1 (<0.1) 
 
- 
-<0.1 (<0.1) 
   
Total government costs Cost 
(SD) 
Incremental cost 
(SD) 
Effectiveness 
(QALY) 
(SD) 
Incremental 
effectiveness 
(SD) 
ICER  
($/QALY gained) 
Adult males 
Status quo 
Genotype screening (blood) 
Genotype screening (buccal) 
Transferrin saturation 
 
146 (151) 
153 (100) 
209 (101) 
161 (111) 
 
- 
7 (56) 
63 (56) 
15 (45) 
 
15.654 (4.062) 
15.658 (4.062) 
15.658 (4.062) 
15.657 (4.060) 
 
- 
0.004 (0.004) 
0.004 (0.004) 
0.003 (0.004) 
 
- 
1,673 
15,233 
4,103 
Adult females 
Status quo 
Genotype screening (blood) 
Genotype screening (buccal) 
Transferrin saturation 
 
92 (135) 
115 (89) 
171 (89) 
109 (102) 
 
- 
23 (52) 
79 (52) 
17 (35) 
 
14.390 (3.955) 
14.390 (3.955) 
14.390 (3.955) 
14.392 (3.958) 
 
-- 
<0.001 (0.005) 
<0.001 (0.005) 
0.002 (0.005) 
 
- 
552,964 
1,872,055 
10,195 
Neonate males 
Status quo 
Genetic screen 
 
17.5 (12.3) 
9.5 (6.1) 
 
- 
-7.9 (5.5) 
 
16.830 (4.386) 
16.900 (4.406) 
 
 
0.070 (0.020) 
 
- 
DOMINANT 
Neonate females 
Status quo 
Genetic screen 
 
5.3 (3.8) 
3.4 (2.2) 
 
- 
-1.9 (1.7)  
 
16.667 (4.602) 
16.723 (4.619) 
 
- 
0.055 (0.016) 
 
- 
DOMINANT 
ICER Incremental cost effectiveness ratio; QALY quality adjusted life year. Note: all costs are reported in 2015 AUD
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Figure 2: Cost-effectiveness acceptability 
curves, total government costs 
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Figure 2a: Status quo v genotype 
(blood)
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Figure 2c: Status quo v TfS
Status quo TfS
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Figure 2b: Status quo v genotype 
(buccal) 
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Figure 2d: Status quo v genotype 
(blood)
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Figure 2e: Status quo v genotpye 
(buccal)
Status quo Genotype (buccal)
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Figure 2f: Status quo v TfS
Status quo TfS
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Figure 2g: Status quo v neonatal 
screening
Status quo Neonatal screening
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Figure 2h: Status quo v neonatal 
screening
Status quo Neonatal screening
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Table 4: Rankings of cost-effectiveness, excluded dominated strategies 
Strategies* Cost QALYs gained ICER 
Male adults: 
Genotype screening (blood)  
Genotype screening (buccal) 
Status quo 
 
153 
209 
146 
 
15.658 
15.658 
15.654 
 
DOMINANT 
WEAKLY DOMINATED 
WEAKLY DOMINATED 
Female adults: 
Transferrin saturation  
Status quo  
 
109 
92 
 
14.392 
14.390 
 
DOMINANT 
WEAKLY DOMINATED 
* Strategies that were strongly dominated were excluded. 
6.5.3 Cases identified 
The number of cases identified (true positives) per 10,000 screenings was calculated for each 
strategy (Table 5). For the status quo, the model projected 2.88 male and 2.03 female 
homozygotes would be identified. For adult strategies, both genotype strategies (blood and 
buccal) were the most effective, identifying 26.64 cases for males and females respectively. 
Population screening using TfS was similarly efficient for males, identifying 24.68 cases, 
however for females only 8.78 cases were identified. The lower sensitivity of TfS for 
identifying female homozygotes was the driver for this difference.  
For the neonatal screening strategy, a lower prevalence rate of 0.0039 was adopted, 
reflecting screening irrespective of ancestry [45]. The model estimated that 35.86 male and 
female homozygotes respectively would be identified, notably higher than the status quo.  
Table 5: Number of C282Y homozygotes identified per 10,000 screenings 
 Male  Female  
Adult strategies: 
Status quo 
Genotype screening (blood)  
Genotype screening (buccal) 
Transferrin saturation 
 
2.88 
26.64 
26.64 
24.68 
 
2.03 
26.64 
26.64 
8.78 
Neonatal strategies: 
Status quo 
Genetic screen  
 
2.88 
35.86 
 
2.03 
35.86 
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6.5.4 Sensitivity analysis 
One-way sensitivity analysis for each parameter that contributed moderate to large variations 
identified in the tornado diagrams was carried out for total government costs (Appendix 6A). 
Parameters were varied ±20%, with the exception of screening uptake and uptake of iron 
studies in homozygote adults screened as neonates (±50%), and the discount rate (0 and 7%).  
Adult males 
For males, the base-case analysis for genotype (blood) screening produced an ICER of 
AUD1,673/QALY gained. This strategy dominated the status quo in all one-way sensitivity 
analyses, with the exception of increasing the discount rate to 7%, which produced an ICER 
of AUD2,674/QALY gained.  
In the base-case analysis for genotyping (buccal) males, an ICER of AUD15,233/QALY gained 
was calculated. Decreasing the discount rate to zero resulted in this strategy dominating the 
status quo. All other sensitivity analyses produced ICERs ranging between AUD6,139 and 
23,882/QALY gained.  
Screening with TfS produced an ICER of AUD4,103/QALY gained in the base-case analysis. This 
strategy was found to dominate the status quo when the discount rate was decreased to zero, 
baseline age for screening was decreased to 20 years, the probability of starting in Category 
1 was decreased (thereby increasing penetrance), increasing the prevalence estimate and 
increasing the probability of transition from Category 1 to 2 (in the absence of treatment). All 
other sensitivity analyses produced ICERs ranging between AUD41 and 5,910/QALY gained. 
Adult females 
In the base-case analysis, genotyping (blood) produced an ICER of AUD552,964/QALY gained. 
Reducing the discount rate to zero resulted in this becoming a dominant strategy, however 
this strategy was dominated by the status quo when the discount rate was increased to 7%, 
baseline age for screening was raised to 55 years, prevalence was increased and the transition 
probability of moving between Categories 2 and 3 (in the absence of treatment) was 
decreased. All other sensitivity analyses produced ICERs above the AUD50,000 WTP 
threshold, ranging between AUD84,605 and 1,245,111/QALY gained.  
Chapter 6: Cost-effectiveness of different population screening strategies for hereditary 
haemochromatosis in Australia 
  
241 | P a g e  
 
The base-case analysis for genotyping (buccal) females had an ICER of AUD1,872,055/QALY 
gained. Reducing the discount rate to zero produced an ICER of AUD13,227/QALY gained, 
however all other sensitivity analyses resulted in this strategy being dominated by the status 
quo or producing ICERs well above the WTP threshold, ranging between AUD331,102 and 
4,315,313/QALY gained.  
Screening with TfS returned an ICER of AUD10,195/QALY gained in the base-case analysis. 
Whilst reducing the discount rate to zero resulted in this strategy dominating the status quo, 
all other sensitivity analyses produced ICERs ranging between AUD797 and 17,500/QALY 
gained.  
Neonatal screening 
One-way sensitivity analyses showed little effect on the base-case results, with neonatal 
screening dominating the status quo in all analyses for both sexes. In particular, assumptions 
regarding the uptake of screening and iron studies in homozygote adults (screened as 
neonates) – which were based on expert opinion – had little impact on the base-case results.  
 6.6 Discussion 
This is the first haemochromatosis screening model to incorporate utilities and costs derived 
from a haemochromatosis cohort. A Markov model with probabilistic decision analysis was 
developed to estimate the cost-effectiveness of screening both adults and neonates in 
Australia .To date, just one other study has used these methods, which was based on a 
hypothetical population of 30 year old German males [37]. We have built on this study by 
using QALYs rather than LYG as the measure of effectiveness, and including females and 
neonates.  
All three screening strategies were cost-effective for adult males in the base-case and 
sensitivity analyses. Applying a WTP threshold of AUD50,000/QALY gained, the probability 
that each strategy would be cost-effective ranged between 74% and 82%. For adult females, 
screening with TfS was the only strategy found to be cost-effective; applying the WTP 
threshold, there was a 61% probability of this strategy being cost-effective. 
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These results differ from a recent screening study for German males from the payer 
perspective [37], in which three screening strategies were compared with no screening for 
males aged 30 in a Markov model using probabilistic sensitivity analysis. Sequential 
population screening (similar to our TfS screening) was reported to have an ICER 
€124,000/LYG and genotype population screening (similar to our genotyping with a blood 
sample) had an ICER of €161,000/LYG.  In contrast, from the government perspective, our 
study estimated an ICER of AUD4,225/QALY gained for the TfS strategy and 1,810/QALY 
gained for genotype screening (blood). There are several reasons for these contrasting results. 
Firstly, different measures of effectiveness were used: LYG and QALYs. Use of QALYs allowed 
for inclusion of a broad range of quality of life impacts related to haemochromatosis [21, 22]. 
Therefore, it is not surprising that our study shows more favourable results for population 
screening as we used a more comprehensive definition of effectiveness that captured effects 
of screening on both length and quality of life. Secondly, the German study limited its state 
costs to those related to cirrhosis and hepatocellular carcinoma; we included a broad range 
of complications as outlined in the EASL categories (Table 1). As a result, our model captured 
a broader range of costs.   
Genotyping with buccal cell samples was the least favourable option, due to the relatively 
high cost of this test. As genotyping with buccal samples is not routinely performed in 
Australia (in favour of blood samples) the economies of scale associated with this have 
resulted in lower comparative costs for genotyping with blood samples rather than buccal 
samples.   As buccal samples represent a non-invasive approach with comparable sensitivity 
and specificity to blood samples, this may change over the coming decade. If this occurs, then 
it is possible that genotyping with buccal samples will become more favourable from a cost-
effectiveness perspective.  
The model was sensitive to the discount rate as it was applied annually to both costs and 
effectiveness which were projected over a long time horizon, thereby impacting on costs and 
QALYs accrued in the future. In the modelled scenarios, immediate costs of screening were 
offset by long-term reductions in costs associated with progression of the severity of disease. 
Similarly, improvements in QALYs accrued in the future due to reduced progression of disease 
severity were reduced due to discounting. While varying the discount rate had a large impact 
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on the absolute costs and QALYs calculated for each scenario, as would be expected in a 
lifetime analysis, the decision as to whether or not the interventions were deemed to be cost-
effective (i.e. fall under the Australian willingness to pay threshold of $50,000) did not change. 
Neonatal screening dominated the status quo for males and females. This appears to be an 
excellent prospect for screening from a cost-effectiveness viewpoint, and avoids exclusion 
from screening based on ancestry. However, establishing cost-effectiveness is just one of 
many elements when considering instituting population screening programs [61]. The current 
Australian guidelines for neonatal screening specify that screened conditions be limited to 
those that should be identified early in life to minimise morbidity or mortality. As 
haemochromatosis does not meet this criterion, HFE genotyping is unlikely to be included in 
neonatal screening protocols at present.  Secondly, the issue of how an adult who, as a 
neonate tested positive for the screening test, would be alerted of this status as an adult, is 
unclear. We did not consider this in our model, however, it is possible that national genetic 
registry programs may be established in the future, which would co-ordinate follow-up of 
individuals carrying genetic mutations that elevate disease risks. 
The adult model predicted that for 10,000 screenings, the status quo would identify an 
estimated 2.88 and 2.03 male and female homozygotes respectively.  Using the prevalence 
estimate of 0.68% for people of northern European ancestry [6], from a population of 10,000 
people of such ancestry, 68 would be expected to be C282Y homozygotes. This suggests that 
the current approach to screening in Australia is of limited efficiency, identifying 
approximately 3% of C282Y homozygotes. In comparison, our model estimated approximately 
40% of homozygotes would be identified through our adult screening approaches (with the 
exception of TfS screening for females), and 92% of neonates. The potential inefficiency of 
the current approach suggests that alternatives should be considered, such as those included 
in our model, which would identify a greater proportion of C282Y homozygotes. Increasing 
the rate of diagnosis and treatment of iron overload will likely to lead to reduced costs [52] 
and importantly, reduced morbidity and mortality [62]. 
An important limitation to the results obtained through our analyses are the uncertainties 
represented by large standard deviations for costs and effectiveness. This is predominantly 
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due to the dispersion of data in the source studies  [22, 52]. The fact that one-way sensitivity 
analyses had limited effect on most base-case results (with the exception of discounting), and 
the CEACs showed high probabilities that most strategies were likely to be cost-effective, 
suggests that the results generated by the model are robust nevertheless.  A further limitation 
was the unavoidable reliance on expert opinion. Whilst this was addressed by conducting one-
way sensitivity analyses on these estimates, more robust estimates would strengthen future 
models. 
There are several strengths of this model.  We used probabilistic decision analysis in a Markov 
model, which allowed for multiple parameter uncertainties to be accounted for in the 
analyses. Use of QALYs allowed for quality of life impacts to be incorporated rather than 
limiting the focus to mortality.  This is the first economic analysis of haemochromatosis 
screening to include comprehensive haemochromatosis-specific costs and utilities.  Finally, 
this is the first model to incorporate costs associated with transfer payments.  
We have developed a comprehensive economic model to examine the cost-effectiveness of 
screening both adults and neonates for haemochromatosis in Australia. The results of this 
model suggest that screening males of northern European ancestry aged 30years with 
genotyping using blood samples is likely to be a cost-effective strategy. For females, screening 
with TfS was the most favourable strategy. Neonatal screening was associated with cost 
savings and improved effectiveness in comparison to the status quo. These results may assist 
decision-makers when considering the implementation of haemochromatosis screening 
programs in Australia.  
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Appendix 6A: Sensitivity analyses 
 Mean costs Mean effectiveness ICER (AUD/QALY gained) 
Model parameters Status 
quo 
 
Genotype 
(blood) 
Genotype 
(buccal) 
TfS Status 
quo 
 
Genotype 
(blood) 
Genotype 
(buccal) 
TfS Genotype 
(blood) 
Genotype 
(buccal) 
TfS 
TOTAL GOVERNMENT COSTS            
Adult males 
Discount rate: 0% 
Discount rate: 7% 
Baseline age: 20 years 
Baseline age: 40 years 
Prevalence: -20%  
Prevalence: +20%  
Probability of starting in category 1:  -20%  
Probability of starting in category 1: +20%  
Transition from category 1 to 2~: -20%  
Transition from category 1 to 2~: +20%  
Transition from category 2 to 3~: -20%  
Transition from category 2 to 3~: +20% 
Category 4 mortality: -20% 
Category 4 mortality: +20% 
Uptake of screening: -50% 
Uptake of screening: +50% 
 
739 
132 
211 
170 
171 
252 
216 
172 
180 
205 
184 
202 
195 
193 
194 
194 
 
582 
139 
196 
168 
166 
229 
196 
171 
173 
193 
177 
190 
185 
183 
188 
180 
 
637 
195 
252 
223 
222 
285 
252 
227 
229 
248 
233 
245 
240 
239 
216 
263 
 
651 
146 
208 
178 
183 
228 
209 
182 
184 
205 
188 
202 
196 
195 
195 
196 
 
42.246 
11.903 
16.051 
14.528 
15.453 
15.451 
15.451 
15.454 
15.453 
15.452 
15.454 
15.452 
15.453 
15.452 
15.452 
15.453 
 
42.264 
11.906 
16.056 
14.531 
15.457 
15.456 
15.456 
15.457 
15.457 
15.456 
15.457 
15.456 
15.457 
15.457 
15.454 
15.459 
 
42.264 
11.906 
16.056 
14.531 
15.457 
15.456 
15.456 
15.457 
15.457 
15.456 
15.457 
15.456 
15.457 
15.457 
15.454 
15.459 
 
42.262 
11.905 
16.055 
14.531 
15.456 
15.455 
15.455 
15.457 
15.457 
15.455 
15.457 
15.455 
15.456 
15.456 
15.454 
15.458 
 
DOMINANT 
2,674 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
 
DOMINANT 
23,882 
9,263 
14,594 
14,279 
6,139 
7,646 
16,167 
12,876 
10,171 
12,996 
10,077 
11,210 
11,281 
11,871 
11,059 
 
DOMINANT 
5,910 
DOMINANT 
2,379 
3,458 
DOMINANT 
DOMINANT 
3,701 
1,257 
DOMINANT 
1,105 
41 
124 
749 
1,030 
293 
Adult females 
Discount rate: 0% 
Discount rate: 7% 
Baseline age: 35 years 
 
313 
71 
115 
 
279 
99 
131 
 
334 
154 
186 
 
284 
93 
127 
 
33.124 
11.286 
15.243 
 
33.126 
11.286 
15.243 
 
33.126 
11.286 
15.243 
 
33.129 
11.287 
15.245 
 
DOMINANT 
DOMINATED 
89,955 
 
13,227 
DOMINATED 
412,446 
 
DOMINANT 
16,726 
5,967 
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Baseline age: 55 years 
Prevalence: -20%  
Prevalence: +20%  
Probability of starting in category 1:  -20%  
Probability of starting in category 1: +20%  
Transition from category 2 to 3~: -20%  
Transition from category 2 to 3~: +20% 
Category 4 mortality: -20% 
Category 4 mortality: +20% 
Uptake of screening: -50% 
Uptake of screening: +50% 
82 
89 
129 
122 
95 
97 
103 
101 
100 
99 
102 
108 
111 
146 
132 
117 
118 
122 
121 
120 
109 
132 
163 
166 
201 
188 
173 
174 
178 
176 
176 
136 
216 
101 
109 
132 
128 
112 
113 
118 
116 
115 
107 
124 
12.865 
14.281 
14.277 
14.280 
14.280 
14.281 
14.280 
14.280 
14.280 
14.280 
14.280 
12.865 
14.281 
14.277 
14.280 
14.280 
14.280 
14.280 
14.280 
14.280 
14.280 
14.280 
12.865 
14.281 
14.277 
14.280 
14.280 
14.280 
14.280 
14.280 
14.280 
14.280 
14.280 
12.866 
14.283 
14.280 
14.282 
14.282 
14.282 
14.281 
14.282 
14.282 
14.281 
14.283 
DOMINATED 
244,675 
DOMINATED 
123,766 
1,245,111 
DOMINATED 
84,605 
679,294 
578,325 
620,125 
620,125 
DOMINATED 
877,007 
DOMINATED 
765,431 
4,315,313 
DOMINATED 
331,102 
2,566,244 
2,174,662 
2,336,773 
2,336,773 
13,330 
17,500 
797 
3,401 
10,304 
10,087 
7,795 
8,693 
8,898 
9,264 
8,649 
 Mean costs Mean effectiveness ICER (AUD/QALY gained) 
 Status quo Neonatal screening Status quo Neonatal screening Neonatal Screening 
Neonatal males 
Discount rate: 0% 
Discount rate: 7% 
Prevalence: -20%  
Prevalence: +20%  
Probability of starting in category 1:  -20%  
Probability of starting in category 1:  +20%  
Transition from category 1 to 2~: -20%  
Transition from category 1 to 2~: +20% 
Transition from category 2 to 3~: -20%  
Transition from category 2 to 3~: +20% 
Category 4 mortality: -20% 
Category 4 mortality: +20% 
Uptake of Fe screening for HMZ: -50% 
Uptake of Fe screening for HMZ: +50% 
 
292 
8 
18 
26 
23 
18 
19 
22 
19 
21 
20 
20 
20 
20 
 
138 
5 
9 
13 
12 
10 
10 
12 
10 
11 
11 
11 
11 
11 
 
65.837 
12.316 
16.612 
16.613 
16.612 
16.613 
16.613 
16.612 
16.613 
16.612 
16.612 
16.612 
16.612 
16.612 
 
66.257 
12.367 
16.681 
16.681 
16.681 
16.681 
16.681 
16.681 
16.681 
16.681 
16.681 
16.681 
16.681 
16.681 
 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
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Uptake of status quo screening: -20% 
Uptake of status quo screening: +20% 
20 
21 
11 
11 
16.613 
16.612 
16.491 
16.981 
DOMINANT 
DOMINANT 
Neonatal females 
Discount rate: 0% 
Discount rate: 7% 
Prevalence: -20%  
Prevalence: +20%  
Cost of neonatal screen: -20% 
Cost pf neonatal screen: +20% 
Probability of starting in category 1:  -20%  
Probability of starting in category 1:  +20%  
Transition from category 1 to 2~: -20%  
Transition from category 1 to 2~: +20% 
Transition from category 2 to 3~: -20%  
Transition from category 2 to 3~: +20%  
Category 4 mortality: -20% 
Category 4 mortality: +20% 
Uptake of Fe screening for HMZ: -50% 
Uptake of Fe screening for HMZ: +50% 
Uptake of status quo screening: -20% 
Uptake of status quo screening: +20% 
 
120 
2 
5 
7 
5 
5 
6 
5 
5 
6 
5 
6 
5 
5 
5 
5 
5 
6 
 
62 
2 
3 
4 
3 
4 
4 
3 
3 
4 
3 
4 
3 
3 
3 
4 
3 
3 
 
68.497 
12.221 
16.540 
16.539 
16.540 
16.540 
16.540 
16.540 
16.540 
16.540 
16.540 
16.540 
16.540 
16.540 
16.540 
16.540 
16.540 
16.540 
 
68.853 
12.261 
16.595 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
16.594 
 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT  
DOMINANT 
DOMINANT 
DOMINANT 
DOMINANT 
* All ICERs are calculated against the status quo; ~ Refers to transitions where no treatment was included 
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Chapter 7: Summary and future directions 
7.1 Preface 
This thesis presented an overview of the current status of the global health economic 
evidence for haemochromatosis screening and interventions, estimates the economic and 
health-related quality of life burden associated with haemochromatosis for the Australian 
setting, and identifies cost-effective population screening strategies.  This chapter provides a 
synopsis, discussion and suggestions for future directions.  
 
7.2 Summary of the thesis 
Chapter 1 provided an overview of haemochromatosis and health economics. One of the most 
common genetic disorders amongst populations of northern European heritage [1, 2], 
haemochromatosis is largely straightforward to both diagnose and treat.  However, as early 
symptoms are non-specific and therefore easily missed, diagnosis is delayed in some cases, 
leading to preventable morbidity and mortality [3, 4]. Population screening programs have 
been suggested to increase early diagnosis and treatment, thereby reducing the associated 
burden of disease [5-8]. To date, a paucity of robust health economic evidence has been a key 
barrier to establishing such programs internationally [5, 9-11]. For governments, who are 
frequently the funding body for screening programs, provision of such interventions incur 
substantial costs. Therefore, it is important to conduct health economic evaluations to assess 
the value-for-money of clinically effective screening strategies. Modelling provides an 
excellent method to quantify the costs and effectiveness associated with proposed screening 
strategies, to inform decision makers when considering funding screening programs [12].  
A systematic review of the global health economic literature pertaining to haemochromatosis 
was provided in Chapter 2. This review identified 38 published papers containing health 
economic data, most of which were modelled studies evaluating the cost-effectiveness of 
screening for haemochromatosis. Whilst the majority of studies concluded that screening for 
haemochromatosis was cost-effective, many included flawed assumptions or methodology, 
Chapter 7: Summary and future directions 
 
253 | P a g e  
 
limiting the validity of the results. The gaps identified in the systematic review regarding 
current knowledge and understanding of health economic aspects of haemochromatosis 
informed the direction of the subsequent PhD projects.  
The review identified that to date, no study had reported on health-related quality of life 
associated with haemochromatosis, in the form of health state utility values (HSUVs). Four 
studies had incorporated HSUVs into their models, however, almost all were unrealistically 
high, likely resulting in underestimates of the effectiveness of screening. Secondly, no 
literature was identified that reported on the economic burden associated with 
haemochromatosis. Quantification of both the health-related quality of life impacts and 
economic burden associated with haemochromatosis would allow for greater understanding 
of its burden, and further, the effects a proposed population screening program may offer. 
Chapter 3 presents a study on the health-related quality of life utility values for 
haemochromatosis. A national online survey was conducted, using the Assessment of Quality 
of Life 4D (AQOL-4D) instrument to elicit HSUVs. Participants were categorised into four 
stages of disease, as recommended by the European Association for the Study of the Liver [9], 
and described in Table 7.1. Mean utilities (standard deviation) were 0.76 (0.21) for Category 
1, 0.81 (0.18) for Category 2, 0.60 (0.27) for Category 3, and 0.50 (0.27) for Category 4. The 
value for Category 4 was similar to those reported for comparable co-morbidities, such as 
liver cirrhosis and heart disease. Self-reported symptoms associated with iron overload were 
negatively associated with HSUV (r=-0.685).  Previous health economic evaluations of 
haemochromatosis screening used unrealistically high HSUVs in most cases: 1.00 for all 
symptoms and co-morbidities with the exception of cirrhosis, which was assigned a utility of 
0.95 [7]; 0.8 for cirrhosis, 0.9 for diabetes, 0.5 for heart failure [13, 14].  Use of inflated utilities 
in health economic analyses is likely to lead to underestimates of gains in effectiveness 
associated with an intervention. The utility values reported in this study, the most robust 
reported to date, can be used to populate future health economic models for 
haemochromatosis interventions. 
Chapter 4 presents data on the economic burden associated with C282Y homozygous 
haemochromatosis in Australia, the first study to quantify this and to provide a breakdown of 
the effects of increasing severity of disease on costs. Through the national cost of illness study 
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estimates of health sector, other sector and time-loss/productivity costs from the 
perspectives of the patient, government and society were obtained. Per patient costs were 
estimated for each category of haemochromatosis. Costs from the societal perspective were 
then extrapolated to the Australian population for asymptomatic (Categories 1 and 2) and 
symptomatic patients (Categories 3 and 4) for both diagnosed and undiagnosed C282Y 
homozygotes.  Whilst the costing methodology was based on previously described costing 
studies [15, 16], an additional novel approach was applied to allow for the estimation of costs 
for undiagnosed patients. This approach allowed for a more comprehensive estimation of 
total costs which is critical for a condition with a low diagnosis rate such as 
haemochromatosis. The total annual cost associated with C282Y homozygous 
haemochromatosis in Australia was estimated to be AUD274 million in 2015.  Sensitivity 
analyses identified substantially lower costs associated with decreased penetrance of 
haemochromatosis. These cost estimates provide the first estimates of the economic burden 
associated with haemochromatosis internationally, and the estimates for each level of 
severity of disease can be used to populate future health economic models. 
Chapters 5 and 6 focus on the health economic model that was developed to analyse the cost-
effectiveness of different haemochromatosis screening strategies in Australia. Chapter 5 
provides an overview of the construction and validation of the model, following the guidelines 
of the International Society for Pharmacoeconomics and Outcomes Research [17]. A Markov 
state-transition model with states based on disease severity was constructed. For the 
purposes of this paper, the model was limited to the status quo approach (cascade and 
incidental screening) for males aged 30 years and females aged 45 years, both of northern 
European ancestry. Costs were reported from the government perspective, and were limited 
to direct medical costs. The model was found to have good face validity, along with internal 
and external validity. The model predicted mean (95%CI) QALYS of 15.7 (7.7-23.7) for males 
and 14.4 (6.7-22.1) for females associated with the status quo approach.  The mean (95% CI) 
discounted lifetime direct medical costs for C282Y homozygote were estimated to be 
AUD22,737 (3,670-75,793) for males and AUD13,840 (1,335-67,377) for females. One-way 
sensitivity analyses revealed that discount rates, prevalence and state probabilities were the 
most influential parameters, and the few parameters that by necessity were based on 
assumptions had little impact on the overall results. 
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Chapter 6, extending upon Chapter 5, presents the results of the model for adults (males aged 
30 years and females aged 45 years) of northern European ancestry and neonates irrespective 
of ancestry (from birth) to enable the assessment of the cost-effectiveness of potential 
screening strategies against the status quo. Four adult screening strategies were modelled: 
the status quo (cascade and incidental screening), genotyping with blood samples, genotyping 
with buccal samples, and transferrin saturation followed by genotyping (TfS); and two 
neonatal strategies: genetic screening and the status quo from birth.  Approximately 3% of 
C282Y homozygotes were estimated to be identified with the status quo approach, compared 
with 40% for most adult strategies and 92% for neonatal strategies. Cost-effectiveness was 
estimated from the government perspective, including direct medical costs and transfer 
payments. For adult males, the most cost-effective strategy was genotyping with a blood 
sample, producing an ICER of AUD1,673 per additional QALY gained; for females, the TfS 
strategy was the most cost-effective, with an ICER of AUD10,195 per additional QALY gained. 
Neonatal screening dominated the status quo for both males and females.  
In summary, the work that has been presented in this thesis has substantially added to the 
haemochromatosis body of literature, and will be useful to researchers, clinicians and 
decision makers. Future directions in this field will now be discussed. 
7.2.1 Integrated conclusions of the thesis  
In Chapter 1, Wilson and Jungner’s criteria for population screening were presented (Textbox 
1) [18], with the observation that, with the exception of criterion point 9, haemochromatosis 
is a condition that meets these criteria [19]. The studies presented in this thesis have provided 
valuable health economic data to specifically address criterion point 9: hereditary 
haemochromatosis, particularly the more severe stages (i.e. Categories 3 and 4) is associated 
with reduced health state utility values (Chapter 3) and an increased economic burden 
(Chapter 4), and that several population screening strategies for haemochromatosis were 
estimated to be cost-effective or cost saving in comparison to the status quo (Chapter 6).  
Over the preceding two decades, a body of literature has developed providing high quality 
evidence of the natural history, diagnostic and treatment approaches for haemochromatosis 
approaches. These data, in combination with the health economic data presented in this 
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thesis, provide a strong evidence base for consideration of a policy to introduce population 
screening for haemochromatosis in Australia. 
Textbox 1: Wilson and Jungner’s screening criteria [18]  
1. The condition sought should be an important health problem; 
2. There should be an accepted treatment for patients with recognized disease; 
3. Facilities for diagnosis and treatment should be available; 
4. There should be a recognizable latent or early symptomatic stage; 
5. There should be a suitable test or examination; 
6. The test should be acceptable to the population; 
7. The natural history of the condition, including development from latent to declared 
disease, should be adequately understood; 
8. There should be an agreed policy on whom to treat as patients; 
9. The cost of case finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible expenditure on medical 
care as a whole; 
10. Case finding should be a continuing process and not a “once and for all” project. 
 
7.3 Future directions 
7.3.1 Incorporating males and females into one model 
The health economic model that was constructed calculated the cost-effectiveness of 
screening interventions for males and females separately. This approach was adopted due to 
the sex-dependent penetrance rates and different ages of onset of iron overload, with males 
experiencing a greater burden of disease. To some degree, this approach reflected the current 
body of literature which has focused on the cost-effectiveness of screening males. The work 
included in this thesis has shown that for adult males, genotype screening with either blood 
or buccal cell samples are likely to be cost-effective strategies, however, for females only the 
sequential strategy was found to be cost-effective. In reality, a screening strategy for 
haemochromatosis is likely to be introduced irrespective of sex, therefore it is important to 
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further refine the model to allow for simulation of a cohort of both males and females, in 
order to calculate the overall cost-effectiveness of each of these strategies compared with 
the status quo. This information is considered essential for decision-makers. 
In Australia, the Medical Services Advisory Committee (MSAC) of the Australian Government 
Department of Health is the key decision making body for funding decisions regarding 
national screening programs. An important next step in this work will be to support the 
national support group, Haemochromatosis Australia, in the preparation of an MSAC 
submission. Therefore, the model will be refined to meet the reporting requirements of this 
body. This work has recently commenced, and publication of the results of the model will 
follow. 
7.3.2 Improving estimates of screening uptake 
In the model described in this thesis, published literature and expert opinion were used to 
inform the estimate of uptake of the proposed screening strategies for adults, as no published 
data were available. The estimate was based on the uptake rates of two Australian population 
screening programs: bowel and cervical cancer. For neonatal screening, expert opinion was 
relied upon to estimate uptake of iron studies for adults who were screened as neonates and 
found to be C282Y homozygotes. Whilst sensitivity analyses of ±50% were conducted for 
these estimates to evaluate how variations in these estimates impact the base-case results, 
it is preferable to use estimates based on more relevant data. Ideally, such an estimate would 
be derived from an evaluation of a real-world population screening strategy. Whilst this is 
feasible for an adult screening strategy, for the neonatal strategy, a follow-up period of 45 
years would be required to evaluate uptake of iron studies of C282Y homozygote females, 
which is unlikely to be considered viable.  
7.3.3 Adapting the model to other settings 
The cost-effectiveness model that was presented in this thesis was developed for Australia, 
based on the status quo approach to diagnosis and using country-specific cost and utility data. 
The model has been constructed to allow for adaptation to other settings. New strategies can 
be simulated, and the parameters of the existing strategies altered. Further, when country-
specific cost and utility data become available, these can be easily incorporated into the 
model. This will provide decision makers with a robust estimate of the cost effectiveness of 
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screening strategies specific to the setting.  
7.3.4 Determination of country-specific cost and health state utility data 
To allow for the cost-effectiveness model to be adapted to other settings, country-specific 
cost and utility are required to produce the most robust and valid results [20]. To date, these 
data have only been published for Australia. For countries with high prevalence of 
haemochromatosis such as Ireland [21]and Sweden [22], these data could be collected and 
used to adapt and validate the model for these settings, thereby providing robust evaluations 
of the cost-effectiveness of screening.  
7.3.5 Conducting a budget impact assessment 
A budget impact analysis is an important element to be included in MSAC submissions. It 
provides estimates to the funding body of the likely costs of implementing and maintaining a 
new intervention such as population screening for haemochromatosis. This work will involve 
constructing a model to allow for estimation of the likely impact on the Australian health 
budget that a screening program would have.  The model will incorporate the most robust 
epidemiological and economic data available, consistent with the cost-effectiveness model. 
This work is planned to be conducted as part of an Honours or Masters project at Menzies 
Institute for Medical Research under the supervision of members of the health economics 
group. 
7.3.6 Collaborating with the Centres for Disease Control and Prevention (CDC) on a 
paper reviewing the quality of evidence used in haemochromatosis models 
In February of 2015, BdG was invited by a senior health economist from the Centres for 
Disease Control and Prevention (CDC), Dr Scott Grosse, to assist in conducting a review of the 
quality of evidence that has been used to populate health economic models for 
haemochromatosis screening. This invitation was a result of the systematic review that was 
published which identified this issue. This work will begin by the end of 2016, with submission 
planned for 2017. 
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